Document:

exv10w1

 

Exhibit 10.1

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.

Confidential

 

DEVELOPMENT AND SUPPLY AGREEMENT

By and Between

CADENCE PHARMACEUTICALS, INC.

and

BAXTER HEALTHCARE CORPORATION

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 
	SECTION	 	 	 	PAGE	 
	1.0
	 	BACKGROUND 	 	 	4	 
	 
	 	 	 	 	 	 
	2.0
	 	DEFINITIONS 	 	 	50	 
	 
	 	 	 	 	 	 
	3.0
	 	COOPERATIVE ORGANIZATION 	 	 	4	 
	 
	 	 	 	 	 	 
	4.0
	 	DEVELOPMENT PROGRAM 	 	 	5	 
	 
	 	 	 	 	 	 
	5.0
	 	PRODUCT REGISTRATIONS 	 	 	8	 
	 
	 	 	 	 	 	 
	6.0
	 	COMMERCIAL SUPPLY 	 	 	9	 
	 
	 	 	 	 	 	 
	7.0
	 	MANUFACTURING FEE 	 	 	12	 
	 
	 	 	 	 	 	 
	8.0
	 	API 	 	 	13	 
	 
	 	 	 	 	 	 
	9.0
	 	EQUIPMENT      	 	 	14	 
	 
	 	 	 	 	 	 
	10.0
	 	QUALITY MANAGEMENT               	 	 	15	 
	 
	 	 	 	 	 	 
	11.0
	 	MARKETING 	 	 	17	 
	 
	 	 	 	 	 	 
	12.0
	 	REPRESENTATIONS AND WARRANTIES 	 	 	17	 
	 
	 	 	 	 	 	 
	13.0
	 	CONFIDENTIALITY 	 	 	20	 
	 
	 	 	 	 	 	 
	14.0
	 	INTELLECTUAL PROPERTY 	 	 	21	 
	 
	 	 	 	 	 	 
	15.0
	 	INDEMNIFICATION 	 	 	25	 
	 
	 	 	 	 	 	 
	16.0
	 	ALTERNATE DISPUTE RESOLUTION 	 	 	27	 
	 
	 	 	 	 	 	 
	17.0
	 	FORCE MAJEURE 	 	 	27	 
	 
	 	 	 	 	 	 
	18.0
	 	RELATIONSHIP OF THE PARTIES 	 	 	28	 
	 
	 	 	 	 	 	 
	19.0
	 	TERM AND TERMINATION 	 	 	28	 
	 
	 	 	 	 	 	 
	20.0
	 	EFFECTS OF TERMINATION 	 	 	29	 
	 
	 	 	 	 	 	 
	21.0
	 	NOTICES 	 	 	32	 

 

 

	 	 	 	 	 	 	 
	SECTION	 	 	 	PAGE	 
	22.0

	 	EXPORT
	 	 	32	 
	 
	 	 	 	 	 	 
	23.0

	 	MISCELLANEOUS
	 	 	33	 

2

 

TABLE OF CONTENTS (Continued)

EXHIBITS

	 	 	 
	EXHIBIT A

	 	•   API SPECIFICATIONS 

	 

	 	•    PRODUCT SPECIFICATIONS

	 

	 	•    FORMULATION SPECIFICATIONS 

	 

	 	•   CONTAINER DESCRIPTION 

	 
	 	 
	 

	 	(Formulation Specifications and Product Specifications are Preliminary as of the
Effective Date of the Agreement and will be agreed upon by the Parties prior to
NDA stability batch production pursuant to Section 4.3.1.)
	 
	 	 
	EXHIBIT B

	 	DEVELOPMENT PLAN (Section 4.1)
	 
	 	 
	EXHIBIT C

	 	REGULATORY STRATEGY (Section 4.2)
	 
	 	 
	EXHIBIT D

	 	DEVELOPMENT FEE SCHEDULE (Section 4.1.4)
	 
	 	 
	EXHIBIT E

	 	BAXTER FACILITY IMPROVEMENTS (Section
4.1.5.2) AND BAXTER OWNED EQUIPMENT (Section 9.1)
	 
	 	 
	EXHIBIT F

	 	MINIMUM BATCH SIZES (Section 6.3) AND
MANUFACTURING FEE (Section 7.1)
	 
	 	 
	EXHIBIT G

	 	QUALITY AGREEMENT (Section 10.0)
	 
	 	 
	EXHIBIT H

	 	COST OF API AND METHODOLOGY FOR CALCULATING
MANUFACTURING YIELD LOSSES (Sections 8.3, 8.4 and
12.3.6)
	 
	 	 
	EXHIBIT I

	 	ADVERSE EVENT HANDLING PROCEDURE (Section 10.4)
	 
	 	 
	EXHIBIT J

	 	CONFIDENTIAL DISCLOSURE AGREEMENT (Sections 13.1)
	 
	 	 
	EXHIBIT K

	 	CADENCE OWNED EQUIPMENT (Section 9.2)
	 
	 	 
	EXHIBIT L

	 	DEFINITIONS (Section 2.0)

3

 

DEVELOPMENT AND SUPPLY AGREEMENT

     This DEVELOPMENT AND SUPPLY AGREEMENT, (the “Agreement”) is
effective as of July 18, 2007 (the “Effective Date”) between CADENCE PHARMACEUTICALS, INC., a
corporation organized and existing under the laws of the State of Delaware and having its principal
office at 12481 High Bluff Drive, Suite 200, San Diego, CA 92130 (“Cadence”) and BAXTER HEALTHCARE
CORPORATION, a corporation organized and existing under the laws of the State of Delaware and
having its principal office at One Baxter Parkway, Deerfield, Illinois 60015 (“Baxter”). All
references to “Cadence” and “Baxter” will include their respective Affiliates.

1.0 BACKGROUND

     Cadence has an exclusive license to rights in the United States and Canada to a particular
intravenous formulation and manufacturing process of the Compound, (collectively the
“Formulation”). Cadence is seeking a contract manufacturing organization that is capable of
producing the Formulation in a market-ready form as the Product, suitable for marketing in the
Territory. Cadence currently plans to market the Product in the Territory.

     Baxter manufactures and markets sterile products in glass containers for parenteral
administration of pharmaceutical preparations. Baxter is interested in providing sterile product
manufacturing services to Cadence.

     Cadence and Baxter entered into a Letter of Intent dated November 27, 2006, as amended
(collectively, the “LOI”), to establish their intent to enter into this Agreement, and the terms
upon which both Parties would begin purchasing certain capital equipment, in addition to Baxter
commencing certain technology transfer-related activities prior to the execution of this Agreement.
Upon the Effective Date, the LOI is superseded in its entirety by this Agreement.

     THEREFORE, the Parties, intending to be legally bound, agree as follows:

2.0 DEFINITIONS

Certain capitalized terms used in this Agreement and not otherwise defined herein have the meanings
assigned to them in Exhibit L.

3.0 COOPERATIVE ORGANIZATION

     In order to facilitate collaboration between the Parties to achieve the objectives of this
Agreement, the Parties agree to the following organizational provisions:

     3.1 Team Leader. Baxter and Cadence will each identify an individual(s) with appropriate
authority to serve as the primary contact with the other Party about the Product and

4

 

the Parties’ relationship under this Agreement (each a “Team Leader”). Baxter will identify a
Team Leader for the Development Program, and a Team Leader for the commercialization phase. Each
Team Leader will be responsible for obtaining cooperation and input from other individuals within
such Team Leader’s organization whose expertise and ability may be required from time to time to
maximize the potential for successful collaboration under this Agreement.

     3.2 Team Leader Responsibilities. Without limiting the scope of the Team Leader’s
responsibilities, particular consideration will be given to key operational aspects of the
relationship, including but not limited to (i) Product development, regulatory matters highlighted
in the Development Plan (Exhibit B) and Regulatory Strategy (Exhibit C); (ii) transitioning team
leadership responsibilities to a corresponding Team Leader once commercialization of the Product is
undertaken, including such matters as Product manufacturing, quality and marketing considerations;
(iii) coordinating manufacturing activities to launch the Product into the marketplace; (iv)
reviewing the status of ongoing contractual commitments under the Agreement; and (v) identifying
and implementing actions which would improve the value of the Product to customers and the Parties.
The Team Leaders will develop a process and procedures to optimize communication and collaboration
between the Parties in order to timely refine the Development Plan and Regulatory Strategy and
achieve the objectives set forth therein. The Team Leaders will communicate regularly during the
Term of the Agreement at mutually agreeable times, and when necessary hold meetings at mutually
agreeable places, to review progress and the challenges and opportunities for effective
collaboration under this Agreement. The Team Leaders will analyze issues that arise during the
Development Program and subsequent commercialization of the Product and attempt to resolve any
differences as to the most appropriate course of action. If the Team Leaders are unable to resolve
any such differences, the matter(s) shall be escalated to the Senior Vice President, Manufacturing
for Cadence and with respect to Baxter, for matters arising prior to release of the first
commercial (salable) batch of Product to the Vice President, Project Management for Baxter’s
BioPharma Solutions’ business and for matters arising or after release of the first commercial
(salable) batch of Product to the Plant Manager at Baxter’s facility in Cleveland, Mississippi (the
“Senior Executives”). If the Senior Executives are unable to resolve any such differences, the
matter shall be handled pursuant to Section 16.0 of this Agreement.

4.0 DEVELOPMENT PROGRAM

     4.1 Development Plan. The Parties desire to collaborate and to mutually agree to a Development
Program and an associated Development Plan, including without limitation, defining upfront
requirements and design parameters. Each Party shall use Commercially Reasonable Efforts to timely
accomplish the tasks that it is assigned under the Development Plan.

          4.1.1 General. The activities and key milestones to occur during the Development Program
include, but are not limited to, the following activities or topics: (i) technical feasibility
assessment; (ii) formulation and analytical development; (iii) stability studies and Product batch
production to support Regulatory Submissions; (iv) Regulatory Submissions, and (v) Regulating
Groups’ review and approval.

5

 

     In general, during the Term of the Agreement, Cadence will be responsible for (i) providing
technical information about the API, (ii) timely providing the API and applicable reference
standards required for implementation of the activities described in the Development Plan, (iii)
compliance with Regulatory Submission reporting requirements regarding manufacture and control of
the API, and (iv) timely review, drafting and filing of all necessary submissions with Regulating
Groups.

     In general, during the Term of the Agreement, Baxter will be responsible for (a) conducting
all development studies identified as a Baxter Development Deliverable in the Development Plan, (b)
manufacturing Product for Regulatory Submissions and as otherwise provided in the Development Plan
and pursuant to the Regulatory Strategy set forth as part of Exhibits B and C, respectively, (c)
preparing those portions of necessary submissions with Regulating Groups consistent with Baxter’s
obligations under the Regulatory Strategy, (d) supporting Cadence in its efforts to obtain and
maintain approval of the Regulating Groups to sell the Product in the Territory, and (e) supplying
Cadence’s Requirements.

          4.1.2 Development Deliverables. Baxter will promptly disclose to Cadence during the Term of
the Agreement, in English and in writing, all Baxter materials set forth in the Development Plan
(“Baxter Development Deliverables”) which include such interim progress reports agreed upon by the
Parties. Cadence will promptly disclose to Baxter during the Term of the Agreement, in English and
in writing, all Cadence materials set forth in the Development Plan (“Cadence Development
Deliverables”).

          4.1.3 Additional Development Deliverables. If the Development Deliverables set forth in
Exhibit B prove to contain insufficient Information for a Party to carry out its responsibilities
under this Agreement, including information required for Cadence to obtain and maintain Regulating
Group approval and registration of the Product in the Territory in accordance with Section 5.0 or
to complete the FDA’s Annual Report and similar reports required by other Regulating Groups in the
Territory, or to obtain patent protection in accordance with Section 14.0, the Parties will in good
faith negotiate an amendment of Exhibit B to include as a Deliverable the additional Information or
activities which are necessary for such purpose. Such negotiations may arise by mutual consensus
of the Parties or following the written request of either Party.

          4.1.4 Development Fees.

               4.1.4.1 General. Development Fees payable by Cadence to Baxter for the Baxter Development
Deliverables are described in Exhibit D, together with payment milestones.

               4.1.4.2 Additional Work. The activities described in Exhibits B and C are the basis for
determination of the Development Fee. Baxter will not be required to perform, nor be entitled to
reimbursement for, any work beyond that described in Exhibits B and C unless and until the Parties
reach written agreement (coordinated through the Team Leaders under Section 3.2) on the scope of
any additional work and the related additional expenses.

6

 

Notwithstanding the foregoing, if any tests, studies or other activities beyond those encompassed
by Exhibits B and C are requested pursuant to Section 3.2 which are required for obtaining or
maintaining approvals or registrations of the Product in the Territory, then such tests, studies or
other activities will be conducted at Cadence’s expense. To the extent Baxter assists Cadence in
conducting such additional tests, studies or other activities, Cadence will pay Baxter a fee to be
negotiated in good faith between the Parties. By way of example, additional development work might
be required in response to Regulating Group requests during review of Regulatory Submissions (such
as laboratory work or environmental assessment), additional tests to demonstrate compliance with
other compendia, or country specific import testing requirements.

          4.1.5 Letter of Credit. Prior to the Effective Date, Cadence has established for Baxter’s
benefit an irrevocable Letter of Credit in a face amount of Three Million Two Hundred Sixty Eight
Thousand Dollars ($3,268,000) in the form delivered and with Silicon Valley Bank (the “Letter of
Credit”). The Letter of Credit shall secure Cadence’s performance of its obligations to reimburse
Baxter for costs associated with the equipment to be purchased and facility improvements outlined
in Section 4.1.5.2 (“Baxter Capex”). In the event Cadence fails to perform its obligations as set
forth in Section 4.1.5.2, Baxter may, in its sole discretion, draw down all or a portion of the
Letter of Credit to satisfy such payment obligation. Baxter’s remedy described in this paragraph
shall be in addition to any other remedy described herein or under applicable law.

               4.1.5.1 Reduction Process. On a calendar quarterly basis, beginning after the Effective Date,
Cadence shall review invoices paid against items in the Baxter Capex for that quarter and provide
Baxter with a letter indicating Cadence’s intention to reduce the face value of the Letter of
Credit, by amendment, for the total amount of the invoices paid in the prior periods (and not yet
credited). If Baxter agrees with the amount of Cadence’s proposed reduction, Baxter will send a
letter to the designated contact of the issuer of the Letter of Credit authorizing the reduction,
with a copy to Cadence. The issuance and maintenance of the Letter of Credit and its amendments
will be at the sole cost and expense of Cadence. Any Letter of Credit amendments shall be in form
and substance satisfactory to Baxter, and shall be implemented with no lapse in coverage.

               4.1.5.2 Equipment Purchases and Facility Improvements. Cadence will fund certain facility
improvements which are attached hereto as Exhibit E and incorporated herein by reference. The
Parties shall mutually agree in writing to any expenditures relating to equipment purchases and
facility improvements in excess of Three Million Two Hundred Sixty-Eight Thousand Dollars
($3,268,000). At the end of each calendar quarter, Baxter shall provide Cadence with an invoice
representing the costs of equipment purchases and facility improvements made by Baxter during the
then calendar quarter. Cadence agrees to pay Baxter in accordance with Section 4.1.6.

          4.1.6 Payment. Development Fees (under Section 4.1.4.1), authorized additional Development Fees
(under Section 4.1.4.2), and costs for equipment purchases and facility improvements (under Section
4.1.5.2) will be paid by Cadence in United States dollars within thirty (30) days after the date of
Cadence’s receipt of each invoice from Baxter following

7

 

completion of the designated activities. Invoices not timely paid will be subject to a late
payment charge of one and one-half percent (1-1/2%) per month, or the highest rate allowed by law
if lower, until paid in full. If any portion of an invoice is disputed, then Cadence shall pay the
undisputed amounts as set forth in the preceding sentence and the Parties shall use good faith
efforts to reconcile the disputed amount within (60) days of receipt; provided, that Cadence shall
not be obligated to pay any late payment fee on any such amount disputed in good faith.

     4.2 Regulatory Strategy. Exhibit C sets forth Cadence’s Regulatory Strategy associated with
development of the Product. Cadence shall be solely responsible for the Regulatory Strategy, which
must be finalized prior to commencement by Baxter of Product stability batch production; provided,
Cadence will discuss with Baxter any elements of its Regulatory Strategy which may reasonably be
expected to have an impact on Baxter’s obligations under this Agreement.

     4.3 Product.

          4.3.1 Product Specifications. Exhibit A includes Product Specifications in provisional form
as of the Effective Date of this Agreement and will be refined and agreed upon by the Parties prior
to NDA stability batch production as part of the Development Program. The Quality Agreement shall
govern the procedures for making changes to Product Specifications for commercial Product or in
connection with further refinements of the Product. Cadence will be responsible for and must
provide final approval of Product Specifications and Formulation Specifications and all changes
thereto prior to implementation.

          4.3.2 Label Copy. All label copy and changes therein, on the Product label itself and other
label copy that Cadence uses to market Product in the Territory, will be the responsibility of
Cadence. Any Product label affixed by Baxter to a Product shall be in the form most recently
approved by Cadence.

     4.4 Technical Issues. “Technical Failure” is defined as [***]. In the event there (i) is a
Technical Failure, (ii) are technical issues that do not constitute a Technical Failure that arise
during the Development Program, or (iii) the integration of the [***] equipment purchased by
Cadence with respect to the Development Program has an adverse effect on the production process
(including, but not limited to, the timing or cost of production) (an “Integration Failure”), the
Parties will negotiate in good faith appropriate amendments to this Agreement, including without
limitation, amendments to the Development Plan, to attempt to develop a technically feasible
product.

5.0 PRODUCT REGISTRATIONS

     5.1 Product Registration Application Ownership. Cadence will be the sole

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

8

 

owner of any registration applications submitted to Regulating Groups for the Product. Cadence
will have responsibility for the documentation and submission of the registration applications to
Regulating Groups for the Product in the Territory and for completing the FDA Annual Report and
similar reports required by other Regulating Groups for Product, with support from Baxter in
providing any information required from Baxter in order to complete such reports. Communications to
and from the FDA and other Regulating Groups that involve the NDA or any other Regulatory
Submissions to Regulating Groups for the Product are subject to the provisions of Section 5.4.

     5.2 Product Registration in the United States.

          5.2.1 Right of Reference – Drug Master File. Baxter acknowledges that it holds a Type III DMF
(DMF Number[***]. Baxter will provide a Letter of Authorization for this Type III DMF to Cadence
to support an intended proposal to conduct parametric release in lieu of end-product testing of the
Product.

          5.2.2 Additional Filing Data. During the Term of the Agreement, Baxter will, following prior
written agreement with Cadence, provide the FDA and all other Regulating Groups in the Territory,
with additional data and information related to the Product which are required for Cadence to
obtain and maintain registration and approval of the Product in good standing in the Territory,
including without limitation, Pre-Existing Specifications, Baxter Background Intellectual Property
Rights and Original Product Data. Baxter reserves the right to inform the FDA and other Regulating
Groups that such information is confidential and to advise the FDA and such Regulating Groups that
Cadence will be entitled to reference such information on a confidential basis during the Term of
the Agreement.

     5.3 Communications to/from Regulating Groups. Baxter will promptly notify Cadence of any
communication from or to the FDA, or any other Regulating Groups, in connection with the Product
(collectively “Communications”), and Cadence will notify Baxter of Communications that are relevant
to Baxter’s activities under this Agreement, and will use reasonable efforts to agree on (i)
whether copies of such Communications and/or other Information should be provided to each other as
additional Development Deliverables pursuant to Section 4.1.3; and (ii) which individuals need to
collaborate on a response to Communications received. Cadence shall have primary responsibility to
respond to all Communications. In the event that Baxter and Cadence are unable to agree on the
foregoing items, then Cadence’s position will prevail as it pertains to all Communications sent to
Regulating Groups relating to the API, Formulation, and the Product.

     5.4 User Fees. Cadence will pay all user and/or filing fees charged to Cadence by Regulating
Groups in the Territory which relate to the registration application and ongoing marketing of the
Product, including, but not limited to, the Application Fee, the annual Drug Product Fee, and a
portion of the Drug Establishment Fee.

6.0 COMMERCIAL SUPPLY

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

9

 

     6.1 Supply and Purchase Obligations. Subject to Baxter’s ability to timely provide the
specified volumes of the Product, during the first three Contract Years (as defined in Section
19.1) of this Agreement, Baxter will be sole supplier to Cadence in the Territory for the first
[***] units of Product produced per Contract Year, and for Contract Years four (4) and five (5),
Baxter will be the supplier for [***] units of Product produced per Contract Year, and Cadence will
purchase from Baxter such purchase requirements of Product, for use or sale in the Territory
(“Requirements”). For the purpose of this Section 6.1, “timely” shall mean that, within any
consecutive [***] period, Baxter has delivered Product sufficient to cover [***] of Cadence’s firm
purchase orders scheduled for delivery during that period.

          6.1.1 Right of First Refusal. Cadence hereby grants to Baxter a right of first refusal for
the supply of any units of Product in excess of [***] per Contract Year on the terms and conditions
set forth in this Section 6.1.1. Cadence shall provide to Baxter, at least ninety (90) days in
advance of the beginning of a Contract Year, notice of its requirements in excess of [***] units of
Product for such Contract Year (“Excess Requirements”). Baxter shall have thirty (30) days
following receipt of such notice to respond to Cadence in writing of its desire to supply all or
any portion of the Excess Requirements. If Baxter declines to supply Cadence with all or any
portion of the Excess Requirements or does not respond in writing to Cadence within such thirty
(30) day period, Cadence shall be free to purchase the Excess Requirements from a third party
supplier. Any Excess Requirements supplied hereunder shall be on the same terms and conditions as
the Requirements for such Contract Year.

          6.1.2 Minimum Purchase Requirement. During the Initial Term, Cadence shall purchase from
Baxter a minimum of [***] units of Product per Contract Year Minimum Purchase Requirement”). These
units will be ordered in the minimum batch size set forth in Exhibit F. If Cadence fails to
purchase the Minimum Purchase Requirement in any Contract Year, within thirty (30) days after the
end of each Contract Year, Cadence shall pay Baxter an amount equal to the amount per unit set
forth in Exhibit F multiplied by the shortfall in units. Cadence shall not be obligated to pay any
shortfall amount if Cadence’s failure to meet the Minimum Purchase Requirement is due to Baxter’s
inability to timely supply Cadence with its Requirements of Product in the applicable Contract Year
and Baxter’s inability to timely supply such Requirement is not due to Cadence’s failure to meet
its obligations under this Agreement.

     6.2 Forecasts. In order to assist Baxter in its production planning of Product for Cadence,
Cadence will provide to Baxter, at least ninety (90) calendar days before the beginning of each
calendar quarter commencing with the first Regulatory Submission to a Regulating Group in the
Territory by Cadence for the Product and continuing thereafter during the Term of the Agreement
rolling twelve (12) month forecasts of Cadence’s estimated Product requirements (“Estimated
Requirements”) and expected monthly requirements for Product during such forecast period. Cadence
will make such Estimated Requirements in good faith given market conditions and other information available to Cadence, but such Estimated Requirements
shall not be binding on Cadence or Baxter except as provided in

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

10

 

Section 6.3.

     6.3 Firm Purchase Orders.

          6.3.1 General. During the Term of the Agreement and upon the terms and conditions set forth in
this Agreement, Baxter shall, or shall cause its Affiliates to, manufacture, or cause the
manufacture of, and supply to Cadence Products, ordered pursuant to the process set forth in this
Section 6.3, including, but not limited to volume variations and subject to the restrictions set
forth herein. Cadence will place firm purchase orders for Product at least ninety (90) calendar
days prior to the beginning of each calendar quarter and shall specify the ship dates for Product.
Firm purchase orders will be placed in increments of no less than the minimum number of units of
Product specified in Exhibit F, or such other number of units as then corresponds to the filling
production lot sizes for Products. Subject to the provisions of Section 6.3.2, firm purchase
orders will not be less than [***] percent ([***]%) nor more than [***] percent ([***]%) of
Cadence’s Estimated Requirements of Product for the calendar quarter most recently updated.
Notwithstanding the foregoing, Baxter will use Commercially Reasonable Efforts to comply with any
of Cadence’s unplanned changes in firm purchase orders, but will not be held liable for its
inability to do so. Subject to this Section, Sections 8.3, 12.2 and 17.1, Baxter will meet
Cadence’s requested ship dates. Both Parties agree to work together to reduce lead time for orders
and deliveries. Firm purchase orders will be made on such form of documentation as Baxter and
Cadence agree from time to time, provided that the terms and conditions of this Agreement will be
controlling over any terms and conditions included in any purchase order form used in ordering
Product. Any term or condition of such purchase order form that is in addition to, different from
or contrary to the terms and conditions of this Agreement will be void, unless the Parties
otherwise agree by a separate written agreement.

          6.3.2 Cancellation of Purchase Orders and Rescheduling. Cadence may cancel a firm Product
purchase order or reschedule requested ship dates to a later date by giving Baxter prior written
notice to such effect. Baxter will use reasonable efforts to comply with Cadence’s requests. If,
however, either (i) a cancellation of a firm purchase order or (ii) a rescheduling of ship dates
for a firm purchase order that causes a rescheduling by Baxter of the Product manufacturing date
(“Cancellation/Rescheduling”), occurs prior to Baxter’s scheduled production date for such firm
purchase order, Cadence will pay Baxter a cancellation fee or rescheduling fee
(“Cancellation/Rescheduling Fee”) equal to the following amounts, based on the date of
Cancellation/Rescheduling as follows:

	 	 	 
	Number of Days prior to Baxter’s	 	 
	Scheduled Production Date	 	Cancellation/Rescheduling Fee payable
	More than sixty (60) days prior

	 	[***]
	More than thirty (30) days and less or
equal to sixty (60) days prior

	 	[***]
	Less than or equal to thirty (30) days prior

	 	[***]

     6.4 Delivery; Shipment. All Product supplied under this Agreement will be

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

11

 

delivered FCA Baxter’s distribution site in Memphis. Baxter will make shipping arrangements with
the appropriate carriers designated in writing by Cadence from the FCA point, under the agreements
that Cadence has with those carriers. Accordingly, Cadence will be deemed the exporter of record
for Product shipped outside of the United States (which should only occur to the extent such areas
are included in the definition of “Territory.”) Cadence warrants that all shipments of Product
outside the United States will be in compliance with all applicable United States export laws and
regulations, including the Export Administration Act, and all applicable import laws and
regulations.

7.0 MANUFACTURING FEE

     7.1 Manufacturing Fee. Baxter will invoice Cadence a Manufacturing Fee per unit of Product in
the amount set forth in Exhibit F, upon release to finished goods inventory of Product that has
been quality control released by Baxter in accordance with the chemistry, manufacturing, and
controls (CMC) information for the Product, as provided by Baxter to support the NDA and Product
Specifications set forth in Exhibit A, as may be amended from time to time. The Quality Agreement
shall ultimately govern release of Product for delivery to Cadence.

     7.2 Adjustments. Upon each annual anniversary of a Contract Year effective on the first day
of the Contract Year, Baxter will increase the Manufacturing Fee by an amount equal to [***] per
unit or [***], whichever is greater. Additionally, the Manufacturing Fee may also be adjusted to
reflect increases in Baxter’s cost of materials for the Product. Baxter will provide Cadence with
written notice ninety (90) days prior to the effective date of any increase in the Manufacturing
Fee, which notice shall set forth the amount and elements of such increase.

     7.3 Additional Work and Fees. The Manufacturing Fee described in Section 7.1 is based upon
the scope of activities that Baxter plans to undertake in the ordinary course to manufacture and
release Product in accordance with the Product Specifications, Quality Agreement (Exhibit G) and
other Exhibits. The Manufacturing Fee does not cover activities or expenses related to matters
that might arise outside the ordinary course of manufacturing and releasing Product in
accordance with the Product Specifications, Quality Agreement, and other Exhibits. By way of
example only, additional work might be required for Product or process changes requested by the FDA
or other Regulating Groups, API source changes or Manufacturing Process changes, USP or other
regulatory requirements changes, excessive or untimely requests by Cadence for label changes or
recalls or other actions by Regulating Groups, or mutually agreed upon expansion of the Territory.
Baxter will not be required to perform, nor be entitled to reimbursement for, any such work until
the Parties negotiate in good faith and reach written agreement on the scope of the additional work
and the related additional expenses.

     7.4 Payment; Late Payment Charges. Cadence will pay the Manufacturing Fee (under Section
7.1), expenses for additional work (under Section 7.3), maintenance-related
costs (under Section 9.3), expenses associated with additional audits (under Section 10.9),
expenses for labeling revisions (under Section 10.10.2) and costs associated with de-installation
and restoration (under Sections 20.4, 20.5 and 20.6) and any other amounts owed to Baxter under
this Agreement, in United States dollars within thirty (30) days after the date of Baxter’s
invoice, by wire transfer in United States dollars, to a bank account designated in writing by
Baxter.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

12

 

Invoices not timely paid will be subject to a late payment charge of [***] per month, or
the highest amount permitted by law, if lower. Notwithstanding the foregoing, should Cadence give
Baxter a Deficiency Notice pursuant to Section 10.5, Cadence’s obligation to pay under this Section
7.4 shall be suspended until the Parties have mutually agreed upon a resolution of the deviation(s)
underlying any such Deficiency Notice.

8.0 API.

     8.1 General. Cadence will, at its cost, supply API to Baxter at Baxter’s manufacturing
facilities designated in the Development Plan, or such other manufacturing facilities as the
Parties may agree upon from time to time. API will be supplied timely, in adequate quantities to
enable Baxter to meet its obligations to develop and manufacture the Product in accordance with the
terms of this Agreement, all in conformance with the API Specifications set forth in Exhibit A, as
may be amended by Cadence from time to time. Baxter and Cadence will agree on appropriate
inventory levels for API and Product and Baxter will manage these inventory levels. Cadence will
retain title to the API while it is in Baxter’s possession. Baxter will not use the API supplied
by Cadence for any purposes other than pursuant to the terms of this Agreement.

     8.2 Change of API Source or API Manufacturing Process. Cadence will neither change its API
source nor any API Manufacturing Process unless and until such change is approved by the FDA and
all other Regulating Groups in the Territory for the Product. Cadence agrees to provide written
notice to Baxter of any proposed change no later than Cadence’s initial notice to the FDA or any
other Regulating Group. Following such written notice to Baxter, Baxter will timely undertake work
reasonably required to support Cadence’s filings with the FDA and other Regulating Groups in the
Territory to obtain approval for such change. Cadence will reimburse Baxter for all reasonable
costs incurred by Baxter directly related to Baxter work performed in support of such API source or
API Manufacturing Process change, including but not limited to the cost of new stability studies,
submissions to the FDA and any other Regulating Groups and return of unused (if any) API from the
prior source or manufactured under prior API Manufacturing Processes. Cadence will pay Baxter in
accordance with Sections 4.1.4 and 4.1.6 if such change occurs during the development phase and
Section 7.4 if such change occurs during the commercial phase. “API Manufacturing Process” is
defined as a process used in the manufacture of API of such a type that a change in such process
would require approval by the FDA or other Regulating Groups in the Territory in order to market,
sell and distribute the Product in the Territory.

     8.3 Risk of Loss of API. Subject to Section 12.2.1, Baxter will have the risk of loss or
damage to the API from the time the API is delivered to Baxter’s manufacturing facility
and during the storage thereof. In the event of loss or damage to the API during such period,
Baxter will immediately notify Cadence and Cadence will provide to Baxter API required for
replacement thereof at the actual replacement cost of the API paid by Cadence to its
supplier

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

13

 

including duty, freight and testing costs. Cadence will provide to Baxter appropriate
documentation evidencing such costs.

	 	8.3.1	 	If the loss or damage occurred other than during the
performance of the Normal Manufacturing Process, then Baxter shall pay Cadence
for such replacement API in an amount equal to the actual cost paid by Cadence
for such API, plus duty, freight and testing costs.
	 
	 	8.3.2	 	Per Section 8.4, if the loss or damage occurred during the
performance of the Normal Manufacturing Process, the amount of API lost or
damaged will be included in the annual yield loss calculation and a
determination will be made at the end of the relevant Contract Year as to what
amount, if any, is owed by Baxter to Cadence for such loss of API.
	 
	 	8.3.3	 	Notwithstanding the foregoing, Baxter shall not be required to
pay Cadence to replace reasonable amounts of API that are consumed in the
course of testing required for incoming receiving and inspection.
	 
	 	8.3.4	 	Baxter will pay amounts owed to Cadence under this Agreement,
including without limitation amounts owed under Sections 8.3.1 and 8.3.2, in
United States dollars within thirty (30) days after the date of Cadence’s
invoice, by wire transfer in United States dollars, to a bank account
designated in writing by Cadence. Invoices not timely paid will be subject to
a late payment charge of [***] per month, or the highest amount permitted by
law, if lower.

     8.4 Manufacturing Yield Losses. The actual yield loss percentage for each Contract Year shall
be calculated, reconciled, and agreed to by Cadence and Baxter within forty-five (45) days
following the end of the Contract Year. Baxter will be responsible for calculating actual yield
loss percentage as per the methodology set forth in Exhibit H which is being provided for
illustrative purposes. The Parties acknowledge and agree that any and all losses occurring other
than during the performance of the Normal Manufacturing Process or any loss due to improper
handling, storage or due to any negligence on the part of Baxter will not be included in the annual
yield loss calculation, but will be reimbursed to Cadence in accordance with Section 8.3.1.

9.0 EQUIPMENT

     9.1 Baxter Owned Equipment and Risk of Loss. All equipment supplied, owned or purchased by
Baxter, including equipment purchased by Baxter and paid for by Cadence as set forth in Exhibit E
(“Baxter Owned Equipment”) shall at all times remain the property of Baxter and Baxter assumes the
risk of loss of such property. Baxter hereby waives any and all rights of recovery against
Cadence, or against its directors, officers, employees,

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

14

 

agents or representatives, for any loss or damage to Baxter Owned Equipment, except if such loss or
damage is caused by Cadence’s gross negligence or willful misconduct.

     9.2 Cadence Owned Equipment and Risk of Loss. All equipment supplied, owned or purchased by
Cadence as set forth in Exhibit K (“Cadence Owned Equipment”) shall at all times remain the
property of Cadence and Cadence assumes the risk of loss of such property. Cadence hereby waives
any and all rights of recovery against Baxter, or against its directors, officers, employees,
agents or representatives, for any loss or damage to Cadence Owned Equipment, to the extent the
loss or damage is covered or could be covered by insurance (whether or not such insurance is
described in this Agreement), except if such loss or damage is caused by Baxter’s gross negligence
or willful misconduct. Baxter will use Cadence Owned Equipment only for activities directly
related to development and commercialization of Product under this Agreement, except as otherwise
agreed to in writing by Cadence.

     9.3 Maintenance-related Costs of Baxter Owned Equipment and Cadence Owned Equipment. Baxter
shall be responsible for maintaining the Cadence Owned Equipment consistent with its practices as
in effect from time to time with respect to Baxter’s manufacturing equipment. Baxter shall be
responsible for all maintenance-related costs for Baxter Owned Equipment. Baxter shall be
responsible for labor-related costs associated with the routine maintenance of Cadence Owned
Equipment. For Cadence Owned Equipment, Cadence shall be responsible and reimburse Baxter for all
costs other than such labor-related routine maintenance costs, including without limitation, the
costs associated with the purchase of spare parts, any labor-related costs incurred by a third
party and costs associated with extraordinary maintenance so long as such extraordinary maintenance
is not caused by Baxter’s failure to provide adequate routine maintenance, or Baxter’s gross
negligence or willful misconduct.

10.0 QUALITY MANAGEMENT

     10.1 Quality Agreement; Compliance with laws. Baxter and Cadence shall, as soon as possible
after the Effective Date but in all events within ninety (90) days following the Effective Date, in
good faith negotiate and execute a Quality Agreement concerning the Product and covering the
appropriate activities under this Agreement. Upon execution and delivery of the Quality Agreement
by both Cadence and Baxter, the Quality Agreement shall automatically become part of this
Agreement, as Exhibit G. In the event of a conflict between this Agreement and the Quality
Agreement with respect to any provisions that specifically relate to quality assurance matters, the
Quality Agreement shall govern or supersede. For clarity purposes, in the event of a conflict
between this Agreement and the Quality Agreement with respect to all other matters, this Agreement
shall govern or supersede. In performing their obligations under this Agreement, Baxter and
Cadence shall comply with any and all applicable provisions of the Quality Agreement and with all
applicable laws, rules and regulations.

     10.2 Changes to Product Specifications. Subject to Section 4.3, Cadence Product
Specifications may not be amended, changed or supplemented by Baxter without the prior written
consent of Cadence. Except as provided in Section 4.3, Cadence will give

15

 

Baxter not less than ninety (90) days advanced written notice of an intention to implement
voluntary changes in Product Specifications initiated by Cadence so that the Parties can
collaborate on a plan to implement any related changes required to meet such changed Product
Specifications in a timely and cost-efficient manner. For Product Specification changes mandated
by Regulating Groups, Baxter shall use Commercially Reasonable Efforts to expedite such changes
upon the request of Cadence. The allocation of the cost of manufacturing and facility changes
required as a result of a change in Product Specifications will be determined by agreement of the
Parties on a case-by-case basis as provided in Section 4.1.4 if such change occurs during the
development phase and Section 7.4 if such change occurs during the commercial phase. Baxter will
provide Cadence with all information needed to amend the Product NDA and other Regulatory
Submissions in the Territory as a result of any approved Product Specification change. Baxter will
continue to supply Cadence with Product approved under Cadence’s existing NDA and other Regulatory
Submissions until such time as the changed Product Specifications are permitted by each of the
applicable Regulating Groups in the Territory, except as the Parties otherwise agree by separate
written agreement.

     10.3 Changes to Drug Product Manufacturing Process. Changes to the Drug Product Manufacturing
Process (as defined below) will ultimately be governed by the Quality Agreement. Baxter will
discuss any proposed changes to the Drug Product Manufacturing Process with Cadence and obtain
approval for any associated change control plan prior to implementation of any development work to
qualify the change. Baxter will follow its established procedures for changes which are made to its
manufacturing process from Product mix to release and which relate to the manufacture of the
Product (“Drug Product Manufacturing Process”). Baxter will notify Cadence of all such
changes/revisions that require notice based on the Quality Agreement and Regulatory Documentation
as provided to Baxter or such changes/revisions that could reasonably be expected to have a
material effect on the Product. Baxter will obtain Cadence’s written approval prior to making any
such change or revision. Any such changes in the Drug Product Manufacturing Process will be done
at Baxter’s expense. Baxter will provide Cadence with all information needed to review and approve
any changes and that are necessary to amend the Product NDA and other Regulatory Submissions in the
Territory as a result of any approved Drug Product Manufacturing Process change. Baxter will
continue to supply Cadence with Product approved under Cadence’s existing NDA and other Regulatory
Submissions until such time as the Product manufactured under the changed process is permitted by
each of the applicable Regulating Groups in the Territory, except as the Parties otherwise agree by
separate written agreement. Notwithstanding the foregoing, in the event any changes to the Drug
Product Manufacturing Process are requested by Cadence, Baxter shall review the requested changes
and Cadence shall obtain Baxter’s written approval, prior to the implementation of any such
changes. The costs associated with any changes to the Drug Product Manufacturing Process requested
by Cadence shall be the responsibility of Cadence. All costs associated with any other changes to
the Drug Product Manufacturing Process shall be mutually determined by the Parties.

     10.4 Complaints and Adverse Event Reports. As between Baxter and Cadence, Cadence will be
solely responsible for the reporting to Regulating Groups of adverse experiences with respect to
the Product. Exhibit I sets forth certain specific provisions

16

 

regarding the handling of customer Product complaints and adverse experiences, including without
limitation adverse event or reaction reports or FDA “field alerts”.

     10.5 Non-Compliance of Product. Cadence will be responsible for reviewing batch documentation
for each batch of Product and for providing Baxter with authorization to ship such Product batch.
Cadence has the right to reject and return, at the expense of Baxter, all or any portion of any
shipment of Products that deviates from the Product Specifications or cGMPs, without invalidating
any remainder of such shipment. Cadence or its designated agent shall inspect the Products
manufactured by Baxter upon receipt of such Products and related Certificate(s) of Analysis and
shall give Baxter written notice (a “Deficiency Notice”) of all claims for Products that deviate
from the Product Specifications or cGMPs within thirty (30) days after Cadence’s receipt of such
Products and related Certificate(s) of Analysis (or, in the case of any defects not reasonably
susceptible to discovery upon receipt of the Product, within thirty (30) days after discovery
thereof by Cadence, but in no event after the expiration date of the Product). Should Cadence fail
to provide Baxter with the Deficiency Notice within the applicable thirty (30)-day period, then the
delivery shall be deemed to have been accepted by Cadence on the 30th day after delivery or
discovery, as applicable. Except as set out in Section 15.2, Baxter shall have no liability for
any deviations for which Cadence has failed to provide notice within the applicable 30-day period.

11.0 MARKETING

     11.1 General. The Parties will cooperate in a reasonable manner to support and facilitate the
sale of the Product in the Territory and communicate regularly to facilitate carrying out their
respective responsibilities.

12.0 REPRESENTATIONS AND WARRANTIES

     12.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the
other Party that, as of the Effective Date (i) this Agreement is legal and valid and the
obligations binding upon such Party are enforceable in accordance with their terms, subject to
bankruptcy, insolvency, moratorium, reorganization or similar laws affecting the rights of
creditors generally and the availability of equitable remedies, (ii) the execution, delivery and
performance of this Agreement does not conflict with any agreement, instrument or understanding,
oral or written, to which such Party may be bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency within the Territory having jurisdiction over
it, and (iii) the Party owns, controls, or has the right to grant to the other Party the licenses
and other rights to use the intellectual property it authorizes the other Party to use in carrying
out the objectives of this Agreement and the Party is not aware of any restrictions, limitations or
interests superior to the Party’s intellectual property rights which would prevent the other Party
from using such intellectual property in carrying out the objectives of this Agreement or which
would cause the other Party to infringe the rights of others. During the Term of the Agreement, if
a Party becomes aware of any events or circumstances that are reasonably likely to cause its
representations and warranties to be untrue, the Party will promptly provide the other Party with
written notice of such events or circumstances, including details

17

 

reasonably requested by the other Party in order to evaluate the impact of such events or
circumstances on this Agreement.

     12.2 Warranties of Cadence.

          12.2.1 API.

               12.2.1.1 General. Cadence represents, warrants and covenants that the API, when delivered to
Baxter hereunder, will, to the best of its knowledge after due inquiry (i) be manufactured, tested,
and packaged in accordance with applicable cGMP regulations and all applicable laws and regulations
of the FDA and other applicable Regulating Groups in the Territory; (ii) meet the API
Specifications; (iii) not be adulterated or misbranded within the meaning of the FD&C Act or any
similar laws or regulations of applicable Regulating Groups in the Territory; and (iv) not be an
article which may not be introduced into interstate commerce under the FD&C Act or any similar laws
or regulations of applicable Regulating Groups in the Territory. Cadence warrants that the Cadence
Owned Equipment (as set forth in Exhibit K) will perform according to its specifications when
operated by Baxter personnel according to documented procedures and the integration of the Cadence
Owned Equipment will not have an adverse impact on the Development Program.

               12.2.1.2 Replacement.

                    (a) In the event of non-acceptance by Baxter of any delivery of API due to its failure upon
inspection or testing by Baxter to meet Cadence’s warranties set forth in Section 12.2.1.1,
Cadence’s sole obligation and Baxter’s exclusive remedy will be limited to replacement of the API
(subject to the provisions of this Section).

                    (b) If, however, the failure of API to meet Cadence’s warranties is not discoverable upon
reasonable physical inspection and testing, but is identified by Baxter after storage and handling
by Baxter in accordance with the Product labeling and after activities utilizing API have commenced
under the Development Plan, then Cadence’s obligation will also include payment to Baxter of an
amount comparable to the Development Fees under Section 4.1.4 attributable to the development
activities that Baxter must repeat with non-defective API, or if during the commercialization
phase, after manufacturing activities utilizing API have commenced, payment to Baxter of the
Manufacturing Fee per unit of Product required to be replaced using non-defective API.

                    (c) Following notice from Baxter and at the direction of Cadence, Baxter will return the then
remaining defective API or Product that incorporates defective API or is otherwise non-compliant to
Cadence or, at Baxter’s option or if requested by Cadence, destroy the same or deliver it to a
third party qualified in such waste disposal. Cadence will bear the cost of any return of API,
Product or work-in-process, including freight and handling, and the costs of API, Product and/or
work-in-process destruction, if requested by Cadence. Cadence will, at its expense, replace
defective API as expeditiously as possible and pay Baxter for Product and work-in-process
incorporating defective API within thirty (30) days of receipt of Baxter’s detailed invoice
following completion of the designated return or destruction hereunder.

     12.3 Warranties of Baxter.

18

 

          12.3.1 General. Baxter represents, warrants and covenants that Product manufactured under
this Agreement, at the time of release at Baxter’s manufacturing facility (i) will be manufactured,
tested, and packaged in accordance with this Agreement, the Quality Agreement, applicable cGMP
regulations and all other applicable laws and regulations of the FDA and other applicable
Regulating Groups in the Territory; (ii) will meet the Product Specifications; (iii) will not be
adulterated or misbranded within the meaning of the FD&C Act or any similar laws or regulations of
applicable Regulating Groups in the Territory; and (iv) will not be an article which may not be
introduced into interstate commerce under the FD&C Act or any similar laws or regulations of
applicable Regulating Groups in the Territory. Notwithstanding the foregoing, this warranty will
not extend to the API or the Formulation, nor to Product labeling, and will not apply to the extent
Cadence has breached its warranty under Section 12.2.1.1.

          12.3.2 Facility. At all times during the Term of the Agreement, Baxter shall (i) perform
Baxter’s obligations under this Agreement in compliance with all applicable cGMP regulations and
all other applicable laws and regulations of the FDA and other applicable Regulating Groups in the
Territory; (ii) use Commercially Reasonable Efforts to protect and maintain the Cadence Owned
Equipment; and (iii) maintain sufficient expertise, with respect to personnel and equipment, to
fulfill the obligations of Baxter established hereunder.

          12.3.3 Product. Baxter represents, warrants and covenants that (i) Baxter or its Affiliate
shall transfer to Cadence good and marketable title to the Products free from any and all liens,
mortgages or encumbrances of any kind; (ii) all Product manufactured and supplied to Cadence under
this Agreement shall have a shelf life of no less than [***]; and (iii) Baxter shall use
Commercially Reasonable Efforts to supply Product under this Agreement with a shelf life of no less
than [***]. Such shelf life shall be measured against the month of expiration that is imprinted on
the label at the time of manufacture. Baxter further represents, warrants and covenants that all
batches of the Product shall be made available by Baxter for pick-up by Cadence or its designee
promptly. For purposes of this Section 12.3.3, “date of its release” shall mean the date the
Product is approved by Baxter quality control as evidenced by the issuance of a certificate of
compliance.

          12.3.4 Debarred Persons. Baxter covenants that it will not in the performance of its
obligations under this Agreement use the services of any person debarred or suspended under 21
U.S.C. §335(a) or (b).

          12.3.5 Cadence Licensed Intellectual Property. Baxter acknowledges and agrees that (A) it has
been informed that Product is to be made subject to the Cadence Licensed Intellectual Property, and
(B) that it will only manufacture Product for the benefit of Cadence and its sublicensees.

          12.3.6 Replacement. Baxter’s sole obligation and Cadence’s exclusive remedy for breach of
Baxter’s warranties set forth in Sections 12.3.1 through 12.3.4, other than if such breach is
caused by the gross negligence or intentional misconduct of Baxter, will be

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

19

 

limited to replacement of the Product and including reimbursement of Cadence’s actual costs
associated with any recall or marketing withdrawal of the Product. Following Baxter’s notice to
Cadence that additional API will be required to replace defective Product, Cadence will promptly
provide to Baxter API necessary for replacement of such Product. Cadence will provide to Baxter
appropriate documentation evidencing the actual replacement cost of the API paid by Cadence to its
supplier including duty, freight and testing costs. Notwithstanding the foregoing, Baxter will pay
no more for the additional API than Cadence’s actual costs for the replacement API, plus duty,
freight and testing costs.

     12.4 Limitation of Warranties. NEITHER PARTY MAKES ANY OTHER EXPRESSED OR IMPLIED WARRANTY
EXISTS, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND EACH
PARTY EXPRESSLY DISCLAIMS ANY SUCH WARRANTIES. Except as provided in Section 15.0, or as otherwise
expressly stated in this Agreement, neither Party will be liable to the other Party for any
proximate, indirect, incidental or consequential damages arising from a breach of warranty under
this Agreement.

13.0 CONFIDENTIALITY

     13.1 Pre-Existing Confidentiality Agreement. The Parties have previously signed a
Confidentiality Agreement effective April 11, 2006, a copy of which is attached to this Agreement
as Exhibit J, to cover the exchange of confidential information and materials relating to [***].

     13.2 Confidentiality. Any Confidential Information of the Parties exchanged hereunder shall be
governed by, and shall be maintained in confidence pursuant to, the confidentiality provisions set
forth in the Confidentiality Agreement.

     13.3 Exceptions. In addition to the exceptions set forth in the Confidentiality Agreement,
Cadence may provide a copy of this Agreement and all its exhibits and amendments to the licensors
of the Cadence Licensed Intellectual Property, Bristol-Myers Squibb Company and SCR Pharmatop;
provided, however, that Cadence will redact all terms related to confidential financial
information, and shall request of such licensors of the Cadence Licensed Intellectual Property the
ability to redact other terms as reasonably requested to be redacted by Baxter prior to providing
such documents to licensors of the Cadence Licensed Intellectual Property.

     13.4 Publicity and SEC Filings. The Parties agree that any public announcement of the
execution of this Agreement shall only be by one or more press releases mutually agreed to by the
Parties. The failure of a Party to return a draft of a press release with its proposed amendments
or modifications to such press release to the other Party within five (5) days of such Party’s
receipt of such press release shall be deemed as such Party’s approval of such press release as
received by such Party. Unless the prior written consent of the other Party is obtained, no Party
shall, except as may be required by law or regulations (including without limitation any United
States Securities and Exchange Commission filings required) in any manner disclose or advertise or
publish or release for publication any statement mentioning the other Party or information
contained in or acquired pursuant to this Agreement, or the fact that any Party has
furnished or contracted to furnish the other Party the items required by this Agreement, or quote

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

20

 

the opinion of any employee of the other Party. In the event Cadence proposes to file with the
Securities and Exchange Commission or the securities regulators of any state or other jurisdiction
a registration statement or any other disclosure document which describes or refers to this
Agreement under the Securities Act of 1933, as amended, the Exchange Act, or any other applicable
law relating to securities matters, Cadence shall notify Baxter of such intention and shall provide
Baxter with a copy of relevant portions of the proposed filing not less than five (5) Business Days
prior to such filing (and any revisions to such portions of the proposed filing a reasonable time
prior to the filing thereof), including any exhibits thereto relating to this Agreement, and shall
use reasonable efforts to obtain confidential treatment of any information concerning this
Agreement that Baxter requests be kept confidential, and shall only disclose Confidential
Information which it is advised by counsel or the Securities and Exchange Commission is legally
required to be disclosed. No such notice shall be required under this Section 13.4 and each Party
may disclose any previously disclosed information if the substance of the description of or
reference to this Agreement contained in the proposed filing or disclosure has been included in any
previous filing made by either Party hereunder or otherwise approved by the other Party. Baxter may
communicate to investors information to the extent made public by Cadence.

     13.5 Survival. The obligations under this Section 13 will extend for the longer of the term
of this Agreement or [***].

14.0 INTELLECTUAL PROPERTY

     14.1 Ownership of Inventions.

          14.1.1 Ownership of Background Intellectual Property Rights. Ownership of Background
Intellectual Property Rights will remain in the Party owning them on the Effective Date of this
Agreement.

          14.1.2 Cadence Ownership. The entire right, title and interest in all discoveries, inventions
and improvements which are conceived or reduced to practice during the course of the work being
performed pursuant to this Agreement (i) solely by Cadence or its employees, agents or other
representatives; or (ii) by Baxter or its employees, agents or other representatives (alone or
jointly with one or more Cadence employees, agents or representatives) useful only in connection
with the Compound, the Product and/or the Formulation (the “Cadence Inventions”) will be owned
solely by Cadence.

          14.1.3 Baxter Ownership. The entire right, title and interest in all discoveries, inventions
and improvements which are conceived or reduced to practice during the course of work being
performed pursuant to this Agreement solely by Baxter or its employees, agents or other
representatives, other than Cadence Inventions and Joint Inventions (the “Baxter Inventions”) will
be owned solely by Baxter, subject to Sections 14.2.2 and 14.3.

          14.1.4 Joint Ownership. Subject to Sections 14.1.2 and 14.1.3, the entire right, title and
interest in all discoveries, inventions and improvements which are
conceived or

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

21

 

reduced to practice during the course of the work being performed pursuant to this Agreement
jointly by (i) Cadence or its employees, agents or other representatives and (ii) Baxter or its
employees, agents or other representatives (the “Joint Inventions”) will be jointly owned by
Cadence and Baxter, each of which will own an undivided one-half (1/2) interest in such invention,
subject to Sections 14.2.2 and 14.3. Each Party will cooperate with the other in completing any
patent applications relating to Joint Inventions, and in executing and delivering any instrument
required to assign, convey or transfer to each Party its undivided one-half (1/2) interest.

          14.1.5 Assignment of Ownership Rights. All employees, consultants, subcontractors and agents
performing services for a Party under this Agreement shall have assigned in writing to such Party
all of their right, title and interest in, to and under any and all discoveries, inventions and
improvements directly related to the Product so as to effectuate the provisions of this Article 14.

     14.2 Reports: Information Developed During Project.

          14.2.1 Content of Reports. Baxter will provide to Cadence reports containing the data, test
results, and specifications or procedures for the Product developed specifically for the Compound
and/or the Formulation (“API/Formulation Specifications”), all as described in detail under the
heading “Reports” in the Development Deliverables set forth in Exhibit B The Reports may also
contain references to (i) pre-existing Baxter standard operating procedures, specifications,
material codes and their specifications, and other information developed by Baxter prior to the
execution of this Agreement, but not including any such procedures, specifications, material codes
and their specifications or other information developed by Baxter in its Grosotto facility and
which is owned or licensed to the licensor of Cadence Licensed Intellectual Property (“Pre-Existing
Specifications”) that fall within Baxter Background Intellectual Property Rights and (ii) original
laboratory notebooks and other Good Laboratory Practices documentation generated by Baxter or its
agents pursuant to this Agreement (“Original Product Data.”).

          14.2.2 Ownership of Reports and Contents. The Reports, the Original Product Data solely as it
relates to the Product, and the data, test results, and API/Formulation Specifications therein,
will become the property of Cadence and will be treated as Cadence’s Confidential Information and
be subject to the provisions of Section 13.0 of this Agreement. For the avoidance of doubt, the
Reports, data, test results and API/Formulation Specifications will become the property of Cadence
even if they constitute Baxter Inventions under Section 14.1.3 or Joint Inventions under Section
14.1.4, subject to the Cadence Product License granted to Baxter under Section 14.3.1.
Pre-Existing Specifications, Baxter Background Intellectual Property Rights, as well as Original
Product Data (other than as it relates to the Product), will remain the property of Baxter and will
constitute Baxter’s Confidential Information and be subject to the provisions of Section 13.0 of
this Agreement, subject to the Baxter License under Section 14.3.2.

          14.2.3 Archiving of Reports. In accordance with Section 10.11, Baxter will retain the
original Reports and Original Product Data for archival purposes.

22

 

     14.3 Licenses.

          14.3.1 To Baxter From Cadence. Cadence hereby grants to Baxter a nonexclusive, royalty-free
license, with a right to sublicense solely to a Baxter Affiliate, to make the Product in the
Territory under Cadence Background Intellectual Property Rights, Cadence Licensed Intellectual
Property, Cadence Inventions and Joint Inventions (the “Cadence Product License”), only to the
extent necessary for Baxter to fulfill Baxter’s obligations under this Agreement. The Cadence
Product License shall be subject and subordinate to the IV APAP Agreement and the Pharmatop License
Agreement. BMS shall be an express third party beneficiary of Baxter’s obligations under the
Cadence Product License that relate to compliance with the terms and conditions of the IV APAP
Agreement with the express right to enforce the same directly against Baxter. Cadence shall
provide Baxter with the text of any amendment or restatement of either the IV APAP Agreement or the
Pharmatop License Agreement within fourteen (14) days after the effective date of such amendment or
restatement; provided, however, that Cadence may redact the text to delete confidential information
solely to the extent such confidential information does not alter the scope of either Party’s
rights under this Agreement. The Cadence Product License shall terminate immediately upon the
termination of the sublicense or license from BMS to Cadence with respect to such right, but
Cadence must provide prompt notice of such termination to Baxter. Cadence shall indemnify Baxter
against any claim of infringement, misappropriation or unauthorized use of Cadence Licensed
Intellectual Property to the extent such claim arises from Baxter’s use of Cadence Licensed
Intellectual Property after termination of the Cadence Product License but before Baxter received
actual notice of such termination.

          14.3.2 To Cadence From Baxter. Baxter hereby grants to Cadence (a) a nonexclusive,
royalty-free, license in the Territory, with a right to sublicense to Cadence Affiliates, licensors
of Cadence Licensed Intellectual Property and, with Baxter’s prior written consent, not to be
unreasonably withheld, conditioned or delayed, Cadence sublicensees, to make, have made, use, sell,
offer for sell and import the Product under Baxter Background Intellectual Property, only to the
extent that such Baxter Background Intellectual Property is actually used in the manufacture of the
Product under this Agreement; and (b) an exclusive, royalty-free, worldwide license, with a right
to sublicense to Cadence Affiliates, licensors of Cadence Licensed Intellectual Property and, with
Baxter’s prior written consent, not to be unreasonably withheld, conditioned or delayed, Cadence
sublicensees, to make, have made, use, sell, offer for sale and import the Product under all Baxter
Inventions and Baxter’s interest in all Joint Inventions, each only to the extent actually used in
connection with the Compound, the Product and/or the Formulation (collectively (a) and (b) of this
Section 14.3.2 shall be known as the “Baxter License”). The license set forth in subsection (b) of
the immediately preceding sentence shall be exclusive, even as to Baxter, only to the extent such
Baxter Inventions and Joint Inventions are actually used in connection with the Compound, the
Product and/or the Formulation. Baxter shall retain full rights to exploit such Baxter Inventions
and Joint Inventions (i) for the purpose of performing its obligations under this Agreement and
(ii) to the extent such Baxter Inventions and Joint Inventions are not used in connection with the
Compound, the Product and/or the Formulation. The license set forth in subsection (b) hereof shall
become nonexclusive, and all sublicenses under the Baxter License (except for sublicenses
 

23

 

to Cadence Affiliates and licensors of Cadence Licensed Intellectual Property) shall terminate,
immediately upon the termination of this Agreement, the IV APAP Agreement or the Pharmatop License
Agreement. Notwithstanding the foregoing, the Baxter License shall survive if this Agreement is
terminated by Cadence pursuant to Sections 19.2.1.2 or 19.2.1.3.

          14.3.3 Pre-Existing Specifications and Original Product Data. Baxter will (i) make
Pre-Existing Specifications referenced in the Reports and Original Product Data available to
Regulating Groups as directed by such Regulating Groups and as provided in Section 5.0, and (ii)
upon Cadence’s reasonable request, provide copies of Pre-Existing Specifications referenced in the
Reports and relevant portions of Original Product Data (but excluding data or information which is
unrelated to the Product) to Cadence for Cadence’s use in Regulatory Submissions outside the United
States if (a) pursuant to Section 5.0 such information is reasonably required for Cadence’s
Regulatory Submission for the Product in the Territory and (b) Cadence agrees to treat all such
information (other than as it relates to the Product and which is owned by Cadence under this
Agreement) as Baxter’s Confidential Information under the provisions of Section 13.0.

     14.4 Patents.

          14.4.1 Patent Filings on Solely-Owned Inventions. Each Party will, in its sole discretion,
prepare, file, prosecute and maintain Patent Applications for inventions as to which it has sole
ownership under Sections 14.1 and 14.2 above and will be responsible for related interference
proceedings. Each Party will endeavor to ensure whenever possible that claims are filed and
prosecuted in such Patent Applications specifically directed to the Field. At least thirty (30)
days prior to the contemplated filing date, each Party responsible for preparing a Patent
Application will submit to the other Party a substantially completed draft of such Patent
Application. Each Party will bear all costs under this Section for inventions as to which it has
sole ownership. Each Party will cooperate with the other Party’s perfection of filings.

          14.4.2 Joint Inventions and Patent Filings. With respect to all Patent Applications on Joint
Inventions (“Joint Patent Applications”), Baxter will prepare and file Joint Patent Applications
and will diligently prosecute and maintain same. At least thirty (30) days prior to the
contemplated filing, Baxter will submit a substantially completed draft of all such Joint Patent
Applications to Cadence for its approval. As to claims contained in any Joint Patent Application
directed to the Field, Cadence shall have the right to comment and to have any such reasonable
comments incorporated into the claims included in such Joint Patent Application prior to filing.
If the parties are unable to resolve any differences regarding the claim language directed to the
Field, the matter will be handled pursuant to Section 16.0 of this Agreement. As to claims
contained in any Joint Patent Applications directed outside the Field, Baxter will confer with
Cadence and shall in good faith consider adopting Cadence’s suggestions regarding the prosecution
of such claims included in the Joint Patent Applications after taking into account the interests of
Cadence and its licensors and sublicensees under the Joint Patent Applications. The Parties will
share equally the costs of the preparation, filing, prosecution and maintenance of any Joint Patent
Applications and will share equally the costs of any related interference proceedings. Baxter will
copy Cadence with any official actions and submissions in such Joint Patent Applications. If
either Party elects not to pay its portion of any shared costs for a Joint Patent

24

 

Application, the other Party may proceed with such Joint Patent Application in its own name and at
its sole expense, in which case the Party electing not to pay its share of costs will assign its
entire right, title and interest in and to such Joint Patent Application to the other Party. Any
such election and related assignment shall be on a jurisdiction-by-jurisdiction basis.

               14.4.3 Public Disclosure. Each Party agrees to delay any public disclosure of the subject
matter of any Patent Application until after filing of such Patent Application, but in no event
less than one hundred eighty (180) days after notice to the other Party of the intent to disclose
such subject matter.

     15.0 INDEMNIFICATION

          15.1 Indemnification By Cadence. Cadence, on its own behalf, and on behalf of its Affiliates,
will defend, indemnify and hold harmless Baxter and its Affiliates, and their respective directors,
officers, shareholders, employees and agents, and each of their successors and permitted assigns,
from and against any and all third party claims, actions, causes of action, liabilities, losses,
damages, costs or expenses, and resulting settlements, awards or judgments, including reasonable
attorneys’ fees (“Damages”), which arise out of or relate to (i) the failure of API provided by
Cadence hereunder to meet the warranties set forth in Section 12.2.1; (ii) a breach by Cadence of
any of its other representations, warranties, covenants, agreements or obligations under this
Agreement; (iii) the negligence or willful misconduct of Cadence in the performance or
nonperformance of any of Cadence’s obligations under this Agreement; (iv) personal injury or
property damage caused by the Product at any time before or after first commercial sale (except to
the extent covered by Baxter’s indemnification obligations set forth in Section 15.2); or (v) any
patent, trade name, trademark, service mark or copyright infringement, or any claim or judgment of
such infringement thereof, relating to the Formulation or API supplied by Cadence, or to the
Product (except to the extent covered by Baxter’s indemnification obligations pursuant to Section
15.2), or the intellectual property licensed to Baxter under Section 14.3.1, or the use or printing
of any trademark(s), trade names or copyrightable materials of Cadence or its Affiliates, as
authorized by this Agreement.

          15.2 Indemnification By Baxter. Baxter, on its own behalf, and on behalf of its Affiliates,
will defend, indemnify and hold harmless Cadence and its Affiliates, and their respective
directors, officers, shareholders, employees and agents, and each of their successors and permitted
assigns, from and against any and all Damages which arise out of or relate to (i) the failure of
Product provided by Baxter hereunder to meet the warranties set forth in Section 12.3; (ii) a
breach by Baxter of any of its other representations, warranties, covenants, agreements or
obligations under this Agreement; (iii) the negligence or willful misconduct of Baxter in
manufacturing Product or in the performance or nonperformance of any of Baxter’s obligations under
this Agreement; or (iv) any patent, trade name, trademark, service mark or copyright infringement,
or any claim or judgment of such infringement thereof, relating to the manufacturing processes or
equipment used by Baxter to manufacture the Product (excluding the Cadence Owned Equipment (as set
forth in Exhibit K) and further except to the extent covered by Cadence’s indemnification
obligations pursuant to Section 15.1), or the intellectual property licensed to Cadence under
Section 14.3.2, or the use of any trademark(s), trade names or

25

 

copyrightable materials of Baxter or its Affiliates, as authorized by this Agreement.

     15.3 Notice; Procedure. The indemnified Party will give the indemnifying Party prompt written
notice of any claim, proceeding or suit for which it seeks indemnification under Sections 15.1 or
15.2 (hereafter, a “Matter”). The indemnifying Party will have fifteen (15) business days after
receipt of the indemnified Party’s notice to notify the indemnified Party that the indemnifying
Party elects to conduct and control the defense of such Matter. If the indemnifying Party does not
give the foregoing notice, the indemnified Party will have the right to defend or settle such
Matter in the exercise of its exclusive discretion, and the indemnifying Party will, upon request
from the indemnified Party, promptly pay to it in accordance with Sections 15.1 or 15.2, as the
case may be, the amount of any Damages resulting from such Matter. Except in the event of a
conflict of interest between the indemnified Party and the indemnifying Party, if the indemnifying
Party gives the foregoing notice, the indemnifying Party will have the obligation to
undertake, conduct and control, through counsel of its own choosing and at the sole expense of the
indemnifying Party, the conduct and control of the defense and any settlement of such Matter and
the indemnified Party will cooperate with the indemnifying Party in connection therewith; provided
that: (a) the indemnifying Party will not thereby permit any lien, encumbrance or other adverse
charge upon any asset of the indemnified Party; (b) the indemnifying Party will permit the
indemnified Party to participate in the defense or settlement through counsel chosen by the
indemnified Party, but the fees and expenses of such counsel will be borne by the indemnified Party
except as provided in clause (c) below; (c) the indemnifying Party will agree to reimburse promptly
under Sections 15.1 or 15.2, as the case may be, the indemnified Party for the full amount of any
liabilities, losses, damages, costs and expenses, including reasonable attorney’’ fees, resulting
from the Matter, except for any fees and expenses of counsel for such indemnified Party incurred
after the assumption of the conduct and control of such Matter by the indemnifying Party; and (d)
the indemnifying Party will not settle or otherwise resolve any Matter without prior notice to the
indemnified Party and the consent of the indemnified Party (which consent shall not be unreasonably
withheld, conditioned or delayed). So long as the indemnifying Party is contesting any Matter in
good faith, the indemnified Party will not pay or settle any such Matter; except that such
indemnified Party will have the right to pay or settle any such Matter but in so doing such
indemnified Party will be deemed to have waived any right to indemnity therefore by the
indemnifying Party under Section 15.1 or 15.2, as the case may be.

     In the event that the indemnified Party reasonably believes that there exists a substantial
conflict of interest with the indemnifying Party, then the indemnified Party will give the
indemnifying Party notice of such conflict of interest and the indemnifying Party will not have the
right or obligation to undertake, conduct and control the defense or settlement of any Matter and
the indemnified Party will have the right to defend or settle such Matter in the exercise of its
exclusive discretion; provided that the indemnifying Party (a) will not thereby permit any lien,
encumbrance or other adverse charge upon any asset of the indemnified Party; and (b) will not
settle or otherwise resolve any Matter without prior notice to the indemnified Party and the
consent of the indemnified Party (which consent shall not be unreasonably withheld, conditioned or
delayed). In such event, the indemnifying Party will, upon request from the indemnified Party,
promptly pay to it in accordance with Section 15.1 or 15.2, as the case may be, the amount of any
liabilities, losses, damages and expenses, including reasonable attorneys’ fees, resulting from
such claim, proceeding or suit.

26

 

     15.4 No Claim for Losses. In no event will either Party or their respective Affiliates be
liable for any special, indirect, incidental or consequential damages arising out of this
Agreement.

     15.5 Insurance. Baxter is self-insured for the types of liabilities for which indemnification
by Baxter is likely to arise under Section 15.2. Prior to commercial launch of the Product,
Cadence will obtain and keep in force at its sole expense during the Term of the Agreement, the
following insurance covering Cadence and its agents, employees, representatives and subcontractors:
(i) Comprehensive or Commercial General Liability in an amount not less than [***] dollars
($[***]) each occurrence combined single limit for bodily injury and property damage for products
completed operations (including vendors coverage), blanket contractual liability, personal injury
and independent contractors protective insurance, which name Baxter as an additional insured and
require at least thirty (30) days written notice to Baxter prior to any cancellation, non-renewal
or material change in coverage. Cadence will provide Baxter with a certificate of insurance
evidencing compliance with this insurance obligation.

16.0 ALTERNATE DISPUTE RESOLUTION

The Parties will attempt to settle any claim or controversy arising out of this Agreement through
good faith negotiations and in the spirit of mutual cooperation. Any issues that cannot be
resolved by the Senior Executives as set forth in Section 3.2 or any other issues between the
Parties will be referred to the Chief Executive Officer of Cadence and the General Manager of
Baxter’s BioPharma Solutions business (the “Executive Officers”) to resolve the dispute. In the
event such Executive Officers cannot resolve the dispute, the dispute will be mediated by a
mutually acceptable mediator to be chosen by the Parties within thirty (30) days after written
notice by the Party demanding mediation. Neither Party may unreasonably withhold consent of the
selection of the mediator and the Parties will share the costs of the mediation equally. The
Parties may agree to replace mediation with some other form of Alternative Dispute Resolution
“ADR”), such as neutral fact-finding or a mini-trial. Any dispute which cannot be resolved by the
Parties through mediation or another form of ADR within one hundred and ninety (90) days of the
date of the initial written demand for mediation may then, and only then, be submitted to the
Federal or state courts, as appropriate, for resolution. Nothing in this Section will prevent
either Party from resorting to judicial process if (i) good faith efforts to resolve the dispute
under these procedures have been unsuccessful or (ii) injunctive relief from a court is necessary
to prevent serious and irreparable injury to one Party or to others.

17.0 FORCE MAJEURE

     17.1 General. Neither Party will be liable, or deemed in breach of its obligations under this
Agreement, for a delay in performance or nonperformance as the result of an act of governmental
authority, war, acts of terrorism, riot, fire, explosion, hurricane, flood, strike, lockout, or
injunction; inability to obtain fuel, power, raw materials, labor, Containers, plastic film or
components, or transportation facilities; accident, breakage of machinery or apparatus

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

27

 

solely to the extent not caused by such Party’s negligence or willful misconduct; or any other
cause beyond its reasonable control preventing the manufacture, shipment, or acceptance, of the
Product, or any component thereof (“Force Majeure”) provided that the affected Party (i) promptly
notifies the other Party of the Force Majeure event as provided in Section 17.2, (ii) uses
reasonable diligence and efforts to remedy the situation if reasonably capable of being remedied by
that Party, (iii) continues performance of its obligations to the extent the Force Majeure event
permits, and (iv) resumes performance of its obligations delayed by Force Majeure events as soon as
possible. This requirement that any Force Majeure be remedied with all reasonable dispatch will
not require settlement of strikes or labor controversies by acceding to the demands of the opposing
parties in such strikes or labor controversies.

     17.2 Notice. A Party affected by Force Majeure will promptly notify the other explaining the
nature, details, and expected duration thereof. The affected Party will advise the other Party
from time to time as to progress in remedying the situation and as to the time when the affected
Party expects to resume its obligations and will notify the other Party as to the expiration of any
Force Majeure as soon as the affected Party knows the date thereof. If a Party anticipates that a
Force Majeure is reasonably likely to occur, that Party will notify the other Party as soon as
practicable, explaining the nature, details, and expected duration thereof.

18.0 RELATIONSHIP OF THE PARTIES

     It is expressly acknowledged and agreed that Baxter and Cadence will be independent
contractors and that the relationship between the two Parties will not constitute a partnership,
joint venture or agency. Neither Party, nor its agents or employees, will be deemed agents or
representatives of the other Party. Neither Party will have the right to enter into any contracts
or commitments in the name of or on behalf of the other Party, without the prior written consent of
the other Party to do so. Nothing herein will be construed as granting any license or right under
any patent or trademark right of either Party, by implication or otherwise, to the other except as
expressly provided herein.

19.0 TERM AND TERMINATION

     19.1 Term and Expiration. This Agreement will be effective as of the Effective Date and will
terminate at the end of the 5th Contract Year (“Initial Term”), unless terminated
earlier as herein provided (“Term of the Agreement”). “Contract Year” is defined as (i) the twelve
(12) month period beginning with the month in which the first regulatory approval of the Product by
a Regulating Group in the Territory (including price approval if applicable in the jurisdiction in
the Territory) is received by Cadence and (ii) each successive twelve (12) month period.

          19.1.2 Automatic Renewal. Upon expiration of the Initial Term, this Agreement will
automatically renew thereafter for consecutive one (1) year terms on each successive annual
anniversary of the Contract Year unless either Party, by not less than two (2) years prior written
notice to the other Party, signifies by such notice its intention to terminate this Agreement upon
the expiration of the applicable Contract Year. By way of clarification, if either Party desires
that this Agreement terminate at the end of the Initial Term, the Party must give

28

 

written notice before the first day of the fourth Contract Year.

     19.2 Early Termination

          19.2.1 Termination by Either Party. Either Party may terminate this Agreement as follows:

               19.2.1.1 effective immediately upon the giving of written notice, if approval of the Product’s
NDA is not received within [***] months from the Effective Date;

               19.2.1.2 effective ninety (90) days after written notice given by the non-breaching Party of a
material breach of this Agreement by the other Party, if such breach is not cured within ninety
(90) days of receipt of such notice containing details of such breach (or such additional time as
is reasonably necessary to cure such breach provided the breaching Party has commenced a cure
within the ninety (90) day period and is diligently pursuing completion of such cure); or

               19.2.1.3 effective immediately upon written notice given by the non-bankrupt Party, if the
other Party files a petition in bankruptcy, or is adjudicated a bankrupt, becomes insolvent, makes
an assignment for the benefit of creditors, is voluntarily or involuntarily dissolved, or has a
receiver, trustee or other court officer appointed for its property.

               19.2.1.4 effective immediately upon written notice by either Party to the other Party if the
Parties are unable to reach agreement following good faith negotiations as described in Section
4.4, if there is a Technical Failure or an Integration Failure; provided, however, that termination
under this Section 19.2.1.4 shall in no event be effective earlier than [***] from the Delivery
Date.

          19.2.2 Termination by Cadence. In the event that Baxter does not agree to the assignment by
Cadence of this Agreement or any of Cadence’s rights or obligations hereunder to a competitor (as
such term is defined in Section 23.1.3, below) of Baxter, Cadence may terminate this Agreement,
effective thirty (30) days after giving written notice to Baxter, subject to Cadence’s fulfillment
of its Minimum Purchase Requirement obligations as set forth in Section 6.1.2.

20.0 EFFECTS OF TERMINATION

     20.1 Payments. Termination will not relieve or release either Party from making any payments
which may be due and owing under the terms of this Agreement.

     20.2 Pre-Commercial Activities. Without limiting the generality of Section 20.1, Cadence will
pay Baxter for any Pre-Commercial Activities performed by Baxter (as defined under the LOI) prior
to the effective date of termination hereunder, including all reasonable expenditures made by
Baxter in accordance with the terms of this Agreement for facility improvements and purchases of
capital equipment, including any non-cancelable expenditures

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

29

 

which are outstanding as of the date of termination of this Agreement.

     20.3 Disposal of API or Product. Upon termination of this Agreement, Baxter will promptly
return all then remaining API to Cadence, or if requested by Cadence and at Baxter’s option,
destroy such API or deliver it for destruction to a third party qualified in such waste disposal.
Return or destruction of API will be at Cadence’s expense if termination of the Agreement arises
under Section 19.2.1.1 (failure of Product NDA to timely issue). Return or destruction of API will
be at the other Party’s expense if termination is initiated by a Party pursuant to Sections
19.2.1.2 through 19.2.1.4 due to an act or omission of such other Party. Product shall be returned
to Cadence promptly at Cadence’s expense and Cadence shall take delivery of and pay for all
undelivered Products that are manufactured and/or packaged pursuant to a Firm Order, at the price
in effect at the time the Firm Order was placed; provided that no such payment shall be due from
Cadence if this Agreement is terminated by Cadence pursuant to Section 19.2.1.2 or 19.2.1.3,
including, but not limited to, termination for Baxter’s failure to provide sufficient quantities
Products in accordance with the Product Specifications and cGMPs; or failure to provide such
Products in a timely manner. If Cadence is responsible for the expense of disposition of API,
Product, or work-in-process, Cadence will pay Baxter all reasonable amounts due Baxter under this
Section within thirty (30) days of receipt of Baxter’s detailed invoice following completion of the
designated return or destruction.

     20.4 De-Installation Costs of Cadence Owned Equipment. Cadence shall be entitled to physical
possession of the Cadence Owned Equipment. Cadence agrees to reimburse Baxter for all reasonable
costs incurred in the de-installation of Cadence Owned Equipment which includes without limitation
the removal, crating and transportation or shipping of Cadence Owned Equipment from Baxter’s
manufacturing facility to a location specified by Cadence.

     20.5 Restoration Costs of Baxter’s Facility. Cadence agrees to reimburse Baxter for all
reasonable costs incurred in the restoration of Baxter’s manufacturing facility to its
pre-installation condition, as set forth in Section 20.6, including, the repair of any damage to
the manufacturing facility caused by or resulting from the removal of the Cadence Owned Equipment,
despite the exercise of reasonable care.

     20.6 De-installation, Removal and Restoration Activities. The de-installation, removal and
restoration activities shall be conducted in a manner that is not unreasonably disruptive to, and
does not impose unreasonable burdens on Baxter or its operations at its manufacturing facility.
Baxter shall provide Cadence with a written estimate of the cost of (i) such disassembly, crating
and removal (ii) the disconnection of any and all connections to the Cadence Owned Equipment
including without limitation electrical, air piping, conduits, dust collecting ducts, in a manner
which preserves in all material aspects the integrity of the structures and fixtures of Baxter’s
facility, and (iii) the restoration of the facility to a “four wall” condition, including the
repair of any damage to the facility, which despite the exercise of reasonable care, was caused by
or resulted from the removal of the machinery, equipment and any other fixed assets. Cadence shall
be responsible for arranging for all transportation and shipping of the Cadence Owned Equipment
being transferred from Baxter’s facility to Cadence’s location, including the timely application in
its own name of any required licenses, permits or any other governmental authorization required to
transfer the Cadence Owned Equipment.

30

 

     20.7 Technology Transfer. Upon the request of Cadence at any time during the Term of the
Agreement, Baxter shall cooperate in the technology transfer of the manufacture of the Products to
a third-party supplier/manufacturer selected by Cadence in its sole discretion. In furtherance of
the technology transfer, Baxter shall make its employees and other internal resources reasonably
available to Cadence and the designated third-party supplier/manufacturer and provide copies of all
technology, documents, data and other information solely related to the Cadence Product License and
the Baxter License. Any such third-party supplier/ manufacturer that Cadence may designate to
manufacture the Products shall be required to sign a customary and appropriate confidentiality
agreement with Baxter with respect to the nondisclosure and the appropriate and limited use of any
Baxter Confidential Information transferred hereunder. With respect to all documents, data and
other information provided in connection with this Section 20.7, (i) Baxter shall be responsible
for the cost of providing a single copy only; and (ii) in addition to paper and other tangible
copies, Baxter shall, upon Cadence’s request, also provide to Cadence and/or the third-party
supplier/manufacturer electronic copies of such documents, data and other information, provided,
that, Baxter or its Affiliates have electronic copies thereof, and provided, further, that Baxter
shall have no obligation to reformat or otherwise alter or modify any such electronic materials.
Notwithstanding the foregoing, this Section 20.7 shall not be construed to give any other
manufacturer, whether or not a competitor of Baxter, access to Baxter’s manufacturing facility,
information in Baxter’s Drug Master File [***], or right of reference to the Drug Master File.
Cadence shall reimburse Baxter for its reasonable costs associated with the transfer of technology
contemplated by this Section 20.7. At the time of the requested technology transfer, Cadence and
Baxter shall discuss the feasibility and costs associated with Baxter providing to Cadence, in
connection with such technology transfer, access to Baxter employees or consultants to facilitate
the technology transfer.

     20.8 Baxter Non-Compete Obligation. Baxter hereby agrees that neither it nor any of its
Affiliates shall develop or commercially produce for itself or for any Third Party any intravenous
formulation of product containing the Compound for distribution or sale in the Territory during the
term of this Agreement and any renewals hereof. At any time during the term of this Agreement,
Cadence may inform Baxter of its intention to commence negotiation with third parties regarding
distribution services to wholesale warehouses for Product in the Territory. In such event, Baxter
shall have the non-exclusive right to negotiate with Cadence for such services; however, neither
party shall be obligated to enter into such agreement and, until such time as Cadence and Baxter
may enter into a definitive written agreement for such services, nothing herein shall be construed
to prevent Cadence from entering into an agreement for such services with any third party.

     20.9 Survival. Expiration or termination of the Agreement will not relieve the Parties of any
obligation accruing prior to such expiration or termination, and the provisions of Sections
12.2.1.1 (Cadence Warranty regarding API), 12.3 (Baxter Warranties), 5.1 (Product Registration
Application Ownership), and Sections 13.0 (Confidentiality), 14.0 (Intellectual Property), 15.0
(Indemnification), 20.0 (Effects of Termination), 21.0 (Notices), 22.0 (Export), and 23.0
(Miscellaneous) will survive the expiration or termination of the Agreement. Any expiration or
termination of this Agreement will be without prejudice to the rights of either Party against the
other accrued or accruing under this Agreement prior to expiration or termination.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

31

 

21.0 NOTICES

     All notices or other communications which are required or permitted under this Agreement will
be in writing and deemed delivered at the time they are personally delivered, or on the business
day next following the date of confirmed transmission when sent by facsimile, or two (2) business
days after being sent by a nationally recognized overnight courier, and addressed as follows:

If to Baxter:

Baxter Healthcare Corporation

BioPharma Solutions

Route 120 and Wilson Road

Round Lake, Illinois 60073

Attention: General Manager

Fax No.: 847-270-3410

With a copy to:

Baxter Healthcare Corporation

One Baxter Parkway

Deerfield, Illinois 60015

Attention: General Counsel

Fax No.: 847-948-2450

If to Cadence:

Cadence Pharmaceuticals, Inc.

12481 High Bluff Drive, Suite 200

San Diego, CA 92130

Attention: Senior Vice President, Pharmaceutical Development and Manufacturing

Fax No: 858-436-1401

With a copy to:

Cadence Pharmaceuticals, Inc.

12481 High Bluff Drive, Suite 200

San Diego, CA 92130

Attention: General Counsel

Fax No: 858-436-8510

22.0 EXPORT

     Each Party will adhere to the United States Export Administration Laws and Regulations and will not
export or re-export any technical data or Information received from the disclosing

32

 

Party or the direct product of such technical data or Information to any proscribed country listed
in the United States Export Administration Regulations, unless properly authorized by the United
States Government.

23.0 MISCELLANEOUS

     23.1 Binding Effect; Assignment.

	 	23.1.1.	 	This Agreement will be binding upon and inure to the benefit of the Parties
and their successors and permitted assigns.
	 
	 	23.1.2.	 	Baxter may not assign this Agreement or any of its rights or obligations
hereunder except with the written consent of Cadence, such consent not to be
unreasonably withheld; provided, however, that Baxter may arrange for
subcontractors to perform specific testing services arising under this
Agreement without the consent of Cadence; provided, further, that Baxter shall
provide advance notice of the name and function of any such subcontractor and
shall ensure such subcontractor’s adherence to the terms of this Agreement,
including, but not limited to, the obligations of confidentiality set forth in
Section 13.0.
	 
	 	23.1.3.	 	Cadence may assign this Agreement or any of its rights or obligations
hereunder, except to a competitor of Baxter, without approval from Baxter;
provided, however, that Cadence shall give prior written notice of any
assignment to Baxter, any assignee shall covenant in writing with Baxter to be
bound by the terms of this Agreement and Cadence shall remain liable hereunder.
For the purposes of this Section 23.1, “competitor” means [***].
	 
	 	23.1.4.	 	Notwithstanding the foregoing provisions of this Section 23.1, either Party
may assign this Agreement to any of its Affiliates or to a successor to,
purchaser or licensee of all or substantially all of its business, provided
that such assignee agrees in writing to be bound hereunder. For purposes of
the foregoing, the phrase “all or substantially all of its business” shall
mean, with respect to Cadence, the business of Cadence relating to the Product
and not necessarily any other products to which Cadence may have rights.

     23.2 Entire Agreement. This Agreement, together with its Exhibits (including without
limitation the Confidentiality Agreement) and the Letter of Credit, contains the entire agreement
between the Parties relating to the subject matter hereof and all prior written and verbal
proposals, discussions, writings, and other understandings, by and between the Parties and relating
to the subject matter, are superseded hereby, including the LOI. None of the terms of this
Agreement will be deemed to be waived by either Party or amended, unless such waiver or amendment
is in writing executed by both Parties and such writing recites specifically that it is a

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

33

 

waiver of or an amendment to the terms of this Agreement.

     23.3 Governing Law. This Agreement will be deemed to have been entered into in the State of
New York and its interpretation and construction and the remedies for its enforcement or breach are
to be applied pursuant to and in accordance with the laws of the State of New York without regard
to the United Nations Convention on Contracts for the International Sale of Goods and without
giving effect to any choice of laws rule that would cause the application of the laws of any
jurisdiction other than the internal laws of the State of New York, to the rights and duties of the
Parties.

     23.4 Severability. In the event that any one or more of the provisions contained in this
Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality
and enforceability of the remaining provisions contained herein will not in any way be affected or
impaired thereby, unless the absence of the invalidated provision(s) adversely affect the
substantive rights of the Parties. The Parties agree to replace any invalid provision or parts
thereof by new provision(s) which closely approximate the economic and proprietary results intended
by the Parties.

     23.5 Waiver. The waiver by either Party hereto of any right hereunder or of a material breach
by the other Party will not be deemed a waiver of any other right hereunder or of any other
material breach by said other Party whether of a similar nature or otherwise.

     23.6 Review with Counsel. Each Party agrees that it has had the opportunity to review this
Agreement with its legal counsel. Accordingly, the rule of construction that any ambiguity in this
Agreement is to be construed against the drafting Party will not apply.

     23.7 Counterparts. This Agreement may be executed in two counterparts, by original or
facsimile signature, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

[Remainder of page intentionally left blank.]

34

 

In Witness Whereof, the Parties have executed this Agreement by their duly authorized
representatives as of the date first set forth above.

	 	 	 	 	 	 	 	 	 
	CADENCE PHARMACEUTICALS, INC.	 	BAXTER HEALTHCARE CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Theodore R. Schroeder
	 	By:	 	/s/ Daniel Tasse	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Name:

	 	Theodore R. Schroeder
	 	Name:	 	Daniel Tasse	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Title:

	 	President and Chief Executive Officer
	 	Title:	 	GM — BPT	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	July 13, 2007
	 	Date:
	 	July 18, 2007	 	 

35

 

EXHIBIT A

API/FORMULATION SPECIFICATIONS

CONTAINER DESCRIPTION

PRODUCT SPECIFICATIONS

Product Definition Assumptions:

	 	 	 
	Formulation (for 100 mL)
	 	 
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	Other Drug Product Specifications
	 	 
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	“Container” as defined in this Agreement includes the following components
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	Packaging
	 	 
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

36

 

EXHIBIT A (cont)

Product Definition Assumptions(cont):

Sterilization release method. [***]

Active Ingredient. The API (paracetamol, USP) will be provided by Cadence free of charge and in a
format suitable for aqueous mixing unless otherwise agreed by Cadence and Baxter. All other
excipients will be provided by Baxter, and their cost has been incorporated into the Unit Price
provided below.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

37

 

EXHIBIT B

DEVELOPMENT PLAN

Cadence Development Activities

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Submission and
	 	 	Initiation	 	Transfer	 	Implementation	 	Approval
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	[***]	 	[***]

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

38

 

EXHIBIT C

PROPOSED REGULATORY STRATEGY

Cadence IV APAP – Transfer to Cleveland, MS

PQA No. [***]

[***]

 

			
	***	 	 Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

39

 

[***]

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

40

 

EXHIBIT D

DEVELOPMENT FEE SCHEDULE

One-time Technology Transfer/Stability Batch/Registration Activities:

	 	 	 	 	 	 	 	 	 	 	 
	All amounts in $1000s	 	 	 	Program Phase
	Activity	 	Expense	 	I	 	II	 	III	 	IV
	[***]
	 	[***]	 	[***]	 	 	 	 	 	 
	[***]
	 	[***]	 	 	 	[***]	 	 	 	 
	[***]
	 	[***]	 	 	 	[***]	 	 	 	 
	[***]
	 	[***]	 	 	 	[***]	 	 	 	 
	[***]
	 	[***]	 	 	 	[***]	 	 	 	 
	[***]
	 	[***]	 	 	 	[***]	 	 	 	 
	[***]
	 	[***]	 	 	 	[***]	 	 	 	 
	[***]
	 	[***]	 	 	 	 	 	[***]	 	 
	[***]
	 	[***]	 	 	 	 	 	 	 	[***]
	[***]
	 	[***]	 	 	 	 	 	 	 	[***]
	[***]
	 	[***]	 	 	 	 	 	 	 	[***]
	[***]
	 	[***]	 	 	 	 	 	 	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Timing of Development Program Payments. A total payment of [***] is required for development
program expenses, portions of which would be due at the time of the completion of each of the
following phases:

Phase I: Program initiation (signing of Letter of Intent or equivalent). Note: As of the
Effective Date of this Agreement, the [***] Program initiation fee, also described as Phase I
Development Activities, has been paid in full by Cadence.

Phase II: Activities leading up to formal scheduling of stability batch production

Phase III: Manufacture of stability batch

Phase IV: Submission of NDA

The Development program assumes the development of 2 container sizes (50 mL; 100 mL) in one
type of glass. If a second glass type is required to be validated, total expenses and required
payment would rise to [***]. The program time line would also be impacted.

* The expenses detailed in the Table above total [***], but a reduced payment of [***] has been
requested by Baxter as an incentive to confine development activities to one glass type.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

41

 

EXHIBIT E

BAXTER FACILITY IMPROVEMENTS AND BAXTER OWNED EQUIPMENT

Facility Improvements and Capital Equipment Owned by Baxter:

	 	 	 	 	 
	Facility Build-Out and Upgrades to create dedicated IV-APAP line
	 	 	 	 
	[***]
	 	 	[***]	 
	Ancillary systems for mixing, sterilization, and packing
	 	 	[***]	 
	Installation costs, taxes, shipping costs
	 	 	 	 
	[***]
	 	 	[***]	 
	TOTAL
	 	 	[***]	 

The preceding expenses are required for Baxter to create the IV-APAP production line and would be
borne entirely by Cadence.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

42

 

EXHIBIT F

MINIMUM BATCH SIZES AND MANUFACTURING FEE

Minimum Batch Size:

The batch size on which all pricing is based is the optimal batch as determined by the Development
Program. As of the Effective Date, the minimum batch size has not been determined. The parties
agree that once the minimum batch size has been established by mutual agreement, all Product will
be produced in the agreed upon batch size.

Manufacturing Fee Structure:

	 	 	 
	 	 	100 mL vial
	The first [***] units ordered
	 	[***]
	Units [***] to [***]
	 	[***]
	Units [***] to [***]
	 	[***]
	Units [***] to [***]
	 	[***]
	Units over [***]
	 	[***]

	 	 	 
	 	 	50 mL vial
	The first [***] units ordered
	 	[***]
	Units [***] to [***]
	 	[***]
	Units [***] to [***]
	 	[***]
	Units [***] to [***]
	 	[***]
	Units over [***]
	 	[***]

For the avoidance of doubt, in a year in which BAXTER accepts Cadence’s Purchase Orders for
[***] units of Product in the 100mL configuration, the first [***] units would be priced at $[***],
the next [***] at $[***], the next [***] million at $[***], the next [***] at $[***], and the
remaining [***] at $[***].

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

43

 

EXHIBIT G

QUALITY AGREEMENT

[TO BE ATTACHED AFTER THE EFFECTIVE DATE]

44

 

EXHIBIT H

COST OF API AND METHODOLOGY FOR CALCULATING MANUFACTURING

YIELD LOSSES

	 	 	 	 	 
	Description of Cadence Material, the 	 	 	 
	Active Pharmaceutical Ingredient (API):	 	IV-APAP	 
	[***]
	 	 	[***]	 
	 
	 	 	 	 
	[***]
	 	 	[***]	 
	 
	 	 	 	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

45

 

EXHIBIT I

ADVERSE EVENT HANDLING PROCEDURE

Each Party will notify the other Party following receipt of any information within the timeframes
specified herein, including but not limited to information regarding any threatened or pending
action by Regulating Groups, that might reasonably affect the safety or efficacy claims of the
Product, activity under the Development Program, production or marketing of the Product, or the
ability of Cadence to supply API. Promptly upon receipt of such notice, the Parties will consult
with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate
action, provided, however, that nothing contained herein will be construed as restricting the right
of either Party to make a timely report of such matter to any Regulating Groups or take other
action that it deems to be appropriate or required by applicable law or regulation.

Baxter shall report to Cadence all adverse event reports on the Product as soon as possible but in
no event later than two (2) business days of notification of the event to Baxter either directly or
through Product Surveillance.

Cadence will be responsible for reporting all adverse events which relate to the Product as
required by applicable legal requirements and the requirements of any Regulating Group.

46

 

EXHIBIT J

CONFIDENTIAL DISCLOSURE AGREEMENT

[***]

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

47

 

EXHIBIT K

CADENCE OWNED EQUIPMENT

The following list details the equipment required for IV-APAP production that has been
assigned as assets that Cadence will purchase and own, along with the anticipated price as of
the date of the LOI. Actual expense may be different, based on the actual specifications of
the equipment selected and any expediting expenses that Cadence may elect to pursue and are the
responsibility of Cadence.

	 	 	 	 	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 

* The selection and purchase of the [***] equipment was already in process at
the time of Baxter’s involvement in the IV-APAP development and commercialization program and continues to be
the responsibility of Cadence.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

48

 

EXHIBIT L

DEFINITIONS

(Section 2.0)

As used in this Agreement the following terms will have the following meanings:

     The term “ADR” will have the meaning set forth in Section 16.0.

     The term “Affiliate” will mean any corporation or business entity that controls, is controlled
by, or is under common control with, Cadence or Baxter. A corporation or business entity will be
deemed to control another corporation or business entity if it owns, directly or indirectly, fifty
percent (50%) or more of the securities or other ownership interests representing the equity, the
voting stock, or general partnership interest of such corporation or business entity.

     The term “API” will mean the Compound supplied to Baxter by Cadence in accordance with the
terms of this Agreement and the Specifications set forth in Exhibit A, as amended from time to
time.

     The term “API/Formulation Specifications” will have the meaning set forth in Section 14.2.1.

     The term “API Manufacturing Process” will have the meaning set forth in Section 8.2.

     The term “Background Intellectual Property Rights” will mean all patents, patent applications,
copyrights, trade secrets, and other intellectual property rights owned by either Party or under
which a Party otherwise has the right to grant licenses without accounting to any third party or to
the other Party, where the inventions claimed, the works of authorship, or the know-how, trade
secrets and the like, were not made in performance of activities pursuant to, or in anticipation
of, this Agreement. For the avoidance of doubt, Baxter Background Intellectual Property rights do
not include any such intellectual property rights developed by Baxter in its Grosotto facility and
which is owned or licensed to the licensor of Cadence Licensed Intellectual Property.

     The term “Baxter Capex” will have the meaning set forth in Section 4.1.5.

     The term “Baxter Development Deliverables” will have the meaning set forth in Section 4.1.2.

     The term “Baxter Patent Rights” will mean the rights granted by any governmental authority
under a Patent that covers a method, apparatus, manufactured article, material or process necessary
or useful for the manufacture of Product, which Patent is owned or Controlled by Baxter.

     The term “Cadence Development Deliverables” will have the meaning set forth in Section 4.1.2.

49

 

     The term “Cadence Licensed Intellectual Property” will mean those certain Patents and Patent
Applications licensed and/or sublicensed to Cadence pursuant to the IV APAP Agreement and the
Pharmatop License Agreement.

     The term “Commercially Reasonable Efforts” will mean means the application by a Party,
consistent with the exercise of prudent technical and business judgment, of diligent and sustained
efforts and of material resources to fulfill the obligation in issue, consistent with the efforts a
Party would devote to a pharmaceutical product of similar market and profit potential or strategic
value at a similar stage in development or product life as the Product in issue, based on
conditions then prevailing.

     The term “competitor” will have the meaning set forth in Section 23.1.3.

     The term “Compound” will mean N-acetyl-para-aminophenol (CAS Registry No. 103-90-2), also
commonly referred to as acetaminophen and/or paracetamol.

     The term “Confidentiality Agreement” will mean the two-way disclosure agreement, signed by the
Parties, copies of which are attached to this Agreement as Exhibit J.

     The term “Confidential Information” will have the meaning set forth in Section 13.0.

     The term “Container” will mean the container portion of the Product as described in Exhibit A,
as may be amended from time to time.

     The term “Contract Year” will have the meaning set forth in Section 19.1.

     The term “Control” will mean possession of the ability to grant the licenses or sublicenses as
provided for in this Agreement without violating the terms of any agreement or arrangement with any
third party.

     The term “cGMP” or “Current Good Manufacturing Practices” will mean the good manufacturing
practices required by the FDA and set forth in the FD&C Act or FDA regulations, policies, or
guidelines (including ICH adopted guidelines) in effect at a particular time, for the manufacture
and testing of pharmaceutical materials.

     The term “Development Deliverables” will have the meaning set forth in Sections 4.1.2 and
4.1.3 and include the materials set forth on Exhibit B).

     The term “Development Fees” will have the meaning set forth in Section 4.1.4.

     The term “Development Plan” will mean the plan for development of the Product, as set forth in
Exhibit B and described generally in Section 4.1.

     The term “Development Program” will mean the development effort hereunder which

50

 

will enable Cadence to file an Regulatory Submissions with Regulating Groups in the Territory
and which encompasses the tasks set forth on Exhibits B and C and the Development Deliverables set
forth on Exhibit B.

     The term “Drug Product Manufacturing Process” will have the meaning set forth in Section 10.3.

     The term “Effective Date” will have the meaning set forth in the preamble to this Agreement.

     The term “Estimated Requirements” will have the meaning set forth in Section 6.2.

     The term “FDA” will mean the United States Food and Drug Administration and any successor
agency and the corresponding regulatory authority of each jurisdiction in the Territory.

     The term “FD&C Act” will mean the United States Federal Food, Drug and Cosmetic Act, as
amended, or any corresponding Act of each jurisdiction in the Territory.

     The term “Field” will mean the development for, registration and manufacture of, the Product.

     The term “Force Majeure” will have the meaning set forth in Section 17.1.

     The term “Formulation” will mean any and all premix, ready-to-use formulations containing the
Compound.

     The term “Formulation Specifications” will mean those specifications for the final release of
the premix, ready-to-use solution that are developed and finalized by the Parties as part of the
Development Program and which, together with the Container, are part of the Product Specifications.

     The term “Information” will mean (i) techniques and data relating to the Field, including, but
not limited to, ideas (including patentable inventions), inventions, practices, methods, knowledge,
trade secrets, documents, apparatus, clinical and regulatory strategies, test data (including
pharmacological, toxicological and clinical test data), analytical and quality control data,
manufacturing, patent and legal data, market data, financial data within the Field and (ii)
chemical formulations, compositions of matter, product samples and assays within the Field.

     The term “Initial Term” will have the meaning set forth in Section 19.1.

     The term “Integration Failure” will have the meaning set forth in Section 4.4.

     The term “Inventions” will have the meaning set forth in Section 14.1.2.

     The term “IV APAP Agreement” shall mean that certain IV APAP Agreement (US and Canada) dated
February 21, 2006, by and between Bristol-Myers Squibb Company and Cadence,

51

 

as the same may be amended from time to time.

     The term “Letter of Credit” will have the meaning set forth in Section 4.1.5.

     The term “Letter of Intent” (LOI) will have the meaning set forth in Section 1.1.

     The term “Manufacturing Fee” will mean the fee per unit paid by Cadence to Baxter for Product
manufactured under this Agreement as described in Section 7.1 and Exhibit F.

     The term “Matter” will have the meaning set forth in Section 15.3.

     The term “Minimum Purchase Requirements” will have the meaning set forth in Section 6.1.2.

     The term “NDA” will mean (i) a New Drug Application, as defined in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, or any corresponding foreign
application, registration, or certification of each jurisdiction in the Territory.

     The term “Normal Manufacturing Process” shall mean the process beginning upon the mixing of
the API by Baxter and ending when the finished Product is released into finished goods inventory at
Baxter’s manufacturing facility.

     The term “Original Product Data” will have the meaning set forth in Section 14.2.1.

     The term “Party” or “Parties” will mean Cadence and Baxter individually, and collectively, as
applicable.

     The term “Patent” will mean (i) valid and enforceable letters patent including any extension,
registration, continuation, reissue, reexamination or renewal thereof and (ii) to the extent valid
and enforceable rights are granted by a governmental authority thereunder, a Patent Application.

     The term “Patent Application” will mean an application for letters patent.

     The term “Pharmatop License Agreement” shall mean that certain License Agreement dated
December 23, 2002, between SCR Pharmatop and Bristol-Myers Squibb Company, as the same may be
amended from time to time.

     The term “Pre-Existing Specifications” will have the meaning set forth in Section 14.2.1.

     The term “Product” will mean a premix, ready-to-use solution incorporating API that has (i)
undergone the formulation process established under the Development Program and (ii) been packaged
and terminally sterilized within the Container, all in accordance with the Product Specifications.

52

 

     The term “Product Specifications” will mean the Formulation Specifications together with the
Container description, which collectively describe the Product and are developed and finalized by
the Parties as part of the Development Program as provided under Section 4.3.1 and thereafter as
agreed by the Parties pursuant to the Quality Agreement. As of the Effective Date, provisional
Product Specifications are set forth in Exhibit A.

     The term “Quality Agreement” will mean the Quality Agreement, pursuant to Section 10.1, to be
set forth in Exhibit G hereto.

     The term “Regulating Groups “ will mean the FDA and its successors and similar governmental
agencies outside the United States and in the Territory which are responsible for granting
manufacturing, marketing, price and/or reimbursement price authorizations and includes applicable
national, supra-national (e.g. the European Commission or the Council of the European Union), state
or local Regulating Groups, department, bureau, commission, council or other governmental entity in
the Territory that has jurisdiction over the API, Compound, Formulation or Product, whether the
development, manufacture, handling, storage, transportation, destruction, or otherwise.

     The term “Regulatory Strategy” will mean the principal regulatory considerations that are
associated with Product development during the Development Program as set forth in Exhibit C and
described generally in Section 4.2.

     The term “Regulatory Submissions” will mean those applications and filings identified in the
Regulatory Strategy and required by FDA regulations, as amended from time-to-time, and the
equivalent applications and filing for each country or super-national jurisdiction in the
Territory, including but not limited to, the Product NDA or Investigational New Drug Application
(INDA).

     The term “Reports” will have the meaning set forth in Section 14.2.1.

     The term “Requirements” will have the meaning set forth in Section 6.1.

     The term “Team Leaders” will have the meaning set forth in Section 3.1.

     The term “Technical Failure” will have the meaning set forth in Section 4.4.

     The term “Term of the Agreement” will have the meaning set forth in Section 19.1.

     The term “Territory” will mean the United States and any additional countries added by written
agreement of the Parties.

     The term “Third Party” will mean any natural person, corporation, general partnership, limited
partnership, joint venture, proprietorship, or other business organization who is not a Party or an
Affiliate of a Party to this Agreement.

53EX-4.1

 

Exhibit 4.1

AMENDED AND RESTATED DECLARATION OF TRUST

AND

TRUST AGREEMENT

OF

BROOKSHIRE RAW MATERIALS (U.S.) TRUST

DATED AS OF                     , 2007

By and Among

BROOKSHIRE RAW MATERIALS MANAGEMENT, LLC,

CSC TRUST COMPANY OF DELAWARE

And

THE LIMITED OWNERS

from time to time hereunder

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	ARTICLE I DEFINITIONS; THE TRUST
	 	 	1	 
	1.01. Definitions
	 	 	1	 
	1.02. Certain Additional Definitions
	 	 	6	 
	1.03. Interpretive Principles
	 	 	7	 
	1.04. Name
	 	 	8	 
	1.05. Delaware Trustee; Business Offices
	 	 	8	 
	1.06. Creation and Declaration of Trust
	 	 	8	 
	1.07. Purposes and Powers
	 	 	9	 
	1.08. Tax Treatment
	 	 	9	 
	1.09. General Liability of the Managing Owner
	 	 	10	 
	1.10. Legal Title
	 	 	10	 
	1.11. Division of the Trust Into Funds
	 	 	10	 
	1.12. Commencement of Business
	 	 	11	 
	1.13. Administrator; Administration Agreement
	 	 	11	 
	1.14. Custodian(s); Custodian Agreement
	 	 	11	 
	 
	 	 	 	 
	ARTICLE II THE TRUSTEE
	 	 	11	 
	2.01. Appointment and Resignation of the Trustee
	 	 	11	 
	2.02. Powers
	 	 	11	 
	2.03. Compensation and Expenses of the Trustee
	 	 	12	 
	2.04. Indemnification
	 	 	12	 
	2.05. Successor Trustee
	 	 	12	 
	2.06. Liability of Trustee
	 	 	13	 
	2.07. Reliance; Advice of Counsel
	 	 	14	 
	 
	 	 	 	 
	ARTICLE III INTERESTS; CAPITAL CONTRIBUTIONS
	 	 	14	 
	3.01. General
	 	 	14	 
	3.02. Establishment of Series, or Funds, of the Trust
	 	 	16	 
	3.03. Establishment of Classes and Sub-Classes
	 	 	17	 
	3.05. Managing Owner’s Required Contribution
	 	 	23	 
	3.06. Assets of Funds
	 	 	23	 
	3.07. Liabilities of Funds
	 	 	24	 
	3.08. Distributions
	 	 	25	 
	3.09. Voting Rights
	 	 	26	 
	3.10. Equality
	 	 	26	 
	3.11. Exchange of Units
	 	 	26	 
	 
	 	 	 	 
	ARTICLE IV THE MANAGING OWNER
	 	 	27	 
	4.01. Management of the Trust
	 	 	27	 
	4.02. Authority of Managing Owner
	 	 	27	 
	4.03. Obligations of the Managing Owner
	 	 	28	 
	4.04. General Prohibitions
	 	 	30	 
	4.05. Liability of Covered Persons
	 	 	32	 
	4.06. Indemnification of the Managing Owner
	 	 	32	 
	4.07. Expenses
	 	 	33	 

i 

 

	 	 	 	 	 
	4.08. Fees Payable to the Managing Owner
	 	 	35	 
	4.09. Valuation of Trust Property
	 	 	37	 
	4.10. Fiduciary Duty
	 	 	38	 
	4.11. Other Business of Owners
	 	 	39	 
	4.12. Voluntary Withdrawal and Removal of the Managing Owner
	 	 	39	 
	4.13. Litigation
	 	 	40	 
	4.14. Prevention or Delay in Performance by the Managing Owner
	 	 	40	 
	 
	 	 	 	 
	ARTICLE V TRANSFERS OF INTERESTS
	 	 	41	 
	5.01. General Prohibition
	 	 	41	 
	5.02. Repurchase of Managing Owner’s General Units
	 	 	41	 
	5.03. Transfer of Limited Units
	 	 	42	 
	 
	 	 	 	 
	ARTICLE VI DISTRIBUTION AND ALLOCATIONS
	 	 	45	 
	6.01. Capital Accounts
	 	 	45	 
	6.03. Allocation of Profit and Loss for United States Federal Income Tax Purposes
	 	 	45	 
	6.06. Liability for State and Local and Other Taxes
	 	 	48	 
	 
	 	 	 	 
	ARTICLE VII REDEMPTIONS
	 	 	49	 
	7.01. Redemption of Units
	 	 	49	 
	7.02. Redemption of the Managing Owner
	 	 	51	 
	7.03. Mandatory Redemptions
	 	 	51	 
	7.04. Exchange of Units
	 	 	52	 
	7.05. Special Redemption Date
	 	 	53	 
	 
	 	 	 	 
	ARTICLE VIII LIMITED OWNERS
	 	 	53	 
	8.01. No Management or Control; Limited Liability
	 	 	53	 
	8.02. Rights and Duties
	 	 	53	 
	8.03. Limitation on Liability
	 	 	55	 
	 
	 	 	 	 
	ARTICLE IX BOOKS OF ACCOUNT AND REPORTS
	 	 	56	 
	9.01. Books of Account
	 	 	56	 
	9.02. Annual Reports and Quarterly Statements
	 	 	56	 
	9.03. Tax Information
	 	 	56	 
	9.04. Calculation of Net Asset Value and National Net Asset Value of a Fund
	 	 	56	 
	9.05. Other Reports
	 	 	57	 
	9.06. Maintenance of Records
	 	 	57	 
	9.07. Certificate of Trust
	 	 	57	 
	 
	 	 	 	 
	ARTICLE X FISCAL YEAR
	 	 	57	 
	10.01. Fiscal Year
	 	 	57	 
	 
	 	 	 	 
	ARTICLE XI AMENDMENT OF TRUST AGREEMENT; MEETINGS
	 	 	58	 
	11.01. Amendments to this Agreement
	 	 	58	 
	11.02. Meetings of the Trust and Funds
	 	 	60	 
	11.03. Action Without a Meeting
	 	 	60	 

ii 

 

	 	 	 	 	 
	11.04. Solicitation of Votes or Consents
	 	 	60	 
	11.05. Reliance on Votes or Consents
	 	 	60	 
	 
	 	 	 	 
	ARTICLE XII TERM
	 	 	61	 
	12.01. Term
	 	 	61	 
	 
	 	 	 	 
	ARTICLE XIII TERMINATION
	 	 	61	 
	13.01. Events Requiring Dissolution of the Trus
	 	 	61	 
	13.02. Events Requiring Dissolution of a Fund
	 	 	62	 
	13.03. No Termination Upon Events Related to Limited Owner
	 	 	62	 
	13.04. Distributions on Dissolution
	 	 	63	 
	13.05. Termination; Certificate of Cancellation
	 	 	63	 
	 
	 	 	 	 
	ARTICLE XIV POWER OF ATTORNEY
	 	 	64	 
	14.01. Power of Attorney
	 	 	64	 
	14.02. Effect of Power of Attorney
	 	 	64	 
	14.03. Limitation on Power of Attorney
	 	 	65	 
	ARTICLE XV MISCELLANEOUS
	 	 	65	 
	15.01. Governing Law
	 	 	65	 
	15.02. Provisions In Conflict With Law or Regulations
	 	 	66	 
	15.03. Construction
	 	 	66	 
	15.04. Notices
	 	 	66	 
	15.05. Counterparts
	 	 	66	 
	15.06. Binding Nature of Agreement
	 	 	66	 
	15.07. No Legal Title to Trust Estate
	 	 	67	 
	15.08. Creditors
	 	 	67	 
	15.09. Integration
	 	 	67	 

iii 

 

AMENDED AND RESTATED DECLARATION

OF TRUST AND TRUST AGREEMENT

     This AMENDED AND RESTATED DECLARATION OF TRUST AND TRUST AGREEMENT of BROOKSHIRE RAW MATERIALS
(U.S.) TRUST (the “Trust”), dated as of                     , 2007 (the “Agreement”), is
entered into by and among BROOKSHIRE RAW MATERIALS MANAGEMENT, LLC, a Delaware limited liability
company (“Brookshire”), CSC TRUST COMPANY OF DELAWARE, a Delaware corporation, in its
capacity as Trustee (“CSC”), and the LIMITED OWNERS (as defined below) from time to time
hereunder.

     WHEREAS, the Trust was formed on August 17, 2006 by the execution and filing by the Trustee of
the Certificate of Trust and by execution and delivery of that certain Declaration of Trust and
Trust Agreement dated August 17, 2006 (the “Original Agreement”) by the Managing Owner and
the Trustee;

     WHEREAS, there have not been to date, and there are not as of the date of this Agreement, any
Limited Owners; and

     WHEREAS, the Managing Owner and the Trustee desire to amend and restate the Original Agreement
in its entirety, as set forth herein.

     NOW, THEREFORE, in consideration of the mutual promises and agreements herein contained, the
receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally
bound, hereby agree as follows:

ARTICLE I

DEFINITIONS; THE TRUST

     1.01. Definitions. In addition to the capitalized terms defined elsewhere in this
Agreement, capitalized terms used in this Agreement shall have the following meanings unless the
context otherwise requires:

     “Accelerated Core Fund” means either the Accelerated Core USD Fund or the Accelerated
Core CDN Fund and “Accelerated Core Funds” means the Accelerated Core USD Fund and the
Accelerated Core CDN Fund together.

     “Adjusted Capital Account” means, as of the last day of a taxable period, an Owner’s
tax capital account as maintained pursuant to Section 6.03, (a) increased by any amounts
which such Owner is obligated to restore pursuant to any provision of this Trust Agreement or is
deemed to be obligated to restore pursuant to Treasury Regulations section 1.704-2, and (b)
decreased by the amount of all losses and deductions that, as of the end of the taxable period, are
reasonably expected to be allocated to such Owner in subsequent years under sections 704(e)(2) and
706(d) of the Code, and the amount of all distributions that, as of the end of such taxable period,
are reasonably expected to be made to such Owner in subsequent years in accordance with the terms
of this Trust Agreement or otherwise to the extent they exceed offsetting increases to such capital
accounts that are reasonably expected to occur during or prior to the year in which such
distributions are reasonably expected to be made. The foregoing definition of Adjusted Capital

 

 

Account is intended to comply with the provisions of Treasury Regulations section
1.704-1(b)(2)(ii)(d) and shall be interpreted consistently therewith.

     “Administrator” means the Person from time to time providing general administrative
and other services to the Trust and/or a Fund pursuant to an Administration Agreement in accordance
with Section 1.13. For the avoidance of doubt, different Funds can have different
Administrators. As of the date of this Agreement, the Administrator for each Fund is Mintz Fund
Services Inc.

     “Affiliate” means, with respect to any Person, (a) any Person directly or indirectly
owning, controlling or holding voting rights with respect to ten percent (10%) or more of the
outstanding voting securities of the first Person; (b) any Person ten percent (10%) or more of the
outstanding voting securities of which are owned, controlled or held by the first Person; (c) any
Person, directly or indirectly, controlling, controlled by or under common control with the first
Person; (d) any employee, officer, director, member, manager or partner of the first Person or (e)
if the first Person is an employee, officer, director, member, manager or partner, any Person for
which the first Person acts in any such capacity.

     “Benefit Plan Investors” means employee benefit plans subject to Title I of ERISA,
benefit plans subject to Section 4975 of the Code, government plans, church plans, Individual
Retirement Accounts, Keogh Plans covering only self-employed persons and no employees, employee
benefit plans covering only the sole owner of a business and/or his spouse and foreign pension
plans.

     “Business Day” means any day when the New York Mercantile Exchange is open for
business.

     “Capital Contribution” means the amount contributed to a Fund by a Subscriber or by
the Managing Owner, as applicable, in accordance with Article III.

     “CDN Funds” mean the Core CDN Fund, the Agriculture CDN Fund, the Energy CDN Fund, the
Metals CDN Fund and the Accelerated Core CDN Fund.

     “CE Act” means the Commodity Exchange Act, 7 USC §1 et seq., as amended from time to
time.

     “Certificate of Trust” means the certificate of trust of the Trust, as filed from time
to time with the Secretary of State pursuant to Section 3810 of the Trust Act.

     “CFTC” means the Commodity Futures Trading Commission.

     “Class” means a separate class of Units in a Fund as provided in Section 3806(b)(1) of
the Trust Act. Such Class will have the rights, duties and privileges with respect to the Trust
Estate of such Fund as are set forth in this Agreement, any document creating such Class and or any
Registration Statement relating thereto.

     “Code” means the Internal Revenue Code of 1986, as amended.

2

 

     “Commodities” means positions in Commodity Contracts, forward contracts, foreign
exchange positions, options and traded physical commodities, as well as cash commodities resulting
from any of the foregoing positions.

     “Commodity Broker” means any Person who engages in the business of effecting
transactions in Commodity Contracts for the account of others or for his or her own account.

     “Commodity Contract” means any contract or option thereon providing for the delivery
or receipt at a future date of a specified amount and grade of a traded physical commodity at a
specified price and delivery point.

     “Contracts” means collectively, contracts, agreements, commitments, licenses,
understandings and other legally binding arrangements.

     “Core Fund” means either the Core USD Fund or the Core CDN Fund, and “Core
Funds” means the Core USD Fund and the Core CDN Fund together.

     “Corporate Trust Office” means, as of any time, the principal office from which the
corporate trust business of the Trustee is administered.

     “Custodian” means a Person from time to time serving as custodian for the Trust and/or
a Fund of securities and cash delivered to such Person by the Trust or such Fund or by the
applicable Subscriber or another Person on behalf of a Subscriber in accordance with Section
1.14. For the avoidance of doubt, different Funds can have different Custodians. As of the
date of this Agreement, the Custodian for each Fund is HSBC Bank USA, National Association.

     “Disposition Gain” means, with respect to each Fund, for each Fiscal Year, the Fund’s
aggregate recognized gain (including the portion thereof, if any, treated as ordinary income)
resulting from each disposition of Fund assets during such Fiscal Year with respect to which gain
or loss is recognized for Federal income tax purposes, including, without limitation, any gain or
loss required to be recognized by the Fund for Federal income tax purposes pursuant to Sections 988
or 1256 (or any successor provisions) of the Code.

     “Disposition Loss” means, with respect to each Fund, for each Fiscal Year, the Fund’s
aggregate recognized loss (including the portion thereof, if any, treated as ordinary loss)
resulting from each disposition of Fund assets during such Fiscal Year with respect to which gain
or loss is recognized for Federal income tax purposes, including, without limitation, any gain or
loss required to be recognized by the Fund for Federal income tax purposes pursuant to Sections 988
or 1256 (or any successor provisions) of the Code.

     “ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

     “Fixed Income Securities” means any and all securities of the type generally known as
fixed income securities and includes, without limitation, any and all government treasury
securities and all other high credit quality short-term fixed income securities.

3

 

     “Fund” means a separate series of Units in the Trust as provided in Sections
3806(b)(2) and 3804 of the Trust Act. Such Units shall represent beneficial interests in the Trust
Estate separately identified with and belonging to such Fund.

     “GAAP” means generally accepted accounting principles in the United States,
consistently applied.

     “General Units” means Units owned by the Managing Owner.

     “Initial Funds” means, collectively, the ten (10) Funds listed in Section
3.02(a) and an “Initial Fund” refers to any such Fund by itself.

     “IRS” means the Internal Revenue Service.

     “Laws” means foreign, federal, state or local laws, statutes, rules, regulations,
interpretations, ordinances, codes, orders and rules of common law.

     “Limited Owner” means a Person holding Limited Units and who is listed as such on the
books and records of the Trust and/or the applicable Fund. For the avoidance of doubt, the term
“Limited Owner” will include any Affiliate of the Managing Owner in the event that the Affiliate
purchases Limited Units.

     “Limited Units” means Units owned by Persons other than the Managing Owner.

     “Losses” means, with respect to each Fund, for each Fiscal Year, losses of the Fund as
determined for Federal income tax purposes, and each item of income, gain, loss or deduction
entering into the computation thereof, except that any gain or loss taken into account in
determining the Disposition Gain or the Disposition Loss of the Fund for such Fiscal Year shall not
enter into such computations.

     “Managing Owner” means (a) as of the date hereof and unless and until replaced in
accordance with Section 4.12, Brookshire and (b) any other Person that may be appointed as
managing owner pursuant to Sections 8.02(d)(iii) or 13.01(b).

     “Margin Call” means a demand for additional funds after the initial good faith deposit
required to maintain a customer’s account in compliance with the requirements of a particular
commodity exchange or of a Commodity Broker.

     “NASAA Guidelines” means the North American Securities Administrators Association,
Inc. Guidelines for the Registration of Commodity Pool Programs, as in effect from time to time.

     “Net Asset Value” means the net asset value of the Trust or a Fund, as applicable, and
shall be equal to the total assets of the Trust or such Fund, as applicable, minus the total
liabilities of the Trust or such Fund, as applicable, in each case determined on an accrual basis
of accounting in accordance with GAAP and in accordance with Section 4.09.

4

 

     “Net Worth” means, with respect to a Subscriber, the net worth of such Subscriber and
shall be calculated in accordance with GAAP, but excluding the value of such Subscriber’s home,
home furnishings and automobiles.

     “NFA” means the National Futures Association.

     “Notional Net Asset Value” means the Net Asset Value of a Fund, taking into account
any notional funding or value or leverage utilized by such Fund.

     “Owners” means the Managing Owner and Limited Owners, as holders of Units of a Fund,
where no distinction is required by the context in which the term is used.

     “Per Unit Net Asset Value” means the Net Asset Value of a Fund per Unit of such Fund
and, as of any time, shall be equal to (a) the Net Asset Value of such Fund as of such time divided
by (b) the number of Units of such Fund issued and outstanding as of such time.

     “Person” means any natural person, partnership, limited liability company, statutory
trust, corporation, business trust, association, Benefit Plan Investor or other legal entity.

     “Profits” means, with respect to each Fund for each Fiscal Year, the income of the
Fund, as determined for Federal income tax purposes, with each item of income, gain, loss or
deduction entering into the computation thereof, except that any gain or loss taken into account in
determining the Disposition Gain or the Disposition Loss of the Fund for such Fiscal Year shall not
enter into such computations.

     “Pyramiding” means the use of unrealized profits on existing Commodities positions to
provide margins for additional Commodities positions of the same or a related commodity.

     “SEC” means the United States Securities and Exchange Commission.

     “Secretary of State” means the Secretary of State of the State of Delaware.

     “Sponsor” means (a) any Person directly or indirectly instrumental in organizing the
Trust or a Fund, (b) any Person who (i) will manage or participate in the management of the Trust
or a Fund, including the Managing Owner or any Affiliate thereof and (ii) pays any portion of the
Organization and Offering Expenses of the Trust or a Fund, and/or (c) any other Person who
regularly performs or selects the Persons who perform services for the Trust or a Fund;
provided, that the term “Sponsor” does not include wholly independent third parties such as
attorneys, accountants, and underwriters whose only compensation is for professional services
rendered in connection with the offering of Units. If a Person is a Sponsor, the Affiliates of
such Person shall also be deemed to be Sponsors.

     “Subscription Agreement” means a subscription agreement, using the form attached to
the Registration Statement as Exhibit ___, pursuant to which Persons may subscribe for
Limited Units.

     “Treasury Regulations” means the final and temporary Income Tax Regulations
promulgated under the Code, as such regulations may be amended from time to time (including
corresponding provisions of succeeding regulations).

5

 

     “Trust Act” means Chapter 38 of Title 12 of the Delaware Code, 12 Del.C. §3801 et
seq., as the same may be amended from time to time.

     “Trustee” means (a) as of the date hereof and unless and until replaced in accordance
with Section 2.05, CSC and (b) any other Person that may from time to time be duly
appointed, qualified and serving as trustee pursuant to Section 2.05. All references to
CSC and/or any other Person as “Trustee” hereunder shall refer to CSC or such Person solely in its
capacity as Trustee hereunder.

     “Trust Estate” means, with respect to a Fund, (a) all Commodity Contracts, Fixed
Income Securities and other securities held by or in respect of such Fund, (b) all cash, cash
equivalents and other liquid assets held by or in respect of such Fund, and (c) all other
properties, assets and rights of or in respect of such Fund, in each case together with all
proceeds therefrom. For the avoidance of doubt, the Trust Estate of a Fund shall include rights of
such Fund pursuant to the Subscription Agreements relating to such Fund and any other Contracts to
which such Fund is a party or to which the Trust, on behalf of such Fund, is a party, and that
relate to such Fund.

     “USD Funds” mean the Core USD Fund, the Agriculture USD Fund, the Energy USD Fund, the
Metals USD Fund and the Accelerated Core USD Fund.

     “Units” means units of beneficial interest of an Owner in the profits, losses,
distributions, capital and assets of a Fund.

     “Valuation Date” means the Business Day on which the Net Asset Value of a Fund is
being determined.

     “Valuation Point” means 6:00 P.M. New York time on a Valuation Date, or such other
time and date as may be determined by the Managing Owner.

     1.02. Certain Additional Definitions. In addition to the terms defined in Section
1.01, the following terms shall have the respective meanings ascribed thereto in the respective
sections of this Agreement set forth opposite each such term below:

	 	 	 
	Term	 	Section
	49% Limitation
	 	5.03(b)(ii)
	Accelerated Core CDN Fund
	 	3.02(a)(x)
	Accelerated Core USD Fund
	 	3.02(a)(ix)
	Administration Agreement
	 	1.13
	Agriculture CDN Fund
	 	3.02(a)(iv)
	Agriculture USD Fund
	 	3.02(a)(iii)
	Agreement
	 	Preamble
	Applicable Fund
	 	3.07(b)(i)
	Brookshire
	 	Preamble
	Capital Contribution
	 	3.04(d)(i)
	Claims
	 	3.07(b)(i)
	Continuous Offering Period
	 	3.04(c)
	Core CDN Fund
	 	3.02(a)(ii)
	Core USD Fund
	 	3.02(a)(i)

6

 

	 	 	 
	Term	 	Section
	Covered Person
	 	4.10(a)
	CSC
	 	Preamble
	Custodian Agreement
	 	1.14
	Decline Date
	 	7.05
	Decline Notice
	 	7.05
	Effective Time of Subscription
	 	3.04(e)(i)
	Energy CDN Fund
	 	3.02(a)(vii)
	Energy USD Fund
	 	3.02(a)(viii)
	Event of Withdrawal
	 	13.01(b)
	Exchange
	 	7.04(a)
	Exchange Date
	 	7.04(a)
	Exchange Request Form
	 	7.04(c)
	Expenses
	 	2.04
	Extraordinary Fees and Expenses
	 	4.07(c)(ii)
	Fiscal Year
	 	10.01
	Indemnified Parties
	 	2.04
	Initial Closing
	 	3.04(b)(i)
	Initial Offering Period
	 	3.04(b)(i)
	Liquidating Trustee
	 	13.04
	Management and Operating Fee
	 	4.08(a)(i)
	Metals CDN Fund
	 	3.02(a)(vi)
	Metals USD Fund
	 	3.02(a)(v)
	Offer Commencement Date
	 	1.12
	Operational Expenses
	 	4.07(b)(ii)
	Organization and Offering Expenses
	 	4.07(a)(v)
	Original Agreement
	 	Recitals
	Reconstituted Trust
	 	13.01(b)
	Redemption Date
	 	7.01(a)
	Redemption Fee
	 	4.08(c)
	Redemption Request Form
	 	7.01(g)
	Registration Statements
	 	3.01(a)
	Selling Agents
	 	3.04(d)
	Special Redemption Period
	 	7.05
	Subordinated Claims
	 	3.07(b)(i)
	Subscriber
	 	3.04(e)(i)
	Subscription Fee
	 	3.04(e)(vii)
	Subscription Funds
	 	3.04(e)(ii)
	Subscription Minimum
	 	3.04(a)(i)
	Tax Matters Partner
	 	1.08(b)
	Trailing Fee
	 	3.04(e)(vii)
	Transfer
	 	5.01(a)
	Trust
	 	Preamble

     1.03. Interpretive Principles. Whenever used in this Agreement, a singular number
shall include the plural and a plural the singular. Pronouns of one gender shall include all

7

 

genders. Accounting terms used and not otherwise defined in this Agreement shall have the meanings
determined by, and all calculations with respect to accounting of financial matters, unless
otherwise provided for herein, shall be computed in accordance with GAAP. References herein to
articles, sections, paragraphs, subparagraphs or the like shall refer to the corresponding
articles, sections, paragraphs, subparagraphs or the like of this Agreement. The words “hereof,”
“herein,” and terms of similar import shall refer to this entire Agreement. Unless the context
clearly requires otherwise, the use of the terms “including,” “included,” “such as,” or terms of
similar meaning, shall not be construed to imply the exclusion of any other particular elements and
shall be deemed to be followed by the words “without limitation”. Unless otherwise specifically
provided for herein, the term “or” shall not be deemed to be exclusive.

     1.04. Name. The name of the Trust is “BrookshireTM Raw Materials (U.S.) Trust.” The
Trustee and the Managing Owner may engage in the business of the Trust, make and execute Contracts
and other instruments on behalf of the Trust and sue and be sued on behalf of the Trust under such
name.

     1.05. Delaware Trustee; Business Offices.

          (a) As of the date of this Agreement, CSC is the Trustee and the Corporate Trust Office is
Little Falls Centre One, 2711 Centerville Road, Wilmington, Delaware, 19808. The Trustee may
hereafter from time to time change the Corporate Trust Office to another address within the State
of Delaware upon written notice to the Owners. The Trustee shall receive service of process on
behalf of the Trust and each Fund in the State of Delaware at the Corporate Trust Office.

          (b) As of the date of this Agreement, the principal offices of the Trust and each Fund are c/o
Brookshire Raw Materials Management, LLC, 1000 Hart Road, Suite 210, Barrington, Illinois 60010.
The Managing Owner may from time to time change the principal offices of, or establish additional
offices for, the Trust and/or one or more Funds, at such place or places inside or outside the
State of Delaware, as the Managing Owner may determine in its sole discretion, with notice thereof
to be given in writing to the Trustee and the Owners.

     1.06. Creation and Declaration of Trust.

          (a) The Trustee hereby (i) acknowledges that the Trust and each Initial Fund has received the
sum of $10 per Initial Fund to be deposited in a separate bank account in the name of each Initial
Fund and controlled by the Managing Owner and (ii) declares that it shall hold such sum and all
other trust property now or hereafter existing in trust, upon and subject to the conditions set
forth herein for the use and benefit of the Owners.

          (b) It is the intention of the parties that the Trust be a statutory trust under the Trust Act
and that this Agreement shall constitute the governing instrument of the Trust. The
parties intend that no general partnership, limited partnership, joint stock association,
corporation, bailment or any form of legal relationship other than a Delaware statutory trust be
created hereby, except to the extent that each Fund is deemed to constitute a partnership under the
Code and applicable state and local tax Laws. Nothing in this Agreement shall be construed to make
the Trust or any Fund a partnership or any Owner a partner of any other Owner or a

8

 

member of a
joint stock association except to the extent such Owners are deemed to be partners under the Code
and applicable state and local tax Laws. Notwithstanding the foregoing, it is the intention of the
parties that each Fund be treated as a partnership under the Code and applicable state and local
tax Laws. In furtherance of the foregoing, neither the Trust nor any Fund shall elect to be
treated as an association taxable as a corporation for Federal income tax purposes.

          (c) The Trustee and the Managing Owner have all of the rights, powers and duties set forth
herein and in the Trust Act with respect to accomplishing the purposes of the Trust or any Fund.
The Trustee has heretofore filed the Certificate of Trust, as required by Section 3810 of the Trust
Act in connection with the formation of the Trust under the Trust Act.

     1.07. Purposes and Powers. The purposes of the Trust and each Fund are (a) to trade,
buy, sell, spread or otherwise acquire, hold or dispose of Commodity Contracts, Fixed Income
Securities and other securities, in each case either within the United States or elsewhere in the
world and (b) to enter into any lawful transaction and engage in any lawful activities in
furtherance of or incidental to the foregoing purposes. The Trust and each Fund shall have all of
the powers specified in Section 15.01, including all of the powers which may be exercised
by a Managing Owner on behalf of the Trust or a Fund under this Agreement.

     1.08. Tax Treatment.

          (a) Each of the parties hereto, by entering into this Agreement, (i) expresses its intention
that the Units of each Fund will qualify under applicable tax Law as interests in a partnership
that holds the Trust Estate of such Fund for the benefit of Owners with respect thereto; (ii)
agrees that it will file its own U.S. federal, state, and local income, franchise, and other tax
returns in a manner that is consistent with the treatment of each Fund as a partnership in which
each of the Owners with respect thereto is a partner; and (iii) agrees to use reasonable efforts to
notify the Managing Owner promptly upon a receipt of any notice from any taxing authority having
jurisdiction over such Owners with respect to the treatment of the Units of each Fund as anything
other than interests in a partnership.

          (b) The Managing Owner shall initially be Tax Matters Partner (as defined in Section 6231 of
the Code and any corresponding state and local tax Law) of each Fund. The Tax Matters Partner, at
the expense of each Fund, (i) shall prepare or cause to be prepared and filed each Fund’s tax
returns as a partnership for Federal, state and local tax purposes and (ii) shall be authorized to
perform all duties imposed by Section 6221 et seq. of the Code, including, without limitation, (A)
the power to conduct all audits and other administrative proceedings with respect to tax items; (B)
the power to extend the statute of limitations for all Owners with respect to tax items; (C) the
power to file a petition with an appropriate Federal court for review of a final administrative
adjustment of any Fund’s tax items; and (D) the power to enter into a settlement
with the IRS on behalf of, and binding upon, those Limited Owners having less than one percent
(1%) interest in any Fund, unless and to the extent that a Limited Owner shall have notified the
IRS and the Managing Owner that the Managing Owner shall not act on such Limited Owner’s behalf and
such notice has the effect of limiting the authority of the Tax Matters Partner under the Code and
the related Treasury Regulations. The designation made by each Owner in this Section
1.08(b) is hereby approved by each Owner as an express condition to becoming an Owner. Each
Owner agrees to take any further action as may be required by regulation or

9

 

otherwise to effectuate
such designation. Subject to Section 4.06, each Fund shall indemnify, to the full extent
permitted by law, the Managing Owner from and against any damages or losses (including attorneys’
fees) arising out of or incurred in connection with any action taken or omitted to be taken by it
in carrying out its responsibilities as Tax Matters Partner of such Fund, provided such action
taken or omitted to be taken does not constitute fraud, negligence or misconduct.

          (c) Each Owner shall furnish the Managing Owner with information necessary to enable the
Managing Owner to comply with United States federal income tax information reporting requirements
in respect of such Owner’s Units.

     1.09. General Liability of the Managing Owner.

          (a) Subject to the last sentence of this Section 1.09 and to Section 4.06, the
Managing Owner shall be liable for the acts, omissions, obligations and expenses of each Fund, to
the extent not paid out of the assets of such Fund, solely to the extent of the General Units owned
by the Managing Owner in such Fund. The foregoing provision shall not, however, limit the ability
of the Managing Owner to limit its liability by contract. Without limiting or affecting the
liability of the Managing Owner as set forth in this Section 1.09, notwithstanding anything
in this Agreement to the contrary, Persons having any claim against the Trust by reason of the
transactions contemplated by this Agreement and any other Contract to which the Trust is a party,
shall look only to the Trust Estate in accordance with Section 3.07 for payment or
satisfaction thereof.

          (b) Subject to Sections 8.01 and 8.03, no Owner, other than the Managing Owner
(solely as and to the extent set forth in Section 1.09(a)), shall have any personal
liability for any liability or obligation of the Trust or any Fund; provided, that the
foregoing shall not relieve a particular Limited Owner of responsibility for any fees or expenses
for which such Owner is responsible under the Registration Statement.

     1.10. Legal Title. Legal title to all of the Trust Estate of each Fund shall be
vested in the Trust or such Fund, as applicable, as a separate legal entity; provided, that
if, under applicable Law in any jurisdiction, any part of the Trust Estate must be held otherwise,
the Managing Owner may cause legal title to all or any applicable portion of the Trust Estate to be
held by or in the name of the Managing Owner or any other Person as nominee.

     1.11. Division of the Trust Into Funds.
The Trust shall be divided into series (each of which is referred to in this Agreement as a
Fund), as provided in Section 3806(b)(2) of the Trust Act. It is the intent of the parties that
Articles IV, V, VI, VII, VIII, IX, X,
XII and XIII shall apply with respect to each Fund as if each Fund were a separate
statutory trust under the Trust Act, and each reference to the term “Trust” in such Articles shall
be deemed to be a reference to each Fund to the extent necessary to give effect to the foregoing
intent. The use of the terms “Trust” or “Fund” in this Agreement shall in no event alter the
intent of the parties that the Trust and each Fund receive the full benefit of the limitation on
inter-series liability as set forth in Section 3804 of the Trust Act.

10

 

     1.12. Commencement of Business. The Trust’s and each Fund’s business and the sale of
Limited Units shall commence at such time as the Managing Owner shall determine in its sole
discretion. Such date is hereinafter referred to as the “Offer Commencement Date.”

     1.13. Administrator; Administration Agreement. Each Fund shall from time to time
enter into an agreement with the Administrator pursuant to which the Administrator will provide
general administrative and other services to such Fund (each, an “Administration
Agreement”). The Managing Owner may at any time appoint and/or terminate the Administrator for
each Fund, or amend or waive any provision of the Administration Agreement, in each case at any
time and without the consent of any Owner. The Administration Agreement may provide that the
Administrator will provide various services and calculations on behalf of the Managing Owner, and
if so performed by the Administrator, such services will be deemed to be performed by the Managing
Owner for purposes of this Agreement.

     1.14. Custodian(s); Custodian Agreement. Each Fund shall from time to time enter into
an agreement with one or more Custodians pursuant to which such Custodian(s) will provide general
custodial and other services with respect to securities and cash delivered to such Fund (each, a
“Custodian Agreement”). The Managing Owner may at any time appoint and/or terminate the
Custodian(s) for each Fund, or amend or waive any provision of the Custodian Agreement, in each
case at any time and without the consent of any Owner.

ARTICLE II

THE TRUSTEE

     2.01. Appointment and Resignation of the Trustee.

          (a) CSC has been appointed, and hereby agrees to serve, as the Trustee of the Trust. The
Trustee shall serve in such capacity until such time as the Managing Owner removes the Trustee or
the Trustee resigns and a successor Trustee is appointed by the Managing Owner in accordance with
Section 2.05.

          (b) The Trustee may resign at any time upon at least sixty (60) days’ prior written notice to
the Managing Owner and the Trust; provided, that such resignation shall not
become effective unless and until a successor Trustee shall have been appointed by the
Managing Owner in accordance with Section 2.05. If the Managing Owner does not act within
such 60-day period, the Trustee may apply to the Court of Chancery of the State of Delaware for the
appointment of a successor Trustee at the expense of the Trust.

     2.02. Powers. Except to the extent expressly set forth in Section 1.06(c) and
this Article II, the Trustee hereby delegates all right, obligation and authority of the
Trustee to manage the business and affairs of the Trust and each Fund to the Managing Owner. The
Managing Owner may further delegate such right, obligation and authority as provided in this
Agreement. All such delegations by the Trustee and the Managing Owner are and will be made
pursuant to Section 3806(b)(7) of the Trust Act. The Trustee shall have only the rights,
obligations and liabilities specifically provided for herein and in the Trust Act and shall have no
implied rights, obligations and liabilities with respect to the business and affairs of the Trust
or any Fund. The Trustee shall have the power and authority to execute, deliver, acknowledge and

11

 

file all necessary documents and to maintain all necessary records of the Trust and each Fund as
required by the Trust Act, and is hereby authorized and directed to execute and file in the office
of the Secretary of State such certificates as may from time to time be required under the Trust
Act or any other applicable Laws; the Trustee shall promptly notify the Managing Owner following
its execution, delivery, acknowledgement or filing of any such documents or certificates. The
Managing Owner shall keep the Trustee reasonably informed of any actions taken by the Managing
Owner with respect to the Trust or any Fund that affect the rights, obligations or liabilities of
the Trustee hereunder or under the Trust Act. Notwithstanding anything set forth herein to the
contrary, the Trustee shall have no power, duty or authority to execute any documents, reports or
certificates required by the Sarbanes-Oxley Act of 2002 with respect to the Trust or any Fund.

     2.03. Compensation and Expenses of the Trustee. The Trustee shall be entitled to
receive from the Managing Owner or an Affiliate of the Managing Owner (other than the Trust) (a)
reasonable compensation for its services hereunder (as set forth in a separate fee agreement
between the Trustee and the Managing Owner) and (b) reimbursement for reasonable out-of-pocket
expenses incurred by the Trustee in the performance of its duties hereunder, including reasonable
fees and out-of-pocket expenses and disbursements of counsel and such other agents as the Trustee
may employ in connection with the exercise and performance of its rights and duties hereunder.

     2.04. Indemnification. The Managing Owner agrees, whether or not any of the Trust or
any Fund shall commence business, to assume liability for, and to indemnify, protect, save and hold
harmless the Trustee and its successors, assigns, legal representatives, officers, directors,
agents and servants (all of the foregoing Persons, collectively the “Indemnified Parties”)
from and against any and all liabilities, obligations, losses, damages, penalties, taxes (excluding
any taxes payable by the Trustee on or measured by any compensation received by the Trustee for its
services hereunder or any indemnity payments received by the Trustee pursuant to this Section
2.04), claims, actions, suits, costs, expenses or disbursements (including reasonable legal
fees and
expenses) of any kind and nature whatsoever (collectively, “Expenses”), which may be
imposed on, incurred by or asserted against the Indemnified Parties in any way relating to or
arising out of the formation, operation or termination of the Trust, the execution, delivery and
performance of any other Contracts to which the Trust is a party or the action or inaction of the
Trustee hereunder or thereunder, except for Expenses resulting from the gross negligence or willful
misconduct of any of the Indemnified Parties. The indemnities contained in this Section
2.04 shall survive the termination of this Agreement or the removal or resignation of the
Trustee. The Indemnified Parties shall not be entitled to indemnification from any Trust Estate.

     2.05. Successor Trustee. Upon the resignation or removal of the Trustee, the Managing
Owner shall appoint a successor Trustee by delivering a written instrument to the outgoing Trustee
and to the Trust. Any successor Trustee must satisfy the requirements of Section 3807 of the Trust
Act. Any resignation or removal of the Trustee and appointment of a successor Trustee shall not
become effective until a written acceptance of appointment is delivered by the successor Trustee to
the outgoing Trustee and the Managing Owner and any fees and expenses due to the outgoing Trustee
are paid. Notice of removal of the Trustee and appointment of a successor Trustee shall be given
to all Owners. Following compliance with the preceding sentence, the successor Trustee shall
become the Trustee for all purposes hereunder and shall be

12

 

fully vested with all of the rights,
powers, duties and obligations of the outgoing Trustee under this Agreement, with like effect as if
originally named as Trustee, and the outgoing Trustee shall be discharged of its duties and
obligations under this Agreement.

     2.06. Liability of Trustee. Except as otherwise provided in this Article II,
in accepting the trust created hereby and serving as Trustee, CSC is acting solely in its capacity
as Trustee and not in its individual capacity, and all Persons having any claim against the Trustee
by reason of the transactions contemplated by this Agreement and any other Contract to which the
Trust or a Fund is a party shall look only to the applicable Trust Estate in accordance with
Section 3.07 for payment or satisfaction thereof; provided, however, that
in no event is the foregoing intended to affect or limit the liability of the Managing Owner as set
forth in Section 1.09. The Trustee shall not be liable or accountable hereunder or under
any other Contract to which the Trust or any Fund is a party, except for its own gross negligence
or willful misconduct. In particular, but without limiting the foregoing:

          (a) The Trustee shall have no liability or responsibility for the validity or sufficiency of
this Agreement or for the form, character, genuineness, sufficiency, value or validity of the Trust
Estate;

          (b) The Trustee shall not be liable for any actions taken or omitted to be taken by it in
accordance with the instructions of the Managing Owner;

          (c) The Trustee shall not have any liability for the acts or omissions of the Managing Owner;

          (d) The Trustee shall not be liable for its failure to supervise the performance of any
obligations of the Managing Owner, any Commodity Broker or any selling agent;

          (e) No provision of this Agreement shall require the Trustee to expend or risk funds or
otherwise incur any financial liability in the performance of any of its rights or powers hereunder
if the Trustee shall have reasonable grounds for believing that repayment of such funds or adequate
indemnity against such risk or liability is not reasonably assured or provided to it;

          (f) Under no circumstances shall the Trustee be liable for indebtedness evidenced by or other
obligations of the Trust or any Fund arising under this Agreement or any other Contracts to which
the Trust or any Fund is party;

          (g) The Trustee shall be under no obligation to exercise any of the rights or powers vested in
it by this Agreement, or to institute, conduct or defend any litigation under this Agreement or any
other Contract to which the Trust or any Fund is party, whether or nor at the request, order or
direction of the Managing Owner or any Owner, unless the Managing Owner or such Owner has offered
to the Trustee security or indemnity satisfactory to the Trustee against the costs, expenses and
liabilities that may be incurred by the Trustee (including the reasonable fees and expenses of its
counsel) therein or thereby; and

          (h) Notwithstanding anything contained herein to the contrary, the Trustee shall not be
required to take any action in any jurisdiction other than in the State of Delaware if the taking
of such action would (i) require the consent or approval or authorization or order of or

13

 

the giving
of notice to, or the registration with or taking of any action in respect of, any state or other
governmental authority or agency of any jurisdiction other than the State of Delaware, (ii) result
in any fee, tax or other governmental charge under the Laws of any jurisdiction or any political
subdivision thereof in existence as of the date hereof other than the State of Delaware becoming
payable by the Trustee or (iii) subject the Trustee to personal jurisdiction, other than in the
State of Delaware, for causes of action arising from personal acts unrelated to the consummation of
the transactions by the Trustee, as the case may be, contemplated hereby.

     2.07. Reliance; Advice of Counsel.

          (a) In the absence of bad faith, the Trustee may conclusively rely upon certificates or
opinions furnished to the Trustee and conforming to the requirements of this Agreement in
determining the truth of the statements and the correctness of the opinions contained therein, and
shall incur no liability to anyone in acting on any signature, instrument, notice, resolutions,
request, consent, order, certificate, report, opinion, bond or other document or paper believed by
it to be genuine and believed by it to be signed by the proper party or parties and need not
investigate any fact or matter pertaining to or in any such document; provided,
however, that the Trustee shall have examined any certificates or opinions so as to
determine compliance of the same with the requirements of this Agreement. The Trustee may accept a
certified copy of a resolution of the board of directors or other governing body of any corporate
party as conclusive evidence that such resolution has been duly adopted by such body and that the
same is in full force and effect. As to any fact or matter the method of the determination of
which is not specifically prescribed herein, the Trustee may for all purposes hereof rely on a
certificate, signed by the president or any vice president or by the treasurer or other authorized
officers of the relevant party, as to such fact or matter, and such certificate shall
constitute full protection to the Trustee for any action taken or omitted to be taken by it in good
faith in reliance thereon.

          (b) In the exercise or administration of the Trust hereunder and in the performance of its
duties and obligations under this Agreement, the Trustee, at the expense of the Managing Owner or
an Affiliate of the Managing Owner (other than the Trust) (i) may act directly or through its
agents, attorneys, custodians or nominees pursuant to Contracts entered into with any of them, and
the Trustee shall not be liable for the conduct or misconduct of such agents, attorneys, custodians
or nominees if such agents, attorneys, custodians or nominees shall have been selected by the
Trustee with reasonable care and (ii) may consult with counsel, accountants and other skilled
professionals to be selected with reasonable care by it. The Trustee shall not be liable for
anything done, suffered or omitted in good faith by it in accordance with the opinion or advice of
any such counsel, accountant or other such Persons.

ARTICLE III

INTERESTS; CAPITAL CONTRIBUTIONS

     3.01. General.

          (a) The Managing Owner shall have the power and authority, without approval from any or all of
the Limited Owners, to issue Units in one or more Funds from time to
time as it deems necessary or
desirable, pursuant to registration statements filed from time to

14

 

time with the SEC in accordance
with all applicable securities Laws (“Registration Statements”). Each Fund shall be
separate from all other Funds in respect of the assets and liabilities allocated to that Fund and
shall represent a separate investment portfolio of the Trust. The Managing Owner shall have the
exclusive power without the requirement of obtaining the approval of any or all Limited Owners to
establish and designate such separate and distinct Funds, including as set forth in Section
3.02, and to fix and determine the relative rights, duties and preferences as between Units of
separate Funds as to right of redemption, management fees, incentive fees, trading advisers,
leverage, special and relative rights as to dividends and other distributions and on liquidation,
conversion rights, and conditions under which Funds shall have separate voting rights or no voting
rights, in each case pursuant to Registration Statements.

          (b) The Managing Owner may, without approval from any or all of the Limited Owners, divide
Units in any Fund into two or more Classes, with Units of each such Class having such preferences
and special or relative rights, duties and privileges (including with respect to management fees,
incentive fees, trading strategies, leverage and exchange rights and selling commissions) as the
Managing Owner may determine and in accordance with Section 3.03, in each case pursuant to
Registration Statements. The fact that a Fund shall have been initially established and designated
without any specific establishment or designation of Classes shall not limit the authority of the
Managing Owner to divide a Fund and establish and designate separate Classes thereof pursuant to
Registration Statements.

          (c) The Managing Owner may, without approval from any or all of Limited Owners, divide Units
in any Class into two or more Sub-Classes, with Units of each such Sub-Class having such
preferences and special or relative rights, duties and privileges (including with
respect to management fees, incentive fees, trading strategies, leverage and exchange rights
and selling commissions) as the Managing Owner may determine and in accordance with Section
3.03, in each case pursuant to Registration Statements. The fact that a Class shall have been
initially established and designated without any specific establishment or designation of
Sub-Classes shall not limit the authority of the Managing Owner to divide a Class and establish and
designate separate Sub-Classes thereof pursuant to Registration Statements.

          (d) The number of Units authorized shall be unlimited, and the Units so authorized may be
represented in part by fractional Units of up to four decimal places. All Units will be held in
book-entry form. No certificates or other evidence of beneficial ownership of Units will be
issued.

          (e) From time to time, the Managing Owner may divide or combine the Units in any Fund, Class
or Sub-Class into a greater or lesser number without thereby changing the proportionate beneficial
interests in such Fund, Class or Sub-Class pursuant to Registration Statements. The Managing Owner
may issue Units of any Fund, Class or Sub-Class thereof for such consideration and on such terms as
it may determine (or for no consideration if pursuant to a Unit dividend or split-up), all without
action or approval from any or all of the Limited Owners. All Units when so issued on the terms
determined by the Managing Owner shall be fully paid and non-assessable. The Managing Owner may
classify or reclassify any unissued Units or any Units previously issued and reacquired of any
Fund, Class or Sub-Class thereof into one or more Funds, Classes or Sub-Classes thereof that may be
established and designated from time to time, in each case pursuant to Registration Statements.
The Managing Owner may hold as treasury

15

 

Units, reissue for such consideration and on such terms as
it may determine, or cancel, at its discretion from time to time, any Units in any Fund, Class or
Sub-Class thereof reacquired by the Trust or any Fund. As of the date of this Agreement, each
Initial Fund has only one Class of Units.

          (f) By virtue of the initial contribution by the Managing Owner to each initial Fund as set
forth in Section 1.06(a), the Managing Owner has become the holder of ten (10) General
Units of each Initial Fund.

          (g) Each Owner, by virtue of having purchased or otherwise acquired a Unit, shall be deemed to
have expressly consented and agreed to be bound by the terms of this Agreement.

     3.02. Establishment of Series, or Funds, of the Trust.

          (a) Without limiting the authority of the Managing Owner as set forth in Section
3.02(b) to establish and designate any additional Funds in the future pursuant to Registration
Statements, the Managing Owner hereby establishes and designates ten (10) Initial Funds, as
follows:

          (i) BrookshireTM Raw Materials (U.S.) Core USD Fund (the “Core USD
Fund”);

          (ii) BrookshireTM Raw Materials (U.S.) Core CDN Fund (the “Core CDN
Fund”);

          (iii) BrookshireTM Raw Materials (U.S.) Agriculture USD Fund (the
“Agriculture USD Fund”);

          (iv) BrookshireTM Raw Materials (U.S.) Agriculture CDN Fund (the
“Agriculture CDN Fund”);

          (v) BrookshireTM Raw Materials (U.S.) Metals USD Fund (the “Metals USD
Fund”);

          (vi) BrookshireTM Raw Materials (U.S.) Metals CDN Fund (the “Metals CDN
Fund”);

          (vii) BrookshireTM Raw Materials (U.S.) Energy USD Fund (the “Energy USD
Fund”);

          (viii) BrookshireTM Raw Materials (U.S.) Energy CDN Fund (the “Energy CDN
Fund”);

          (ix) BrookshireTM Raw Materials (U.S.) Accelerated Core USD Fund (the
“Accelerated Core USD Fund”); and

16

 

          (x) BrookshireTM Raw Materials (U.S.) Accelerated Core CDN Fund (the
“Accelerated Core CDN Fund”).

          (b) The establishment and designation of any Fund and Units thereof other than the Initial
Funds shall be effective only upon the execution by the Managing Owner of a written instrument
setting forth such establishment and designation and the relative rights and preferences of such
Fund (or such later time as may be specified in such instrument) and in accordance with the
applicable Registration Statement. At any time when there are no Units outstanding of a previously
established and designated Fund, the Managing Owner may by written instrument abolish that Fund and
the establishment and designation thereof. Each instrument referred to in this paragraph shall
constitute an amendment to this Agreement for all purposes of this Agreement.

     3.03. Establishment of Classes and Sub-Classes. The division of any Fund into two or more
Classes or two or more Sub-Classes and the establishment and designation of such Classes or
Sub-Classes shall be effective upon the execution by the Managing Owner of an instrument setting
forth such division, and the establishment, designation, and relative rights and preferences of
such Classes or Sub-Classes, or as otherwise provided in such instrument, in each case pursuant to
Registration Statements. The relative rights and preferences of the Classes of any Fund and the
Sub-Classes of any Class may differ in such respects as the Managing Owner may determine to be
appropriate, subject to such differences being set forth in the aforementioned instrument and such
differences not altering the allocations described in Article VI. At any time when there
are no Units outstanding of a previously established and designated Class or Sub-Class, the
Managing Owner may by a written instrument abolish that Class or Sub-Class and the establishment
and designation thereof. Each
instrument referred to in this paragraph shall constitute an amendment to this Agreement for all
purposes of this Agreement.

     3.04 Offer of Units.

          (a) Maximum and Minimum Number of Units to Be Offered During the Initial Offering Period
and the Continuous Offering Period.

          (i) Minimum Number of Units.

          (A) In order for the Core Funds to commence trading, a minimum of not less than
1,000,000 Units in the Core Funds (i.e., both the Core USD Fund and the Core
CDN Fund on a combined basis) must be sold. For the avoidance of doubt, in the
event that such 1,000,000 minimum number of Units are sold in one Core Fund and such
Core Fund commences trading, then the other Core Fund shall also commence trading
without regard to the number of Units sold in such other Core Fund.

          (B) In order for any Initial Fund other than the Core Funds to commence
trading, (1) at least one of the Core Funds must commence trading and (2) a minimum
of 100 Units of such Fund must be sold.

The minimum subscription amount for a Fund to commence trading, as set forth above in this
Section 3.04(a)(i), is hereinafter referred to as the “Subscription
Minimum.”

17

 

          (ii) All determinations of whether the Subscription Minimum for a Fund has been
satisfied will be made after taking into account the Units purchased by the Managing Owner
or any of the other Persons enumerated in Section 3.04(i). The Managing Owner may
in its sole discretion waive the Subscription Minimum for any Fund.

          (b) Offering of Units During the Initial Offering Period.

          (i) During the period from the Offer Commencement Date until the sixtieth
(60th) day following the Offer Commencement Date (the “Initial Offering
Period”), Units in each Initial Fund will be offered for sale pursuant to Rule 415 of
Regulation C promulgated under the Securities Act. The Managing Owner may from time to time
extend the Initial Offering Period with respect to one or more Initial Funds for such
periods of time as the Managing Owner may determine in its sole discretion;
provided, that the Initial Offering Period may not be extended past the
240th day following the Offer Commencement Date. Notwithstanding the foregoing,
at any time when sufficient Units in an Initial Fund are sold to satisfy a Subscription
Minimum, then a closing with respect to such Fund (and in the case of a Core Fund, the other
Core Fund) shall occur (each, an “Initial Closing”). For the sake of clarity, (x)
in the event that one or more Initial Funds satisfy the Subscription Minimum applicable to
such Funds, but one or more other Initial Funds have not yet satisfied (or do not satisfy)
Subscription
Minimum applicable to such other Funds, the Initial Closing for the Initial Funds that
have satisfied the Subscription Minimum applicable to such Funds (including in the case of a
Core Fund, the other Core Fund) shall occur and the Initial Offering Period for the Initial
Funds that have not satisfied the Subscription Minimum applicable to such Funds shall
continue and (y) the Initial Offering Period with respect to certain Funds may continue even
as the Continuous Offering Period with respect to other Funds occurs.

          (ii) If (A) the Subscription Minimum for an Initial Fund is not sold during the Initial
Offering Period (as extended by the Managing Owner pursuant to Section 3.04(b)(i))
or (B) the offering of an Initial Fund is terminated, then all Subscription Funds
theretofore paid in respect of such Fund will promptly (but in no event later than ten (10)
Business Days thereafter) be refunded directly to the applicable Subscriber or payor, as the
case may be, via first class U.S. mail, without interest and without deduction for expenses;
provided, however, that if the return of the Subscription Funds within such ten (10)
Business Day period cannot be accomplished, such return will occur as soon thereafter as
possible.

          (iii) During the Initial Offering Period, all Subscription Funds will be deposited with
and held by the Escrow Agent in an interest bearing escrow account in the name of the
applicable Fund. Until the earlier of (A) the Initial Closing for an Initial Fund or (B)
the termination of the offering of such Fund and the return of all Subscription Funds
theretofore paid by Subscribers or other Persons with respect to such Fund, the Managing
Owner shall direct the Escrow Agent to invest all Subscription Funds held in escrow by the
Escrow Agent only in U.S. Treasury Obligations or other investments specified by the
Managing Owner that are consistent with the provisions of Rule 15c2-4 of the Securities
Exchange Act. Upon satisfaction of the Subscription Minimum for an

18

 

Initial Fund, all
interest earned on Subscription Funds from accepted Subscribers for such Fund will be
contributed to such Fund. At the Initial Closing, the Capital Contribution of each Limited
Owner in such Fund will be increased by an allocation of income relating to such interest on
a pro rata basis (taking into account the timing and amount of such Limited Owner’s
subscription).

          (c) Offering of Units During the Continuous Offering Period. In the event that the
Subscription Minimum for an Initial Fund is satisfied, such Fund may continue to offer Units and
admit additional Subscribers as Limited Owners and/or accept additional subscriptions from existing
Limited Owners of such Fund, during the Continuous Offering Period. The “Continuous Offering
Period,” with respect to any Initial Fund, means the period commencing on the Initial Closing
of such Fund and ending on the date when the maximum number of Units of such Fund that have been
registered are then issued and outstanding. The Managing Owner may terminate the Continuous
Offering Period with respect to any Initial Fund at any time and without regard to whether the
Managing Owner terminates the Continuous Offering Period for any other Fund.

          (d) Arrangements for the Offering. The Managing Owner shall make such arrangements,
and shall appoint such selling agents (“Selling Agents”) to sell Units, on such terms and
conditions as it shall deem appropriate in its sole discretion, for the sale of Units in the
Initial Funds.

          (e) Subscription Process.

          (i) In order to validly subscribe for Units in an Initial Fund (either during the
Initial Offering Period or the Continuous Offering Period),

          (A) a prospective Subscriber must submit to such Person’s Selling Agent a duly
completed Subscription Agreement;

          (B) a prospective Subscriber must demonstrate that an investment in Units is a
suitable and appropriate investment for such prospective Subscriber, based on
information provided by the prospective Subscriber regarding his, her or its
financial situation and investment objectives, and satisfy the requirements
applicable to such person under applicable Law and as established by the Managing
Owner (including with respect to the suitability standards described in the NASAA
Guidelines and in applicable state Laws);

          (C) a prospective Subscriber must have received a copy of the prospectus
relating to the applicable Fund at least five (5) Business Days prior to the date of
such prospective Subscriber’s Subscription;

          (D) the subscription of such prospective Subscriber must not result in Benefit
Plan Investors owning 25% or more of the value of the applicable Initial Fund;

          (E) a prospective Subscriber must not be a resident of Canada for purposes of
the Income Tax Act (Canada);

19

 

          (F) the subscription of such prospective Subscriber must not result in more
than 25% of the fair market value of the total investments in all of the Funds being
owned by persons and partnerships that are “affiliated” with the Administrator if
such Administrator is a corporation or trust resident in Canada, or a Canadian
partnership, all within the meaning of the Income Tax Act (Canada); and

          (G) the Managing Owner must have receive cleared funds from or on behalf of
such Person in accordance with Section 3.04(e)(ii) for the full amount of a
subscription.

A Person who has satisfied the requirements of clauses (A) through (G) above, and whose
subscription has been accepted by the Managing Owner, is referred to in this Agreement as a
“Subscriber,” and the time when a Person has satisfied such requirements and whose
subscription has been accepted by the Managing Owner is referred to in this Agreement as the
“Effective Time of Subscription”; provided, that if the satisfaction of the
requirements set forth in clauses (A) through (G) above and the acceptance of subscription
by the Managing Owner occurs after 4:00 P.M. New York time on a Business Day or on a day
that is not a Business Day, then the “Effective Time of Subscription” for such Subscriber
shall be deemed to be the next Business Day. Settlement of subscriptions (both during the
Initial Offering Period and the Continuous
Offering Period) will occur at 6:00 P.M. New York time on the Effective Time of
Subscription.

          (ii) All subscription funds for an Initial Fund (“Subscription Funds”) must be
paid in the applicable currency of the applicable Fund (i.e., USD for USD Funds and
CDN for CDN Funds) by check or via wire transfer to the account or accounts set forth in the
Subscription Agreement, or by such other means and/or in such other currency as the Managing
Owner may permit in its sole discretion.

          (iii) All subscriptions are subject to acceptance, in whole or in part, by the Managing
Owner and the Administrator. The Managing Owner or Administrator may reject subscriptions
for any reason whatsoever, including: (A) lack of suitability of a prospective Subscriber;
(B) hostile market conditions; (C) inability of the Managing Owner to calculate the Net
Asset Value for Units of the applicable Fund; (D) all then registered Units in the
applicable Fund having been issued and being outstanding; (E) acceptance of all or part of
the subscription would result in the ownership of 25% or more of the value of the applicable
Fund by Benefit Plan Investors; and/or (F) acceptance of all or part of the subscription
would result in the ownership of 25% or more of the value of the total investments in all of
the Funds by persons and partnerships that are “affiliated” with the Administrator if such
Administrator is a corporation or trust resident in Canada, or a Canadian partnership, all
within the meaning of the Income Tax Act (Canada). In the event that the Managing Owner or
Administrator rejects a subscription, any and all interest earned thereon will be retained
by the applicable Fund for the benefit of all investors in such Fund. Proceeds for rejected
subscriptions will be returned directly to the applicable investor via first class U.S.
mail, without interest and without deduction for expenses.

20

 

          (iv) No Person may revoke, withdraw, rescind or terminate a subscription after the
Effective Time of Subscription for such Person; provided, however, a Person
may revoke his subscription if such Person did not receive the prospectus relating to the
applicable Fund at least five (5) Business Days prior to the date of submitting his
Subscription Agreement.

          (v) All Subscribers will receive written confirmation from the Managing Owner of the
acceptance of a subscription for Units in the applicable Fund.

          (vi) As soon as reasonably practicable following the Initial Closing of an Initial
Fund, and thereafter from time to time during the Continuous Offering Period following the
Effective Time of Subscriptions, the Managing Owner will admit the accepted Subscribers in
such Fund as Limited Owners of such Fund by (A) causing such Limited Owners to have been
deemed to execute this Agreement pursuant to the Power of Attorney included in the
Subscription Agreement and (B) making an entry on the books and records of such Fund
reflecting that such Subscribers have been admitted as Limited Owners of such Fund. Each
such accepted Subscriber will be deemed to be a Limited Owner of the applicable Fund upon
completion of the actions described in the preceding sentence.

          (vii) Subscription Fee. As described in Section 4.07(d), a
subscription fee (the “Subscription Fee”) of 0.5% to 3% of the Subscription Funds
paid by each Limited Owner will be deducted from such Subscription Funds and paid to the
applicable Selling Agents, and the Capital Contribution of such Limited Owner shall be
reduced accordingly. Subject to the terms of the Contract with the applicable Selling
Agent, each Selling Agent and the relevant Subscriber may negotiate the Subscription Fee to
be charged to such Subscriber, provided, that the Subscription Fee shall not be less
than 0.5%, nor more than 3%, of the purchase price of the Units.

          (viii) Trailing Fee. As described in Section 4.07(e), each Initial
Fund will pay monthly trailing fees (the “Trailing Fees”) to the applicable Selling
Agent equal to 1% per annum of such Fund’s Net Asset Value, calculated daily and paid
monthly, on behalf of the applicable Limited Owner. Trailing Fees will be paid to Selling
Agents for on-going services on a continuous basis which may include advising Limited Owners
of the Net Asset Value of the Trust, of the relevant Fund and of their Units in such Fund,
responding to Limited Owners’ inquiries about monthly statements and annual reports and tax
information provided to them, advising Limited Owners whether to make additional capital
contributions to the Funds or to redeem or exchange their Units, assisting with exchanges or
redemptions of Units, providing information to Limited Owners with respect to futures and
forward market conditions and providing further services which may be requested by Limited
Owners. Trailing Fees may not be waived by any Selling Agent; provided, that no
further Trailing Fees shall be payable from and after such time as the Trailing Fees
theretofore paid in respect of a Unit, when added together with the Subscription Fees paid
in respect of such Unit, are equal to or exceed 10% of the purchase price of such Unit.

21

 

          (ix) The Managing Owner in its sole discretion may change any or all procedural, notice
or other requirements related to subscription upon written notice to Subscribers or
potential Subscribers.

          (f) Calculation of Capital Contributions and Units to be Received by Each Subscriber.

          (i) The Capital Contribution of each Subscriber shall be equal to the net amount of
Subscription Funds received by the applicable Fund from such Subscriber, whether pursuant to
an initial or subsequent investments.

          (ii) Each Limited Owner shall receive a number of Limited Units equal to the initial or
additional Capital Contribution then being made by such Subscriber divided by the price per
Unit specified in Section 3.04(g).

          (g) Price of Units during the Initial Offering Period and Continuous Offering Periods.

          (i) During the Initial Offering Period, Limited Units will be sold at a price of
US$10.00 per Unit in each USD Fund and CDN$10.00 per Unit in each CDN Fund.

          (ii) During the Continuous Offering Period, until the maximum number of then-registered
Units in an Initial Fund are sold and outstanding, Units will be sold at a price equal to
the Per Unit Net Asset Value of the applicable Fund calculated as of the Valuation Point.

          (h) Minimum Subscription Denominations.

          (i) Except as provided in the remainder of this Section 3.04(h), (A) the
minimum initial subscription amount for any Subscriber in any Initial Fund shall be
USD$2,000 (in the case of any USD Fund) or CDN$2,000 (in the case of any CDN Fund).
Subscribers may subscribe, whether during the Initial Offering Period or the Continuous
Offering Period, for additional Units in subscription amounts equal to even multiples of
USD$500 (in the case of a USD Fund) or CDN$500 (in the case of a CDN Fund).

          (ii) Except as provided in the remainder of Section 3.04(h), Benefit Plan
Investors shall have no minimum subscription amount, whether during the Initial Offering
Period or the Continuous Offering Period and whether with respect to initial or additional
subscriptions; provided, however, that all subscriptions by Benefit Plan
Investors (including Individual Retirement Accounts) shall be in subscription amounts equal
to even multiples of $500, or USD$500 (in the case of a USD Fund) or CDN$500 (in the case of
a CDN Fund).

          (iii) The minimum initial subscription amount for any Person that is a resident of
Texas (including a Benefit Plan Investor or an Individual Retirement Account) shall be
USD$5,000 (whether in the case of a USD Fund or a CDN Fund). Residents of

22

 

Texas (including
Benefit Plan Investors or Individual Retirement Accounts) may subscribe, whether during the
Initial Offering Period or the Continuous Offering Period, for additional Units in
subscription amounts equal to even multiples of USD$500 (in the case of a USD Fund) or
CDN$500 (in the case of a CDN Fund).

          (iv) In the event that applicable Law imposes a larger minimum subscription amount on a
particular Subscriber than is set forth above (either with respect to the initial or
additional subscriptions for Units), then the minimum subscription amount for such
Subscriber shall be the minimum subscription amount imposed under applicable Law.

          (v) The Managing Owner may, in its sole discretion and to the extent permitted by
applicable Law, waive the above minimum subscription amounts set forth in clauses (i) to
(iii) of this Section 3.04(h) and accept smaller subscription amounts, whether
during the Initial Offering Period or the Continuous Offering Period and whether with
respect to initial or additional subscriptions.

          (i) Purchase of Units by Managing Owner, its Affiliates and Others. Subject to
approval by the Managing Owner, any Commodity Broker, or any principal, stockholder, director,
officer, employee and/or Affiliate of the Managing Owner or a Commodity Broker may
purchase any number of Limited Units and will be treated as a Limited Owner with respect to
such Units.

     3.05. Managing Owner’s Required Contribution. Subject to all applicable Laws, other
than the Managing Owner’s previous cash contributions with respect to the General Units, the
Managing Owner shall not be required to make any cash contributions to the Trust or to any Fund.
The Managing Owner has purchased General Units in each Initial Fund. In the event that any
Affiliate of the Managing Owner purchases any Limited Units, the Affiliate shall, with respect to
such Limited Units, enjoy all of the rights and privileges and be subject to all of the obligations
and duties of a Limited Owner, except as otherwise provided herein.

     3.06. Assets of Funds. All net consideration received by the Trust or any Fund for
the issue or sale of Units of a Fund, together with all of the Trust Estate in which such
consideration is invested or reinvested, all income, earnings, profits, and proceeds thereof,
including any proceeds derived from the sale, exchange or liquidation of such assets, and any funds
or payments derived from any reinvestment of such proceeds in whatever form the same may be, shall
irrevocably belong to such Fund for all purposes, subject only to the provisions of Sections
4.06, 4.07 and 4.08, the rights of creditors of such Fund and except as may
otherwise be required by applicable tax Laws, and shall be so recorded upon the books of account of
the Trust and such Fund. Separate and distinct records shall be maintained for each Fund and the
assets associated with a Fund shall be held and accounted for separately from the other assets of
the Trust or any other Fund (except for cash maintained at the Trust level). In the event that
there is any Trust Estate, or any income, earnings, profits, and proceeds thereof, funds or
payments which are not readily identifiable as belonging to any particular Fund, the Managing Owner
shall allocate them among the Funds in proportion to their respective Net Asset Values as of the
next prior Valuation Point at the time of the allocation. Each such allocation by the Managing
Owner if made in good faith shall be conclusive and binding upon all Owners for all purposes.

23

 

     3.07. Liabilities of Funds.

          (a) The Trust Estate of each Fund shall be charged only with (i) the liabilities, expenses,
costs, charges and reserves attributable to such Fund and (ii) its share (as set forth in
Section 4.07) of the fees and expenses of the Trust. Each written Contract made or issued
by or on behalf of a particular Fund shall, to the maximum extent practicable, include a recitation
limiting the obligation or claim represented thereby to that Fund and its assets.

          (b) Without limitation of the foregoing provisions of this Section, but subject to the right
of the Managing Owner to allocate general liabilities, expenses, costs, charges or reserves as
herein provided, the debts, liabilities, obligations and expenses incurred, contracted for or
otherwise existing with respect to a particular Fund shall be enforceable (i) solely against the
assets of such Fund and the Managing Owner (solely to the extent of the General Units owned by the
Managing Owner in such Fund), and (ii) not against the assets of the Trust generally or of any
other Fund. Except as otherwise expressly provided in this Agreement, the
debts, liabilities, obligations and expenses incurred, contracted for or otherwise existing
with respect to the Trust generally shall be enforceable against the assets of the Fund or Funds to
which such debts, liabilities, obligations or expenses are allocable. Notice of this limitation on
inter-series liabilities shall be set forth in the Certificate of Trust (whether originally or by
amendment), and upon the giving of such notice in the Certificate of Trust and the filing of such
notice in the Office of the Secretary of State, the statutory provisions of Section 3804 of the
Trust Act relating to limitations on inter-series liabilities (and the statutory effect under
Section 3804 of setting forth such notice in the Certificate of Trust) shall become applicable to
the Trust and each and every Fund. Every Unit, note, bond, Contract, instrument, certificate or
other undertaking made or issued by or on behalf of a Fund shall, to the maximum extent
practicable, include a recitation limiting the obligation on Units represented thereby to the
assets of that Fund.

          (i) Except as set forth below, any debts, liabilities, obligations, indebtedness,
expenses, interests and claims of any nature and all kinds and descriptions (collectively,
“Claims”), if any, of the Managing Owner and the Trustee (the “Subordinated
Claims”) incurred, contracted for or otherwise existing, arising from, related to or in
connection with a Fund and its assets (the “Applicable Fund”) and the assets of the
Trust shall be expressly subordinate and junior in right of payment to any and all other
Claims against the Trust and the Applicable Fund and any of their respective assets which
may arise as a matter of Law or pursuant to any Contract, provided, however,
that bona fide Claims of either the Managing Owner or the Trustee, if any, against the
Applicable Fund shall be pari passu and equal in right of repayment and distribution with
all other bona fide Claims against the Applicable Fund;

          (ii) The Managing Owner and the Trustee will not take, demand or receive from any Fund
or the Trust or any of their respective assets (other than the Applicable Fund or its
assets) any payment for the Subordinated Claims, except in accordance with Section
3.07(b)(i);

          (iii) Subject to Section 3.07(b)(i), the Claims of the Managing Owner and the
Trustee with respect to the Applicable Fund shall only be asserted and

24

 

enforceable against
the Applicable Fund’s assets and
the Managing Owner and its assets, and shall not be
asserted or enforceable for any reason whatsoever against the assets of any other Fund or
the Trust generally;

          (iv) If the Claims of the Managing Owner or the Trustee against the Applicable Fund or
the Trust are secured in whole or in part, each of the Managing Owner and the Trustee hereby
waives (under section 1111(b) of the Bankruptcy Code (11 U.S.C. § 1111(b))) any right to
have any deficiency Claims (which deficiency Claims may arise in the event such security is
inadequate to satisfy such Claims) treated as unsecured Claims against the Trust or any
other Fund, as the case may be;

          (v) In furtherance of the foregoing, if and to the extent that the Managing Owner
and/or the Trustee receive monies in connection with the Subordinated Claims from a Fund or
the Trust (or their respective assets) other than the Applicable Fund or the Managing Owner
and their respective assets and except as permitted by this
Section 3.07(b), the Managing Owner and/or the Trustee, as the case may be,
shall be deemed to hold such monies in trust and shall promptly remit such monies to the
Fund or the Trust that paid such amounts for distribution by such Fund or the Trust in
accordance with the terms hereof; and

          (vi) The provisions of this Section 3.07(b) shall apply at all times
notwithstanding that the Claims are satisfied, and notwithstanding that the agreements in
respect of such Claims are terminated, rescinded or canceled.

          (vii) Any Contract entered into by the Trust, any Fund, or the Managing Owner, on
behalf of the Trust generally or any Fund with the Managing Owner or the Trustee, including
the Subscription Agreements entered into with each Subscriber, will, to the maximum extent
possible, include language substantially similar to the language set forth in Section
3.07(b).

     3.08. Distributions.

          (a) Distributions with respect to Units of a particular Fund or any Class or Sub-Class thereof
shall be made in accordance with Section 6.04 and shall be paid with such frequency as the
Managing Owner may determine, which may be daily or otherwise, to the Owners in that Fund, Class or
Sub-Class, from such of the income and capital gains, accrued or realized, from the Trust Estate
belonging to that Fund, or in the case of a Class, belonging to that Fund and allocable to that
Class, or in the case of a Sub-Class, belonging to that Class and allocable to that Sub-Class, as
the Managing Owner may determine, in its sole discretion, after providing for actual and accrued
liabilities belonging to that Fund. Such distributions may be made in cash or Units of that Fund,
Class or Sub-Class or a combination thereof as determined by the Managing Owner, in its sole
discretion, or pursuant to any program that the Managing Owner may have in effect at the time for
the election by each Owner of the mode of the making of such dividend or distribution to that
Owner.

           (b) The Units in a Fund, a Class or a Sub-Class shall represent beneficial interests in the
Trust Estate belonging to such Fund or in the case of a Class, belonging to such

25

 

Fund and allocable
to such Class or in the case of a Sub-Class, belonging to such Class and allocable to such
Sub-Class. Each Owner in a Fund, Class or Sub-Class shall be entitled to receive its share of
distributions of income and capital gains made with respect to such Fund, Class or Sub-Class, in
each case as provided in Section 6.04. Such distributions shall be paid solely out of the
funds and property of such Fund or in the case of a Class, the funds and property of such Fund and
allocable to such Class of the Trust or in the case of a Sub-Class, the funds and property of such
Class and allocable to such Sub-Class of the Trust. Upon liquidation or termination of a Fund,
Owners in such Fund, Class or Sub-Class shall be entitled to receive a share of the Trust Estate
belonging to such Fund or in the case of a Class, belonging to such Fund and allocable to such
Class, or in the case of a Sub-Class, belonging to such Class and allocable to such Sub-Class, in
each case as provided in Section 13.04.

     3.09. Voting Rights.
Notwithstanding any other provision hereof, on each matter submitted to a vote of the Owners
of a Fund, each Owner shall be entitled to a proportionate vote based upon the product of the Per
Unit Net Asset Value of such Fund multiplied by the number of Units, or fraction thereof, standing
in such Owner’s name on the books of such Fund. As to any matter which affects Units of more than
one Fund, the Owners of each affected Fund shall be entitled to vote, and each such Fund shall vote
as a separate class, as specified in the preceding sentence.

     3.10. Equality. Except as provided herein or in the instrument designating and
establishing any Class, Sub-Class or Fund, all Units of a Fund shall represent an equal
proportionate beneficial interest in the assets belonging to that Fund subject to the liabilities
belonging to that Fund, and each Unit of a Fund, Classes or Sub-Class shall be equal to each other
Unit of that Fund, Class or Sub-Class; provided, that the provisions of this sentence shall
not restrict any distinctions permissible under Section 3.08 that may exist with respect to
dividends and distributions on Units of the same Fund, Class or Sub-Class. The Managing Owner may
from time to time divide or combine the Units of a Fund, Class or Sub-Class into a greater or
lesser number of Units of that Fund, Class or Sub-Class without thereby changing the proportionate
beneficial interest in the assets belonging to that Fund or in any way affecting the rights of
Owners of any other Fund, Class or Sub-Class.

     3.11. Exchange of Units. Subject to compliance with the requirements of applicable
Law and the provisions of any applicable Registration Statement, the Managing Owner shall have the
authority to provide that Owners of any Fund shall have the right to exchange said Units into one
or more other Funds in accordance with such requirements and procedures as may be established by
the Managing Owner. The Managing Owner shall also have the authority to provide that Owners of any
Class of a Fund shall have the right to exchange said Units into one or more other Classes of that
Fund or any other Fund in accordance with such requirements and procedures as may be established by
the Managing Owner. The Managing Owner shall also have the authority to provide that Owners of any
Sub-Class of a Fund shall have the right to exchange said Units into one or more other Sub-Classes
of that Fund or any other Fund in accordance with such requirements and procedures as may be
established by the Managing Owner. Any such exchange shall be treated as a redemption of the Units
in one Fund or Class followed by an immediate purchase of Units in the second Fund or Class. The
exchange provisions applicable to the Initial Funds are set forth in Section 7.04.

26

 

ARTICLE IV

THE MANAGING OWNER

     4.01. Management of the Trust. Pursuant to Section 3806 of the Trust Act, the Trust
and each Fund shall be managed by the Managing Owner and the conduct of the Trust’s business shall
be controlled and conducted solely by the Managing Owner in accordance with this Agreement, the
Registration Statement and applicable Law.

     4.02. Authority of Managing Owner. In addition to and not in limitation of any rights
and powers conferred by Law, the Registration Statement or any other provision of this Agreement,
and except as limited, restricted or prohibited by the express provisions of this Agreement, the
Registration Statement or the Trust Act, the Managing Owner shall have and may exercise on behalf
of the Trust and each Fund all powers and rights necessary, proper, convenient or advisable to
effectuate and carry out the purposes, business and objectives of the Trust and each Fund,
including the following:

          (a) To enter into, execute, deliver and maintain Contracts, and any or all other documents and
instruments, and to do and perform all such things, as may be in furtherance of the purposes of the
Trust or any one or more Funds or necessary or appropriate for the offer and sale of Units and the
conduct of Trust or Fund activities, including entering into, executing, delivering and maintaining
Contracts with third parties for:

          (i) Commodity and Fixed Income Securities brokerage services, as well as administrative
services necessary to the prudent operation of the Trust or any Fund;

          (ii) Commodity trading advisory services relating to the purchase and sale of all
Commodities positions on behalf of Funds, if not performed by the Managing Owner or
Affiliate(s) of the Managing Owner; and

          (iii) Fixed Income Securities advisory services relating to the purchase and sale of
Fixed Income Securities on behalf of the Funds, if not performed by the Managing Owner or
Affiliate(s) of the Managing Owner.

          (b) To establish, maintain, deposit into, sign checks and/or otherwise draw upon accounts on
behalf of the Trust or any Fund with appropriate banking and savings institutions, and execute
and/or accept any instrument or Contract incidental to the Trust’s or any Fund’s business and in
furtherance of its purposes, any such instrument or Contract so executed or accepted by the
Managing Owner in the Managing Owner’s name shall be deemed executed and accepted on behalf of the
Trust or the applicable Fund by the Managing Owner;

          (c) To deposit, withdraw, pay, retain and distribute the Trust Estate or any portion thereof
in any manner consistent with the provisions of this Agreement;

          (d) To pay or authorize the payment of distributions to the Owners and expenses of the Trust
and the Funds;

27

 

          (e) To invest or direct the investment of funds of the Trust and/or any Fund and prohibit any
transactions contemplated hereunder which may constitute prohibited transactions under ERISA or the
Code;

          (f) To make any elections on behalf of the Trust and/or any Fund under the Code, or any other
applicable federal or state tax Law as the Managing Owner shall determine to be in the best
interests of the Trust and/or any Fund;

          (g) To redeem mandatorily any Limited Owner in accordance with Section 7.03;

          (h) To admit Affiliate(s) of the Managing Owner as additional Managing Owners, subject to the
approval of a majority of the Limited Owners;

          (i) To override any trading instructions: (i) that the Managing Owner, in its sole discretion,
determines in good faith to be in violation of any trading policy or limitation of the Trust or any
Fund; or (ii) as and to the extent necessary, to fund distributions, redemptions (including special
redemptions), or to pay the expenses of any Fund. For the avoidance of doubt, the Managing Owner’s
right to override trading instructions shall not limit the Managing Owner’s right to make trading
decisions with respect to Commodities or Fixed Income Securities at any time.

     4.03. Obligations of the Managing Owner. In addition to the obligations expressly
imposed upon the Managing Owner by the Trust Act, the Registration Statement or elsewhere in this
Agreement, the Managing Owner shall:

          (a) Devote such of its time to the business and affairs of the Trust and each Fund as it
shall, in its good faith discretion, determine to be necessary to conduct the business and affairs
of the Trust and each Fund for the benefit of the Trust, each Fund and the Limited Owners;

          (b) Execute, file, record and/or publish all certificates, statements and other documents and
do any and all other things as may be appropriate for the formation, qualification and operation of
the Trust and each Fund and for the conduct of their respective business in all appropriate
jurisdictions;

          (c) Retain independent public accountants to audit the accounts of each Fund;

          (d) Employ attorneys to represent the Trust and/or each Fund;

          (e) Use its best efforts to maintain the status of the Trust as a “statutory trust” for state
Law purposes and the status of each Fund as a partnership that is not a publicly traded partnership
for Federal income tax purposes;

          (f) Monitor the trading policies and limitations of each Fund, such that the trading policies
of each Fund conform to the description of such Fund in the Registration Statement under the
heading “FUNDS,” and the activities of each Fund in carrying out those policies in compliance with
the Registration Statement;

28

 

          (g) Monitor the brokerage fees charged to each Fund, and the services rendered by Commodity
Brokers to each Fund, to determine whether the fees paid by, and the services rendered to, each
Fund for futures and fixed income brokerage are at competitive rates and are the best price and
services available under the circumstances, and if necessary, renegotiate the brokerage fee
structure to obtain such rates and services for each Fund;

          (h) Subject to Section 4.10, have fiduciary responsibility for the safekeeping and use
of the Trust Estate of each Fund, whether or not in the Managing Owner’s immediate possession or
control, and not to employ or permit others to employ funds or assets of any Fund (including any
interest earned thereon) except as and to the extent permitted by the NASAA Guidelines for the
benefit of each Fund, including, among other things, with respect to the utilization of any portion
of the Trust Estate as a compensating balance for the exclusive benefit of the Managing Owner. The
Managing Owner shall at all times act with integrity and good faith and exercise due diligence in
all activities relating to the conduct of the business of the Trust and/or each Fund and in
resolving conflicts of interest. Neither the Trust nor any Fund shall permit any Limited Owner to
contract away the fiduciary duty owed to the Limited Owners by the Managing Owner under this
Agreement or the Trust Act, but the duties and liabilities of any Covered Person may be expanded or
restricted by the provisions of this Agreement.

          (i) Admit substitute Limited Owners in accordance with this Agreement;

          (j) Refuse to recognize attempted Transfers or assignments of Units not made in accordance
with Article V;

          (k) Maintain (i) with respect to each Fund, a current list in alphabetical order, of the names
and last known addresses and, if available, business telephone numbers of, and number of Units
owned by, each Limited Owner, and (ii) the other documents related to the Trust and the Funds
described in Section 9.06, in each case at the Trust’s principal place of business. Each
such list shall be printed on white paper in clearly legible print and shall be updated quarterly.
Upon request by a Limited Owner or its representative, and payment by the Limited Owner of the cost
of reproduction and mailing (if applicable), the Managing Owner will make available a copy of such
list for the applicable Fund during normal business hours for inspection or furnish a copy of such
list, as requested, to the Limited Owner or its representative within ten (10) Business Days of the
request therefor, for any purpose reasonably related to the Limited Owner’s interest as a
beneficial owner of the applicable Fund, including matters relating to a Limited Owner’s voting
rights hereunder or the exercise of a Limited Owner’s rights under federal proxy law;
provided, however, that the Limited Owner requesting such list shall give written
assurance that the list will not be used for any commercial purpose. Limited Owners and their
representatives shall be permitted access to review all other records of the Trust, and each Fund
in which they own Units, upon reasonable written notice, at any time during the business hours of
the Trust.

          (l) Not itself receive, or permit any of its Affiliates to receive, rebates, or engage in or
permit any of its Affiliates to any reciprocal business arrangements which would circumvent the
foregoing prohibition;

29

 

          (m) Not effect any transactions in Commodity Contracts with any futures commission merchant
that is directly or indirectly an Affiliate of the Managing Owner, unless such transactions are
effected at competitive rates;

          (n) Maintain compliance with the applicable registration requirements under the CE Act;

          (o) Establish minimum income and Net Worth suitability standards for Subscribers based on the
NASAA Guidelines and applicable state Laws, as set forth in the Registration Statement;

          (p) Maintain a net worth in excess of the minimum net worth requirements under the NASAA
Guidelines, and not take or voluntarily permit to be taken any affirmative action to reduce its net
worth below any regulatorily-required amounts;

          (q) Not file any document with a public authority in Canada in accordance with the securities
legislation of Canada or of any province in order to permit the distribution of interests in the
Trust to a resident of Canada for purposes of the Income Tax Act (Canada); and

          (r) Not direct any promotion of investments in any of the Funds in the Trust principally at a
person that the Managing Owner knows, or ought to know after reasonable inquiry, is at that time
resident in Canada for purposes of the Income Tax Act (Canada).

     4.04. General Prohibitions. Neither the Trust nor any Fund shall:

          (a) Borrow money from or loan money to any Owner or other Person, in each case other than with
respect to (i) the deposit on margin with respect to the initiation and maintenance of Commodities
positions of any Fund, (ii) in the case of the Accelerated Core Funds, incurring leverage, as and
to the extent described in the Registration Statement or (iii) obtaining lines of credit for the
trading of forward contracts; provided, however, neither the Trust nor any Fund
shall incur any indebtedness on a non-recourse basis;

          (b) Create, incur, assume or suffer to exist any lien, mortgage, pledge conditional sales or
other title retention agreement, charge, security interest or encumbrance, except (i) the right
and/or obligation of a Commodity Broker to close out sufficient Commodities positions of a Fund so
as to restore the Fund’s account to proper margin status in the event that the Fund fails to meet a
Margin Call; (ii) liens for taxes not delinquent or being contested in good faith and by
appropriate proceedings and for which appropriate reserves have been established; (iii) deposits or
pledges to secure obligations under workmen’s compensation, social security or similar Laws or
under unemployment insurance; (iv) deposits or pledges to secure Contracts (other than Contracts
for the payment of money), leases, statutory obligations, surety and appeal bonds and other
obligations of like nature arising in the ordinary course of business; (v) mechanic’s,
warehousemen’s, carrier’s, workmen’s, materialmen’s or other like liens arising in the ordinary
course of business with respect to obligations which are not due or which are being contested in
good faith, and for which appropriate reserves have been established if required by generally
accepted accounting principles; or (vi) liens arising under ERISA;

30

 

          (c) Commingle its assets with those of any other Person, except to the extent permitted under
the CE Act and the regulations promulgated thereunder;

          (d) Directly or indirectly pay or award any finder’s fees, commissions or other compensation
to any Persons engaged by a potential Limited Owner for investment advice as an inducement to such
advisor to advise the potential Limited Owner to purchase Limited Units in the Trust, except for
payments to properly registered broker-dealers and other properly licensed
sales Persons of customary sales commissions and fees paid in connection with the sale of
Limited Units;

          (e) Engage in Pyramiding of its Commodities positions;

          (f) Enter into any Contract with the Managing Owner or any Affiliate thereof (except for
Contracts related to the sale of Units) (i) which has a term of more than one year and which cannot
be canceled by the Trust or the applicable Fund without penalty on not more than sixty (60) days’
prior written notice or (ii) for the provision of goods and services, except at rates and terms at
least as favorable as those which may be obtained from third parties in arms-length negotiations;

          (g) Permit churning of its Commodity or Fixed Income Securities trading account(s) for the
purpose of generating excess brokerage commissions;

          (h) Enter into any exclusive brokerage Contract;

          (i) Operate the Trust in any manner so as to contravene section 3804 of the Trust Act;

          (j) Cause the Trust or any Fund to elect to be treated as an association taxable as a
corporation for Federal income tax purposes;

          (k) Permit rebates to be received by the Managing Owner or any Affiliate of the Managing
Owner, or permit the Managing Owner or any Affiliate of the Managing Owner to engage in any
reciprocal business arrangements which would circumvent the foregoing prohibition;

          (l) Pay brokerage commissions that exceed amounts permitted under the NASAA Guidelines, NASD,
Inc. rules and regulations, or applicable state Laws;

          (m) Not file any document with a public authority in Canada in accordance with the securities
legislation of Canada or of any province in order to permit the distribution of interests in the
Trust to a resident of Canada for purposes of the Income Tax Act (Canada); or

          (n) Not direct any promotion of investments in any of the Funds in the Trust principally at a
person that the Managing Owner knows, or ought to know after reasonable inquiry, is at that time
resident in Canada for purposes of the Income Tax Act (Canada).

31

 

     4.05. Liability of Covered Persons. No Covered Person shall have any liability to the
Trust, any Fund, any Owner or any other Covered Person for any loss suffered by the Trust or any
Fund which arises out of any action or inaction of such Covered Person if (i) such Covered Person,
in good faith, determined that such course of conduct was in the best interest of the Trust or the
applicable Fund, and (ii) such course of conduct did not constitute negligence or misconduct of
such Covered Person.
Subject to the foregoing, neither the Managing Owner nor any other Covered Person shall be
personally liable for the return or repayment of all or any portion of the capital or profits of
any Limited Owner or assignee thereof, it being expressly agreed that any return of capital or
profits pursuant to this Agreement shall be made solely from the assets of the Trust or the
applicable Fund, as the case may be, without any rights of contribution from the Managing Owner or
any other Covered Person.

     4.06. Indemnification of the Managing Owner.

          (a) To the maximum extent permitted by applicable Law, each Fund shall indemnify and hold
harmless the Managing Owner (x) in full against any liability or loss suffered by the Managing
Owner in connection with the Managing Owner’s activities in respect of such Fund and (y) for such
Fund’s pro rata share as Extraordinary Fees and Expenses of any liability or loss suffered by the
Managing Owner in connection with the Managing Owner’s activities in respect of the Trust, if all
of the following conditions are satisfied (i) the Managing Owner was acting on behalf of or
performing services for the Trust or the applicable Fund and in good faith determined that such
course of conduct was in the best interests of the Trust or the applicable Fund and such liability
or loss was not the result of negligence, misconduct or a breach of this Agreement on the part of
the Managing Owner and (ii) any such indemnification will only be recoverable from the Trust Estate
of the applicable Fund.

          (b) Notwithstanding the provisions of Section 4.06(a), the Managing Owner and any
Person acting as broker-dealer for the Trust or any Fund shall not be indemnified for any losses,
liabilities or expenses arising from or out of an alleged violation of Federal or state securities
Laws unless (i) there has been a successful adjudication on the merits of each count involving
alleged securities Law violations as to the particular indemnitee; (ii) such claims have been
dismissed with prejudice on the merits by a court of competent jurisdiction as to the particular
indemnitee; or (iii) a court of competent jurisdiction approves a settlement of the claims against
a particular indemnitee and finds that indemnification of the settlement and related costs should
be made.

          (c) In the case of Section 4.06(b), the court of law considering the request for
indemnification shall have been advised of the position of the SEC and the position of any state
securities regulatory authority where the Units were offered or sold, with respect to the issue of
indemnification for violations of securities Laws; provided, that the court need only be
advised and consider the positions of the securities regulatory authorities of those states in
which the party seeking indemnification claims it was offered or sold Units.

          (d) Neither the Trust nor any Fund shall incur the cost of that portion of any insurance which
insures any party against any liability, the indemnification of which is herein prohibited.

32

 

          (e) Expenses incurred in defending a threatened or pending civil, administrative or criminal
action, suit or proceeding against the Managing Owner shall be paid by each Fund (as specified in
accordance with Section 4.06(a)) in advance of the final disposition of such action, suit
or proceeding, only if (i) the legal action relates to acts or omissions with respect to the
performance of duties or services by the Managing Owner on behalf of the Trust or
such Fund, as applicable; (ii) the legal action is initiated by a third party who is not a
Limited Owner or the legal action is initiated by a Limited Owner and a court of competent
jurisdiction specifically approves such advance; and (iii) the Managing Owner undertakes to repay
the advanced funds together with interest thereon at the applicable legal rate of interest to the
applicable Fund in cases in which it is not entitled to indemnification under this Section
4.06.

          (f) The term “Managing Owner” as used in this Section 4.06 shall include, in addition
to the Managing Owner, any other Covered Person performing services on behalf of the Trust or the
applicable Fund and acting within the scope of the Managing Owner’s authority as set forth in this
Agreement.

          (g) In the event the Trust is made a party to any claim, dispute, demand or litigation or
otherwise incurs any loss, liability, damage, cost or expense as a result of or in connection with
any Limited Owner’s (or assignee’s) obligations or liabilities unrelated to Trust business, such
Limited Owner (or assignees cumulatively) shall indemnify, defend, hold harmless, and reimburse the
Trust for all such loss, liability, damage, cost and expense incurred, including attorneys’ and
accountants’ fees.

          (h) Any amounts payable pursuant to this Section shall be treated as Extraordinary Fees and
Expenses for purposes of Section 4.07 with respect to payment and allocation of liabilities
and other amounts, as appropriate, among the applicable Funds.

     4.07. Expenses.

          (a) Organization and Offering Expenses.

          (i) Organization and Offering Expenses related to the Trust will be paid by the
Managing Owner or one or more Affiliates thereof, and recovered by the Managing Owner solely
as part of the Management and Operating Fee.

          (ii) Organization and Offering Expenses related to a Fund will be paid by the Managing
Owner or one or more Affiliates thereof, and recovered by the Managing Owner solely as part
of the Management and Operating Fee.

          (iii) For purposes of this Agreement, “Organization and Offering Expenses” mean
those expenses relating to the Trust or the Funds incurred in connection with their
formation, the qualification and registration of the Units and in offering, distributing and
processing Units under applicable federal and state Law, and any other expenses actually
incurred and, directly or indirectly, related to the organization of the Trust and the Funds
or the initial and continuous offering of the Units, including expenses such as: (A) initial
and ongoing registration fees, filing fees, escrow fees and taxes; (B) costs of preparing,
printing (including typesetting), amending, supplementing, mailing and distributing the
Registration Statement, the exhibits thereto and the

33

 

prospectus, whether incurred prior to
or during the Initial Offering Period and the Continuous Offering Period; (C) the costs of
qualifying, printing (including typesetting), amending, supplementing, mailing and
distributing sales materials used in connection with the offering and issuance of the Units
during the Initial Offering Period and the Continuous Offering Period, whether incurred
prior to or during the Initial Offering
Period and the Continuous Offering Period; (D) travel, telegraph, telephone and other
expenses incurred in connection with the offering and issuance of the Units, whether
incurred prior to or during the Initial Offering Period and the Continuous Offering Period;
(E) accounting, auditing and legal fees (including disbursements related thereto), incurred
in connection therewith, whether incurred prior to or during the Initial Offering Period and
the Continuous Offering Period; and (F) any extraordinary expenses related thereto including
legal claims and liabilities and litigation costs and any permitted indemnification
associated therewith.

          (b) Extraordinary Fees and Expenses.

          (i) Each Fund shall pay, whether to the Managing Owner, one or more of its Affiliates
or to the appropriate third party, (A) all Extraordinary Fees and Expenses of such Fund and
(B) its pro rata share (based on the Net Asset Value of each Fund, as of the Valuation Point
on the date on which the Extraordinary Fees and Expenses are paid) of all Extraordinary Fees
and Expenses of the Trust.

          (ii) “Extraordinary Fees and Expenses” mean fees and expenses which are
non-recurring and unusual in nature, such as legal claims and liabilities, litigation costs
and any permitted indemnification payments related thereto, and include material expenses
which are not currently anticipated obligations of the Trust or a Fund, such as the payment
of partnership taxes or governmental fees associated with payment of such taxes;
provided, that Extraordinary Fees and Expenses will not include (A) routine
operational, administrative and other ordinary expenses of the Trust or a Fund or (B) fees
and expenses imposed on a Fund or the Trust due to the status of a particular Limited Owner
(which shall be paid by such Limited Owner, not by the Managing Owner or the Trust or any
Fund).

          (c) Fees and Expenses Payable by Limited Owners. If the Managing Owner or any
Affiliate thereof pays any fee or expense for which a Limited Owner is responsible (including a fee
or expense described in Sections 4.06(g), 4.07(d), 4.07(e),
4.07(f), 4.08(b), 5.03(f)(i), 5.03(i) and/or 6.06(b)), the
Managing Owner or its Affiliate shall be entitled to be reimbursed for such fee or expense by the
applicable Limited Owner or through a proportional redemption of such Limited Owner’s Units, with
the Managing Owner being reimbursed through the proceeds therefrom.

          (d) Subscription Fee. In accordance with Section 3.04(e)(vii), the applicable
Fund will pay the applicable Selling Agent the Subscription Fee on behalf of the applicable Limited
Owner. No Subscription Fees shall be paid on Units sold to the Managing Owner or any of its
members, principals or Affiliates.

34

 

          (e) Trailing Fees. In accordance with Section 3.04(e)(viii), the applicable
Fund will pay the applicable Selling Agent the Trailing Fees on behalf of the applicable Limited
Owner. No Trailing Fees shall be paid on Units sold to the Managing Owner or any of its members,
principals or Affiliates.

          (f) Fees Payable to Administrator. Each Fund will pay, on behalf of and from the
account of each Limited Owner, applicable transaction fees, account maintenance fees, and other
fees assessed by the Administrator pursuant to the terms of an Administration Agreement and the
Registration Statement, each as may be amended from time to time. All other fees payable to the
Administrator by a Trust or any Fund shall be included in the Management and Operating Fee.

          (g) Limitations on Reimbursement. Notwithstanding anything to the contrary in
paragraphs (a) through (f) of this Section 4.07, (i) the Managing Owner and/or its
Affiliate shall only be entitled to receive reimbursement for the actual cost to the Managing Owner
or such Affiliate of any expenses which it advances on behalf of the Limited Owner, the Trust
and/or the applicable Fund for which payment the Limited Owner, the Trust or such Fund is
responsible and (ii) neither the Managing Owner nor any of its Affiliates shall be entitled to
receive reimbursement for indirect expenses incurred in performing services for the Trust or such
Fund, such as salaries and fringe benefits of officers and directors, rent or depreciation,
utilities and other administrative items generally falling within the category of the Managing
Owner’s or such Affiliate’s “overhead.”

          (h) Allocation of Income and Expenses. The Managing Owner shall have full discretion,
to the extent not inconsistent with GAAP, applicable Law, this Agreement or any applicable
Registration Statement, to determine which items shall be treated as income and which items as
capital, and each such determination and allocation if made in good faith shall be conclusive and
binding upon the Owners. Subject to the foregoing provisions of this Section 4.07, the
Managing Owner shall allocate general liabilities, expenses, costs, charges or reserves among the
Funds in proportion to their respective Net Asset Values as of the times the Managing Owner deems
fair and equitable, and each such allocation by the Managing Owner if made in good faith shall be
conclusive and binding upon the Owners.

     4.08. Fees Payable to the Managing Owner.

          (a) Management and Operating Fee.

          (i) Each Fund shall pay the Managing Owner a management and operating fee (the
“Management and Operating Fee”) in an amount equal to 3.0% per annum of the Notional
Net Asset Value of such Fund. The Management and Operating Fee shall be calculated on a
daily basis as of the Valuation Point and paid monthly. The Management and Operating Fee is
not subject to a cap. The Managing Owner may, in its sole discretion, pay all or any
portion of the Management and Operating Fee to introducing brokers.

          (ii) The Management and Operating Fee payable by each Fund will cover:

35

 

          (A) The management fee payable to the Managing Owner;

          (B) All expenses related to the organization and offering of
Units (both during the Initial Offering Period and the
Continuous Offering Period), including legal and accounting fees
and expenses associated with the organization and offering of Units,
but not including subscription fees and trailing fees;

          (C) All fees payable to the Custodian;

          (D) All fees payable to the Administrator (except for fees which
each individual Limited Owner is responsible for paying);

          (E) All brokerage and futures commission merchant commissions
and transaction fees (including, but not limited to, delivery,
insurance, storage, and other charges incidental to trading,
clearinghouse, NFA, exchange, give-up fees (if any), pit brokerage
and other transactional related fees); provided, that brokerage
commissions shall not exceed the limits imposed under the NASAA
Guidelines;

          (F) All routine on-going operational, administrative and other
ordinary expenses, including, but not limited to, computer services,
fees and expenses of the Trust and Trustee, legal and accounting fees
and expenses, tax preparation expenses, filing fees, and printing,
mailing and duplication costs;

          (G) A license fee to Brookshire for the non-exclusive use of the
indices and other licensed intellectual property; and

          (H) Certain expenses of the Managing Owner and any Affiliates
retained by it incurred on behalf of the Trust and the Fund

     ; provided, that for the avoidance of doubt, the Managing and Operating Fee
does not include any Extraordinary Fees and Expenses.

          (iii) The Managing Owner may in its sole discretion and without notice to any Limited
Owner, waive all or a part of the Management and Operating Fee by rebate or otherwise, with
respect to Units of any Limited Owner in any Fund, including with respect to Limited Owners
who are employees and Affiliates of the Managing Owner.

          (iv) For purposes of calculating the Management and Operating Fee, the Net Asset Value
and Notional Net Asset Value of a Fund will be determined before reduction for any
Management and Operating Fees accrued or Extraordinary Fees and

36

 

Expenses accrued as of such
month-end, and before giving effect to any distributions or redemptions accrued during or as
of such month-end.

          (b) Redemption Fee. In the event that Units are redeemed within a 90-day period
beginning on the effective date of issuance of such Units (in the case of Units purchased
during the Initial Offering Period, within 90 days following commencement of trading in the
applicable Fund), a redemption fee equal to 2% of the Net Asset Value attributable to such Units (a
“Redemption Fee”) shall be deducted from the Limited Owner’s redemption proceeds, as
described in Section 7.01(b), and paid to the Managing Owner as an early redemption fee.
For avoidance of doubt, the Redemption Fee is the liability of the redeeming Limited Owner, and not
the applicable Fund. The Managing Owner may, in its sole discretion, waive such Redemption Fee, in
whole or in part.

     4.09. Valuation of Trust Property.

          (a) On each Business Day, as soon as is reasonably practicable following the Valuation Point,
the Managing Owner shall determine the Net Asset Value and Notional Net Asset Value of each Fund
and the Trust and the Per Unit Net Asset Value as of the Valuation Point.

          (b) For purposes of determining the assets in the Trust Estate of each Fund,

          (i) The assets of each Fund shall include any unrealized profit or loss on open
Commodities positions, and any other credit or debit accruing to a Fund but unpaid or not
received by such Fund;

          (ii) All open Commodity Contracts traded on United States exchanges shall be calculated
at their then current market value, which shall be based upon the settlement price for the
particular Commodity Contract traded on the applicable United States exchange at the
Valuation Point; provided, that if a Commodity Contract traded on a United States
exchange could not be liquidated on the Valuation Point, due to the operation of daily
limits or other rules of the exchange upon which that position is traded or otherwise, the
settlement price on the last previous day on which the position could be liquidated shall be
the basis for determining the market value of such position for the Valuation Point;

          (iii) The current market value of all open Commodity Contracts traded on non-United
States exchanges shall be based upon the liquidating value for that particular Commodity
Contract traded on the applicable non-United States exchange on the Valuation Point;
provided, that if a Commodity Contract traded on a non-United States exchange could
not be liquidated on the Valuation Point, due to the operation of rules of the exchange upon
which that position is traded or otherwise, the liquidating value on the last previous day
on which the position could be liquidated shall be the basis for determining the market
value of such position for the Valuation Point;

          (iv) The current market value of all open forward contracts entered into by a Fund
shall be the mean between the last bid and last asked prices quoted by the bank, dealer or
financial institution which is a party to the contract as of the Valuation

37

 

Point;
provided, that if such quotations are not available on such date, the mean between
the last bid and asked prices on the last previous day on which such quotations are
available shall be the basis for determining the market value of such forward contract
as of the Valuation Point; and

          (v) Interest earned on a Fund’s commodity brokerage account shall be accrued at least
monthly.

          (vi) Notwithstanding the foregoing, the Managing Owner may in its discretion value any
of the Trust Estate pursuant to such other principles as it may deem fair and equitable so
long as such principles are consistent with normal industry standards.

          (c) For purposes of determining the liabilities of each Fund, the Managing Owner shall
subtract all accrued expenses and other liabilities of each Fund, as of the Valuation Point. For
the sake of clarity, any fees or expenses for which a particular Owner is liable under Sections
4.06(g), 4.07(d), 4.07(e), 4.07(f), 4.08(b),
5.03(f)(i), 5.03(i) and/or 6.06(b) shall not be included in the calculation
of a Fund’s liabilities pursuant to this Section 4.09(c).

     4.10. Fiduciary Duty.

          (a) To the extent that, at law or in equity, the Managing Owner or any officer, director,
employee, or agent thereof or any Affiliate of the Managing Owner (collectively, the “Covered
Persons”) has duties (including fiduciary duties) and liabilities relating thereto to the
Trust, any Fund, the Owners or any other Person, the Managing Owner acting under this Agreement
shall not be liable to the Trust, any Fund, the Owners or any other Person for its good faith
reliance on the provisions of this Agreement in compliance with the standard of care set forth in
Section 4.05. The provisions of this Agreement, to the extent that they restrict the
duties and liabilities of the Managing Owner otherwise existing at law or in equity are agreed by
the parties hereto to replace such other duties and liabilities of the Managing Owner.

          (b) Unless otherwise expressly provided herein:

          (i) Whenever a conflict of interest exists or arises between the Managing Owner or any
of its Affiliates, on the one hand, and the Trust, any Fund, the Owners or any other Person,
on the other hand; or

          (ii) Whenever this Agreement or any other agreement contemplated herein provides that
the Managing Owner shall act in a manner that is, or provides terms that are, fair and
equitable to the Trust, any Fund, the Owners or any other Person,

the Managing Owner shall resolve such conflict of interest, take such action or provide such terms,
considering in each case the relative interest of each party (including its own interest) to such
conflict, agreement, transaction or situation and the benefits and burdens relating to such
interests, any customary or accepted industry practices, and any applicable generally accepted
accounting practices or principles. In the absence of bad faith by the Managing Owner, the
resolution, action or terms so made, taken or provided by the Managing Owner shall not

38

 

constitute a
breach of this Agreement or any other Contract contemplated herein or of any duty or obligation of
the Managing Owner or the Covered Person at law or in equity or otherwise.

          (c) Notwithstanding any other provision of this Agreement or applicable Law, whenever in this
Agreement the Managing Owner or Covered Person is permitted or required to make a decision:

          (i) In its “discretion” or under a grant of similar authority, the Managing Owner shall
be entitled to consider such interests and factors as it desires, including its own
interests, and, to the fullest extent permitted by applicable Law, shall have no duty or
obligation to give any consideration to any interest of or factors affecting the Trust, any
Fund, the Owners or any other Person; or

          (ii) In its “good faith” or under another express standard, the Managing Owner shall
act under such express standard and shall not be subject to any other or different standard.

          (d) The Managing Owner and its Covered Persons may engage in or possess an interest in other
profit seeking or business ventures of any nature or description, independently or with others,
whether or not such ventures are competitive with the Trust or any Fund, and the doctrine of
corporate opportunity, or any analogous doctrine, shall not apply to the Managing Owner or any of
its Covered Persons. If the Managing Owner acquires knowledge of a potential transaction,
agreement, arrangement or other matter that may be an opportunity for the Trust or any Fund, it
shall have no duty to communicate or offer such opportunity to the Trust or any Fund, and neither
the Managing Owner nor any Covered Person shall be liable to the Trust, any Fund, the Owners or any
other Person for breach of any fiduciary or other duty by reason of the fact that the Managing
Owner or the Covered Person pursues or acquires for, or directs such opportunity to another Person
or does not communicate such opportunity or information to the Trust or any Fund. Neither the
Trust, any Fund, the Owners or any other Person shall have any rights or obligations by virtue of
this Agreement or the trust relationship created hereby in or to such independent ventures or the
income or profits or losses derived therefrom, and the pursuit of such ventures, even if
competitive with the activities of the Trust or any Fund, shall not be deemed to be wrongful or
improper. Except to the extent expressly provided herein, the Managing Owner and any Covered
Person may engage or be interested in any financial or other transaction with the Trust, any Fund,
the Owners or any other Person.

     4.11. Other Business of Owners. Except as otherwise specifically provided herein, any
Owner and any shareholder, officer, director, employee or other Person holding a legal or
beneficial interest in an Owner, may engage in or possess an interest in other business ventures of
any nature and description, independently or with others, and the pursuit of such ventures, even if
competitive with the business of the Trust and/or any Fund, shall not be deemed wrongful or
improper.

     4.12. Voluntary Withdrawal and Removal of the Managing Owner.

          (a) Voluntary Withdrawal. The Managing Owner may withdraw voluntarily as the Managing
Owner of the Trust and/or a Fund only upon 120 days’ prior written notice to all

39

 

applicable Limited
Owners and the Trustee. If the withdrawing Managing Owner is the last remaining Managing Owner of
the Trust, Limited Owners holding Units representing at least a
majority of the Net Asset Value of each Fund (excluding Units held by the Managing Owner and
its Affiliates) may vote to elect and appoint, effective as of a date on or prior to the
withdrawal, a successor Managing Owner who shall carry on the business of the Trust. If the
withdrawing Managing Owner is the last remaining Managing Owner of a Fund, Limited Owners holding
Units representing at least a majority of the Net Asset Value of such Fund (excluding Units held by
the Managing Owner and its Affiliates) may vote to elect and appoint, effective as of a date on or
prior to the withdrawal, a successor Managing Owner who shall carry on the business of such Fund.
If the Managing Owner withdraws as Managing Owner and the Limited Owners or remaining Managing
Owner(s) elect to continue the Trust or Fund, as the case may be, the withdrawing Managing Owner
shall pay all expenses incurred as a result of its withdrawal.

          (b) Removal. The Managing Owner may be removed, with respect to a Fund, upon sixty
(60) days’ prior written notice by Limited Owners holding Units representing at least a majority of
the Net Asset Value of such Fund (excluding Units held by the Managing Owner and its Affiliates).
The Managing Owner may be removed, with respect to the Trust, on reasonable prior written notice by
Limited Owners holding Units representing at least a majority of the Net Asset Value of each Fund
(excluding Units held by the Managing Owner and its Affiliates). In the event of its removal or
withdrawal, the Managing Owner shall be entitled to a redemption of its Units at the Net Asset
Value of the applicable Fund(s) on the next Redemption Date following the date of removal or
withdrawal.

     4.13. Litigation. The Managing Owner is hereby authorized to prosecute, defend,
settle or compromise actions or claims at law or in equity as may be necessary or proper to enforce
or protect the Trust’s and/or any Fund’s interests. The Managing Owner shall satisfy any judgment,
decree or decision of any court, board or authority having jurisdiction or any settlement of any
suit or claim prior to judgment or final decision thereon, first, out of any insurance proceeds
available therefor, next, out of the Trust’s and/or the applicable Fund’s, as the case may be,
assets and, thereafter, out of the assets (to the extent that it is permitted to do so under the
various other provisions of this Agreement) of the Managing Owner.

     4.14. Prevention or Delay in Performance by the Managing Owner. No Covered Person
shall incur any liability to any Owner if, by reason of any provision of any present or future Law
or governmental or regulatory authority or stock exchange, or by reason of any act of God or war or
terrorism or other circumstances beyond its control, such Covered Person is prevented or forbidden
from, or would be subject to any civil or criminal penalty on account of, or is delayed in, doing
or performing any act or thing that, by the terms of this Agreement, it is provided shall be done
or performed, and, accordingly, the Covered Person does not do that thing or does that thing at a
later time than would otherwise be required. No Covered Person will incur any liability to any
Owner by reason of any non-performance or delay in the performance of any act or thing that, by the
terms of this Agreement, it is provided may be done or performed, or by reason of any exercise of,
or failure to exercise, any discretion provided for in this Agreement.

40

 

ARTICLE V

TRANSFERS OF INTERESTS

     5.01. General Prohibition.

          (a) A Limited Owner may not sell, assign, transfer or otherwise dispose of, or pledge,
hypothecate or in any manner encumber, any or all of his Units or any part of his right, title and
interest in the capital or profits of any Fund, whether or not for value (collectively,
“Transfer”) except as expressly permitted in this Article V. Any Transfer in
violation of this Article V shall be null and void ab initio and shall not be binding upon
or recognized by the Managing Owner, the Trust or any Fund (regardless of whether the Managing
Owner shall have knowledge thereof), unless approved in writing by the Managing Owner.

          (b) The parties hereby agree that the restrictions set forth in this Article V are
necessary and desirable in order to (i) maintain each Fund’s tax classification as a partnership,
(ii) avoid having any Fund classified as a publicly traded partnership, (iii) prevent the ownership
by Benefit Plan Investors of 25% or more of the value of the Trust and/or any Fund, (iv) avoid
having Limited Owners who are residents of Canada for purposes of the Income Tax Act (Canada), (v)
avoid having more than 25% of the fair market value of the total investments in all of the Funds
being owned by persons and partnerships that are “affiliated” with the Administrator if such
Administrator is a corporation or trust resident in Canada, or a Canadian partnership, all within
the meaning of the Income Tax Act (Canada) and/or (vi) avoid adverse legal consequences to the
Trust and/or any Fund.

     5.02. Repurchase of Managing Owner’s General Units.

          (a) Upon an Event of Withdrawal (as defined in Section 13.01), the Managing Owner’s
General Units in each Fund shall be purchased by such Fund for a purchase price in cash equal to
the Net Asset Value thereof as of the Valuation Point on the day on which the Event of Withdrawal
occurs. The Managing Owner shall not cease to be a Managing Owner of the Trust and/or the
applicable Fund merely upon its making an assignment for the benefit of creditors, filing a
voluntary petition in bankruptcy, filing a petition or answer seeking for itself any
reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief
under any Law, filing an answer or other pleading admitting or failing to contest material
allegations of a petition filed against it in any proceeding of this nature or seeking, consenting
to or acquiescing in the appointment of a trustee, receiver or liquidator for itself or of all or
any substantial part of its properties.

          (b) To the maximum extent permitted by Law, nothing in this Agreement shall be deemed to
prevent or require the consent of any Owner with respect to the merger of the Managing Owner with
another Person, the reorganization of the Managing Owner into or with any other Person, the
transfer of all the capital interest of the Managing Owner or the assumption of the Units, rights,
duties and liabilities of the Managing Owner by, in the case of a merger, reorganization or
consolidation, the surviving corporation by operation of law.

          (c) For the avoidance of doubt, the assignment of all of the Managing Owner’s Units shall not
result in or cause the Managing Owner to cease to be the Managing

41

 

Owner of the Trust or any Fund,
or to cease to have the power to exercise any rights or powers as the Managing Owner, or to cease
to have liability for the obligations of the Trust or any Fund under Section 1.09, until an
additional Managing Owner, who shall carry on the business of the Trust and/or the applicable
Fund(s), has been admitted to the Trust and/or the applicable Fund(s) as Managing Owner.

     5.03. Transfer of Limited Units.

          (a) Definitions. For purposes of this Agreement, (i) a “Substituted Limited
Owner” means a Person who has been admitted to a Fund as a Limited Owner in such Fund with all
of the rights and powers of a Limited Owner in such Fund as a result of a Transfer of Units in such
Fund by the previous Limited Owner in accordance with this Section 5.03; and (ii) a
“Permitted Assignee” means a Person to whom a Limited Owner has assigned his Limited Units with the
consent of the Managing Owner in accordance with this Section 5.03, but who has not become
a Substituted Limited Owner.

          (b) Prohibitions on Transfers and Assignments. No Transfer or assignment of any Unit
may be made which would result in any of the following:

          (i) The Limited Owners and the Permitted Assignees in the applicable Fund owning,
directly or indirectly, individually or in the aggregate, 50% or more of the stock or
capital or profits interests both (A) of such Fund and (B) of the Managing Owner or any
related person as defined in Sections 267(b) and 707(b)(1) of the Code; provided,
that if any such Transfer or assignment would otherwise be made by bequest, inheritance or
operation of Law, the Unit(s) so Transferred or assigned shall be deemed sold by the
transferor or assignor to the applicable Fund immediately prior to such Transfer or
assignment (with such sale price being paid within ninety (90) days after the date of the
Transfer or assignment);

          (ii) In any particular twelve (12) consecutive month period, any Transfer or assignment
of Units which would result in increasing the aggregate total of Units previously assigned
and/or transferred in said period to 49% or more of the total interest in a Fund’s capital
and profits, as determined by the Managing Owner (the “49% Limitation”);
provided, that the 49% Limitation shall not apply to a Transfer (A) by gift, bequest
or inheritance or (B) to the Trust or the applicable Fund, and provided,
further, that if, after the 49% Limitation is reached in any consecutive 12 month
period, a Transfer or assignment would otherwise take place by operation of law (other than
a Transfer or assignment described in the preceding proviso) and such a Transfer or
assignment would cause a violation of the 49% Limitation, then said Unit(s) shall be deemed
to have been sold by the Transferor or the assignor to the applicable Fund immediately prior
to such Transfer or assignment for a price equal to the Net Asset Value of the applicable
Fund on the date of such Transfer or assignment (with such sale price being paid within
ninety (90) days after the date of the Transfer or assignment);

          (iii) A violation of (A) this Agreement or the Trust Act, (B) any of the standards
imposed by the Managing Owner, the Trust and/or the applicable Fund for the purchase of new
Units (as set forth in Section 3.04(e)), (C) applicable Federal securities

42

 

and state
“Blue Sky” laws or (D) the rules of any other applicable governmental authority;

          (iv) the Transferee being a resident of Canada for purposes of the Income Tax Act
(Canada); or

          (v) the Transfer resulting in more than 25% of the fair market value of the total
investments in all of the Funds being owned by persons and partnerships that are
“affiliated” with the Administrator if such Administrator is a corporation or trust resident
in Canada, or a Canadian partnership, all within the meaning of the Income Tax Act (Canada).

          (c) Requirements for Recognition of Transfers and Assignments. Subject to the
prohibitions on Transfers and assignments under Section 5.03(b), a Limited Owner shall have
the right to Transfer or assign all or any of his Limited Units to any Person or assignee subject
to compliance with the following:

          (i) The written consent of the Managing Owner to such Transfer or assignment shall have
been obtained;

          (ii) A duly executed and acknowledged written instrument of Transfer or assignment
(using the form prescribed by the Managing Owner) shall have been filed with the Trust
and/or the applicable Fund setting forth the intention of the Transferor or assignor that
the transferee or assignee become a Substituted Limited Owner or Permitted Assignee in his
place;

          (iii) The transferring/assigning Limited Owner and the transferee/assignee shall have
executed and acknowledged and/or delivered such other instruments as the Managing Owner may
deem necessary or desirable to effect such admission, including his execution,
acknowledgment and delivery to the Managing Owner, of a counterpart to this Agreement by a
Power of Attorney in the form set forth in the Subscription Agreement; and

          (iv) Upon the request of the Managing Owner, an opinion of the Trust’s or the
applicable Fund’s independent legal counsel shall have been obtained to the effect that (1)
the Transfer/assignment will not jeopardize any Fund’s tax classification as a partnership
or otherwise be in contravention of any of the restrictions set forth in Section
5.01(b) or 5.03(b) and (2) the Transfer/assignment does not violate this
Agreement or the Trust Act;

provided, that the condition set forth in clause (i) shall not apply if the Transferee
or assignee is (A) an ancestor or descendant of the applicable Limited Owner, (B) the personal
representative or heir of a deceased Limited Owner, (C) the trustee of a trust whose beneficiary
is the Limited Owner or another person to whom a transfer could otherwise be made or (D) the
shareholders, partners, or beneficiaries of a corporation, limited liability
company, partnership or trust upon its termination or liquidation, then the “effective date” of
an assignment of a Unit in the Trust shall be the first Business Day immediately following

43

 

the
Business Day on which the written instrument of assignment is received by the Managing Owner.

          (d) Substituted Limited Owners. Subject to satisfaction of all of the conditions
provided in Section 5.03(b) and 5.03(c), the Managing Owner shall admit a Person as
a Substituted Limited Owner in the applicable Fund by making an entry on the books and records of
such Fund reflecting such admission. Such Permitted Assignee shall be deemed to be a Limited Owner
as of and following such time as such admission is reflected on the books and records of the
applicable Fund. No consent or action of any other Limited Owner shall be required for a Permitted
Assignee to become a Substituted Limited Owner.

          (e) Permitted Assignees. Subject to satisfaction of all of the conditions provided in
Section 5.03(b) and 5.03(c), the Managing Owner shall admit a Person as a Permitted
Assignee with respect to the applicable Fund by making an entry on the books and records of such
Fund reflecting the status of such Person as a Permitted Assignee. A Permitted Assignee shall have
no right to vote, to obtain any information on or account of any Fund’s transactions or to inspect
the Trust’s or Fund’s books, but shall only be entitled to receive the share of the profits, or the
return of the Capital Contribution, to which his assignor would otherwise be entitled as set forth
in Section 5.03(d), to the extent of the Limited Units assigned. Except as expressly
stated above or elsewhere in this Agreement, where the context requires, references to a Limited
Owner shall include a Permitted Assignee.

          (f) General Provisions.

          (i) A Limited Owner shall bear all extraordinary costs (including attorneys’ and
accountants’ fees), if any, related to any Transfer or assignment of his Limited Units.

          (ii) Any Person admitted to any Fund as a Substituted Limited Owner or Permitted
Assignee shall be subject to all of the provisions of this Agreement as if an original
signatory hereto.

          (iii) A Substitute Limited Owner or Permitted Assignee shall be entitled to receive
distributions from the applicable Fund by reason of such Transfer or assignment from and
after the effective date of the Transfer or assignment, which effective date shall be the
second Business Day after all of the conditions to such Transfer or assignment have been
satisfied.

          (iv) The Managing Owner shall incur no liability to any Person for any action or
inaction by it in connection with the provisions of this Article V, provided it has
acted in good faith.

          (v) Notwithstanding anything to the contrary herein, the Trust, each applicable Fund
and the Managing Owner shall be entitled to treat a Transferring or assigning Limited Owner
as the absolute owner of the applicable Units in all respects, and
shall incur no liability for distributions made in good faith to such Limited Owner,
until such time as all conditions to a Transfer or assignment have been satisfied.

44

 

          (g) The Managing Owner, in its sole discretion, may cause each Fund to make, refrain from
making, or once having made, to revoke, the election referred to in Section 754 of the Code, and
any similar election provided by state or local Law, or any similar provision enacted in lieu
thereof.

          (h) The Managing Owner, in its sole discretion, may cause each Fund to make, refrain from
making, or once having made, to revoke the election by a qualified fund under Section
988(c)(1)(E)(iii)(V) of the Code and any similar election provided by state or local law, or any
similar provision enacted in lieu thereof.

          (i) Each Limited Owner hereby agrees to indemnify and hold harmless the Trust and each other
Owner against any and all losses, damages, liabilities or expense (including tax liabilities or
loss of tax benefits) arising, directly or indirectly, as a result of any Transfer or assignment or
purported Transfer or assignment by such Limited Owner in violation of any provision contained in
this Section 5.03.

ARTICLE VI

DISTRIBUTION AND ALLOCATIONS

     6.01. Capital Accounts. A separate capital account shall be established and
maintained for each Owner on the books of the Fund in which the Owner owns Units (such account
sometimes hereinafter referred to as a “book capital account”). The initial balance of
each Owner’s book capital account with respect to any Fund shall be the amount of his initial
Capital Contribution to that Fund. Such book capital account balance shall be increased by the
amount of all additional Capital Contributions made to the Fund with respect to the Fund Units, and
shall be further adjusted as provided in Section 6.02.

     6.02. Book Capital Account Allocations. As of the close of business (as determined by
the Managing Owner) on each Business Day during each Fiscal Year of the Trust, the following
determinations and allocations shall be made:

          (a) First, any increase or decrease in the Net Asset Value of a Fund as of such date, as
compared to the next previous determination of Net Asset Value of a Fund, shall be credited or
charged to the book capital accounts of the Owners of such Fund in the ratio that the balance of
each Owner’s book capital account bears to the balance of all Owners’ book capital accounts.

          (b) The amount of any distribution to be made to an Owner and any amount to be paid to an
Owner upon redemption of his Units shall be charged to that Owner’s book capital account as of the
applicable record date and Redemption Date, respectively.

     6.03. Allocation of Profit and Loss for United States Federal Income Tax Purposes.
As of the end of each Fiscal Year, the recognized profit and loss of a Fund shall be allocated
among the Owners of that Fund (and among Classes of a Fund as appropriate) pursuant to the
following subparagraphs for Federal income tax purposes. Except as otherwise provided herein, such
allocations of profit and loss shall be pro rata from Disposition Gain (or Disposition Loss) and
Profits (or Losses).

45

 

          (a) First, the Profits or Losses of the Fund shall be allocated to the Owners in accordance
with the book capital allocations of such items pursuant to Section 6.02.

          (b) Next, Disposition Gain or Disposition Loss from the Fund’s trading activities for each
Fiscal Year of the Trust shall be allocated among the Owners as follows:

          (i) There shall be established a tax capital account with respect to each Owner’s Units
in a Fund. The initial balance of each tax capital account shall be the amount paid by the
Owner to the Fund for the Units. Tax capital accounts shall be adjusted as of the end of
each Fiscal Year as follows: (A) Each tax capital account shall be increased by the amount
of all Capital Contributions made to the Fund with respect to the Fund Units during that
Fiscal Year and by the amount of income (Profits or Disposition Gain) which shall have been
allocated to the Owner pursuant to Section 6.03(a) above and Sections
6.03(b)(ii), 6.03(b)(iii) and 6.03(b)(iv) below; (B) Each tax capital
account shall be decreased by the amount of expense or loss (Losses or Disposition Losses)
which shall have been allocated to the Owner pursuant to Section 6.03(a) above and
Sections 6.03(b)(v), 6.03(b)(vi) and 6.03(b)(vii) below and by the
amount of any distribution which shall have been received by the Owner with respect to the
Units (other than in full redemption of Units); and (C) If an Owner’s Units are fully
redeemed, the tax capital account with respect to such Units shall be eliminated on the
Redemption Date after final allocations thereto.

          (ii) Disposition Gain shall be allocated first to each Owner, if any, who redeemed or
exchanged all or a portion of his, her or its Units up to the amount of the excess, if any,
of the amount such Owner received in respect of the redeemed Units or the value of the Units
received in the exchange over the portion of the balance of such Owner’s tax capital account
attributable to such redeemed or exchanged Units (the “Gain Disparity”);
provided, however, that if such Disposition Gain is insufficient to cover
all such allocations, it shall be allocated among such Owners in the ratio that the Gain
Disparity of each such Owner bears to the sum of the Gain Disparities of all such Owners.

          (iii) Disposition Gain that remains after the allocation pursuant to Section
6.03(b)(ii) above shall be allocated first among all Owners whose book capital accounts
shall be in excess of their tax capital accounts (after making the adjustments, other than
adjustments resulting from the allocations to be made pursuant to this Section
6.03(b)(iii), described in Section 6.03(b)(i)) in the ratio that each such
Owner’s excess shall bear to all such Owner’s excesses.

          (iv) Disposition Gain that remains after the allocation pursuant to Section
6.03(b)(iii) shall be allocated to the Owners in the ratio that each Owner’s book
capital account bears to all Owners’ book capital accounts.

          (v) Disposition Loss shall be allocated first to each Owner, if any, who redeemed or
exchanged all or a portion of his, her or its Units up to the amount of the excess, if any,
of the portion of the balance of such Owner’s tax capital account attributable to the
redeemed or exchanged Units over the amount such Owner received in

46

 

respect of the redeemed
Units or the value of the Units received in the exchange (the “Loss Disparity”);
provided, however, that if such Disposition Loss is insufficient to cover
all such allocations, it shall be allocated among such Owners in the ratio that the Loss
Disparity of each such Owner bears to the sum of the Loss Disparities of all such Owners.

          (vi) Disposition Loss that remains after the allocation pursuant to Section
6.03(b)(v) shall be allocated first among all Owners whose tax capital accounts shall be
in excess of their book capital accounts (after making the adjustments, other than
adjustments resulting from the allocations to be made pursuant to this Section
6.03(b)(vi), described in Section 6.03(b)(i)) in the ratio that each such
Owner’s excess shall bear to all such Owners’ excesses.

          (vii) Disposition Loss that remains after the allocation pursuant to Section
6.03(b)(vi) shall be allocated to the Owners in the ratio that each Owner’s book capital
account bears to all Owners’ book capital accounts.

          (c) If any Owner unexpectedly receives any adjustments, allocations, or distributions
described in Treasury Regulations sections 1.704-1(b)(2)(ii)(d)(4), (5), or (6), items of Fund
income and gain shall be specially allocated to such Owner in an amount and manner sufficient to
eliminate a deficit in its Adjusted Capital Account created by such adjustments, allocations, or
distributions as quickly as possible. This Section 6.03(c) is intended to qualify as a
“qualified income offset” within the meaning of Treasury Regulations section 1.704-1(b)(2)(ii)(d).

          (d) The tax allocations prescribed by this Section 6.03 shall be made to each holder
of Units whether or not the holder is a substituted Limited Owner. For purposes of this Section
6.03, tax allocations shall be made to the Managing Owner’s Units on a Unit-equivalent basis.

          (e) The allocation of income and loss (and items thereof) for Federal income tax purposes set
forth in this Section 6.03 is intended to allocate taxable income and loss among Owners
generally in the ratio and to the extent that net profit and net loss shall be allocated to such
Owners under Section 6.02 so as to eliminate, to the extent possible, any disparity between
an Owner’s book capital account and his tax capital account, consistent with the principles set
forth in Sections 704(b) and (c) of the Code.

          (f) Notwithstanding anything to the contrary in this Section 6.03, to the extent any
item of loss or deduction otherwise allocable to an Owner pursuant to Section 6.02(a) is in
excess of such Owner’s positive Adjusted Capital Account balance (following adjustment to
reflect the allocation of all other items for such period), the item of loss or deduction shall
instead be allocated to the other Owners in accordance with their positive capital account
balances; provided, that the allocation of any such item to such other Owners shall only be
made hereunder to the extent the allocation would not result in or increase a negative balance in
the Adjusted Capital Account of such other Owner.

47

 

          (g) When allocating Profits and Losses under this Section 6.03, such allocations and
other special allocations pursuant to this paragraph (g) be made so as to offset any prior
allocations under paragraphs (c) and (f) of this Section 6.03 to the greatest extent
possible so that, after such offsetting allocations are made, each Owner’s tax capital account
balance is, to the extent possible, equal to the tax capital account balance such Owner would have
had if the allocations pursuant to paragraphs (c) and (f) of this Sections 6.03 were not
part of the Agreement and all items were allocated pursuant to paragraphs (a) and (b) of this
Section 6.03.

     6.04. Allocation of Distributions. Distributions shall be made by the Managing Owner,
and the Managing Owner shall have sole discretion in determining the amount and frequency of
distributions, other than redemptions, which the Trust shall make with respect to the Units;
provided, however, that the Trust shall not make any distribution that would
violate the Trust Act. The aggregate distributions made in a Fiscal Year (other than distributions
on termination, which shall be allocated in the manner described in Section 13.02) shall be
made to the holders of record of Units in a particular Fund in the ratio in which the number of
Units held of record by each of them bears to the number of Units held of record by all of the
Owners of that Fund as of the record date of such distribution; provided, however,
that any distribution made in respect of a Unit shall not exceed the book capital account for such
Unit.

     6.05. Admissions of Owners; Transfers. For purposes of this Article VI, Owners
shall be deemed admitted, and a tax and book capital account shall be established in respect of the
Units acquired by such Owner or in respect of additional Units acquired by an existing Owner, as of
the Business Day falling on the second Business Days after the date on which such Owner’s
Subscription Agreement or Exchange Request, as the case may be, is received by 4:00 P.M. NYT,
provided, the Managing Owner shall have been in receipt of such Subscription Agreement or
Exchange Request for at least two Business Days, or in which the transfer of Units to such Owner is
recognized, except that persons accepted as subscribers to a Fund pursuant to Section
3.04(e) shall be deemed admitted on the date determined pursuant to such Section. The Managing
Owner, in its sole and absolute discretion, may change such notice requirement upon written notice
to the Owner. Any Owner to whom Units have been Transferred or assigned shall succeed to the tax
and book capital accounts attributable to the Units Transferred or assigned.

     6.06. Liability for State and Local and Other Taxes.

          (a) In the event that the Trust or any Fund shall be separately subject to taxation by any
state or local or by any foreign taxing authority, the Trust or the Fund shall be obligated to pay
such taxes to such jurisdiction.

          (b) In the event that the Trust or a Fund shall be required to make payments to any Federal,
state or local or any foreign taxing authority in respect of any Owner’s allocable share of Fund
income, the amount of such taxes shall be considered a loan by the particular Fund to such Owner,
and such Owner shall be liable for, and shall pay to the Fund, any taxes so required to be withheld
and paid over by the Fund within 10 days after the Managing Owner’s request therefor. Such Owner
shall also be liable for (and the Managing Owner shall be entitled to redeem additional Units of
the foreign Owner as necessary to satisfy) interest on the amount of taxes paid over by the Trust
or Fund to the IRS or other taxing authority, from the date of the

48

 

Managing Owner’s request for
payment to the date of payment or the redemption, as the case may be, at the rate of 2% over the
prime rate charged from time to time by U.S. Bank National Association. The amount, if any,
payable by the Fund to the Owner in respect of its Units so redeemed, or in respect of any other
actual distribution by the Fund to such Owner, shall be reduced by any obligations owed to the
Trust or Fund by the Owner, including, without limitation, the amount of any taxes required to be
paid over by the Trust or Fund to the IRS or other taxing authority and interest thereon as
aforesaid. Amounts, if any, deducted by the Fund from any actual distribution or redemption payment
to such Owner shall be treated as an actual distribution to such Owner for all purposes of this
Trust Agreement.

ARTICLE VII

REDEMPTIONS

     7.01. Redemption of Units. The Owners recognize that the profitability of each Fund
depends upon long-term and uninterrupted investment of capital. It is agreed, therefore, that
profits and gains of each Fund shall be automatically reinvested, and that distributions, if any,
of profits and gains to Owners will be on a limited basis. Nevertheless, the Owners contemplate
the possibility that one or more of the Limited Owners may elect to realize and withdraw profits,
or withdraw capital through the redemption of Units prior to the dissolution of a Fund. In that
regard and subject to the provisions of Section 4.02(g):

          (a) Subject to the conditions set forth in this Article VII, each Limited Owner (or
any permitted assignee thereof) shall have the right to redeem a Limited Unit or portion thereof on
any Business Day. Redemption requests shall be made using the Redemption Request Form (as defined
below). Subject to paragraphs (d) and (f) of this Section 7.01, redemption requests on a
duly completed Redemption Request Form that are received by the Administrator by 4:00 P.M. New York
time on any Business Day will be effective on that date; provided, that redemption requests
received by the Administrator after 4:00 P.M. New York time shall be effective on the next Business
Day; and provided, further, that redemption requests not made on a duly completed
Redemption Request Form shall be effective when the Administrator has received a duly completed
Redemption Request Form. For all purposes, the effective redemption date (the “Redemption
Date”), will be the date on which a Limited Owner’s Units are actually redeemed. Limited
Owners bear the risk of any decline in Net Asset Value of the applicable Fund from the
time and date notice of intent to redeem is given until the Valuation Point on the Redemption
Date. The Managing Owner, in its sole and absolute discretion, may change the notice requirements
related to redemptions upon written notice to a redeeming Owner.

          (b) Units will be redeemed on a “first in, first out” basis based on time of receipt of
redemption requests in accordance with Section 7.01(a) at a redemption price equal to the
Per Unit Net Asset Value of the applicable Fund as of the Valuation Point on the Redemption Date,
less (i) any amount owing by such Limited Owner to the Managing Owner, the Trust and/or the
applicable Fund pursuant to Sections 4.06(g), 4.07(d), 4.07(e),
4.07(f), 4.08(b), 5.03(f)(i), 5.03(i) and/or 6.06(b); and
(ii) if redemption of a Unit shall be requested by a Permitted Assignee, all amounts which shall be
owed to the Trust and/or the applicable Fund pursuant to Sections 4.06(g), 4.07(d),
4.07(e), 4.07(f), 4.08(b), 5.03(f)(i), 5.03(i) and/or
6.06(b) by the Owner of record, as well as all amounts which shall be owed by the Permitted
Assignee(s) of such Units. If an Owner (or permitted assignee thereof) is permitted to redeem any
or all of

49

 

his Units as of a date other than a Redemption Date, such adjustments in the
determination and allocation among the Owners of Disposition Gain, Disposition Loss, Profits,
Losses and items of income or deduction for tax accounting purposes shall be made as are necessary
or appropriate to reflect and give effect to the redemption.

          (c) Limited Owners shall be notified in writing within ten (10) Business Days following the
date of receipt of redemption requests in accordance with Section 7.01(a) whether or not
their Units shall be redeemed, unless settlement for the redeemed Units is made within that ten
(10) Business Day period, in which case notice shall not be required. Except as provided in the
remainder of this paragraph, payment in respect of a redemption will normally be made at the time
of settlement; provided, that all liabilities, contingent or otherwise, of the Trust or the
applicable Fund (other than liabilities to Owners on account of their Capital Contributions), shall
have been paid or there remains property of the applicable Fund sufficient to pay them; and
provided, further, that under extraordinary circumstances (as determined by the
Managing Owner in its sole discretion), including the inability to liquidate Commodity positions as
of the Redemption Date, or default or delay in payments due the applicable Fund from Commodity
Brokers, banks or other Persons, or significant administrative hardship, the applicable Fund may
delay payment to Limited Owners requesting redemption of Units of the proportionate part of the
value of redeemed Units represented by the sums which are the subject of such default or delay, in
which event payment for redemption of such Units will be made to Limited Owners as soon thereafter
as is practicable.

          (d) Payment will be made by wire transfer to the redeeming Limited Owner, less applicable wire
transfer fees. Alternative arrangements for payment and delivery of the redemption proceeds may be
made with the Administrator at the withdrawing Limited Owner’s cost. Redemptions will be paid in
the currency corresponding to the Fund being redeemed.

          (e) Except as described in paragraph (c) of this Section 7.01 or the remainder of this
paragraph, all timely redemption requests in proper form will be honored and the applicable Fund’s
Commodities or fixed income positions will be liquidated to the extent necessary to effect such
redemptions. The Managing Owner may suspend temporarily any and all redemptions if the effect of
such redemptions, either alone or in conjunction with other redemptions, would be to impair the
Trust’s or the applicable Fund’s ability to operate in pursuit
of its objectives (for example, if the Managing Owner believes a redemption, if allowed, would
advantage one Limited Owner over another Limited Owner). The Managing Owner anticipates suspending
redemptions only under extreme circumstances, such as in the event of a natural disaster, force
majeure, act of war, terrorism or other event which results in the closure of financial markets.
Such suspension of redemptions could last up to thirty (30) days, although the actual number of
Business Days may be less.

          (f) Redemption requests of Limited Owners affiliated with the Trustee, the Managing Owner or
their respective Affiliates will not receive favorable treatment over non-affiliated Limited
Owners.

          (g) A Limited Owner (or any permitted assignee thereof) wishing to redeem Units must provide
the Managing Owner with written notice of his intent to redeem using the Redemption Request Form,
which notice shall specify the name and address of the redeeming

50

 

Limited Owner and the amount of
Limited Units sought to be redeemed. The “Redemption Request Form” means a form annexed to
the Subscription Agreement or another form acceptable to the Managing Owner. The Managing Owner
shall be entitled to require additional supporting documentation to approve a redemption request,
such as trust instruments, death certificates, appointments as executor or administrator or
certificates of corporate authority.

          (h) A Limited Owner may revoke his intention to redeem at any time before the settlement date
of his redemption request by written instruction to the Administrator. If a Limited Owner revokes
his notice of intent to redeem and thereafter wishes to redeem, such Limited Owner will be required
to again submit written notice thereof in accordance with Section 7.01(a). The Managing
Owner, in its sole and absolute discretion, may change such notice requirement upon written notice
to such Limited Owner.

     7.02. Redemption of the Managing Owner. Notwithstanding any provision in this
Agreement to the contrary, but subject to Section 7.01(g), for so long as it shall act as
the Trust’s Managing Owner, the Managing Owner and any of its Affiliates may transfer or redeem any
of the Managing Owner’s General Units or its Affiliates’ Limited Units (if any) without notice to
the Limited Owners.

     7.03. Mandatory Redemptions.

          (a) As provided in Section 4.02(g), and for the reasons set forth in Section
7.03(b), the Managing Owner may require a mandatory redemption of all or any portion of the
Units held by any Limited Owner without any prior notice to or consent from such Limited Owner. In
the case of such a mandatory redemption, the Redemption Date shall be the close of business on the
date written notice is given by the Managing Owner to the relevant Limited Owner. The Managing
Owner may revoke such notice by written notice from the Managing Owner to the Limited Owner at any
time prior to the date on which payment for the redeemed Units. No Redemption Fee will be payable
in connection with a mandatory redemption pursuant to this Section 7.03. The redemption
price of Units pursuant to this Section 7.03 shall be the
price specified in Section 7.01(b), and redemptions pursuant to this Section
7.03 shall be subject to the limitations set forth in Section 7.01(c) and
7.01(d).

          (b) The Managing Owner may require a mandatory redemption of all or any portion of Units held
by a Limited Owner:

          (i) In the case of any Limited Owner, whenever there has been an unauthorized Transfer
or assignment of Units as determined pursuant to the provisions of Article V;

          (ii) In the case of a Limited Owner that is a Benefit Plan Investor, whenever the
Managing Owner determines in its sole discretion that the redemption is necessary (A) to
prevent Benefit Plan Investor ownership of the Units in the Trust and/or any Fund from
equaling or exceeding 25% of the value of the Trust and/or any Fund; or (B) to avoid or
prevent any transaction that would violate any Law, or any transaction that would constitute
a prohibited transaction under ERISA or the Code where such transaction is not covered by a
statutory, class or individual exemption from the

51

 

prohibited transaction provisions of ERISA
or the Code (or where the Managing Owner in its sole discretion determines not to apply for
such an exemption);

          (iii) If a Limited Owner is a resident of Canada for purposes of the Income Tax Act
(Canada);

          (iv) If the ownership of Units by a Limited Owner results in more than 25% of the fair
market value of the total investments in all of the Funds being owned by persons and
partnerships that are “affiliated” with the Administrator if such Administrator is a
corporation or trust resident in Canada, or a Canadian partnership, all within the meaning
of the Income Tax Act (Canada);

          (v) The Limited Owner is or becomes a Person not permitted to invest in any Fund as a
result of a breach of such Limited Owner’s representations and warranties set forth in
number paragraphs (11) through (15) of the Subscription Agreement; and/or

          (vi) In the case of a Limited Owner who is responsible for a fee or expense described
in Section 4.07(d) and has not paid such fee or expense, to the extent necessary to
pay such fee or expense or reimburse the Managing Owner or its Affiliate therefore.

     7.04. Exchange of Units.

          (a) From and after commencement of trading in a Fund, Limited Owners of such Fund may
exchange, without any fee, Units in that Fund for Units of another Class of Units in such Fund or
for Units in another Fund which has also commenced trading (an “Exchange”);
provided, however, all Exchanges shall be made only on the last Wednesday of each
month (the “Exchange Date”), unless that day or the following day is not a Business Day, in
which case the
Exchange Date shall be two (2) Business Days prior to the last Wednesday of that month. The
Administrator must receive a duly completed Exchange Request Form from the applicable Limited Owner
by 4:00 P.M. New York time on the Exchange Date. Exchanges will be calculated at the applicable
Funds’ Per Unit Net Asset Value at the Valuation Point on the Exchange Date, and settlement of
exchange requests will be completed at such date and time. Exchanges between Funds denominated in
different currencies shall be completed using the currency exchange rate then available to the
Trust from its bankers at the Valuation Point on the Exchange Date.

          (b) Each Exchange will be subject to satisfaction of the restrictions and provisions relating
to redemptions that are set forth in Section 7.01 or in the applicable Registration
Statement on the applicable day, as well as the requirement that the Fund being exchanged into is
then offering registered Units.

          (c) A Limited Owner wishing to exchange Units pursuant to this Section 7.04 must
provide the Administrator with written notice of his intent to redeem using the Exchange Request
Form, which notice shall specify the name and address of the redeeming Limited Owner and the amount
of Limited Units sought to be exchanged and the Fund, Class or Sub-Class into which such Units are
to be exchanged. The “Exchange Request Form” means a form annexed to

52

 

the Subscription Agreement or another form acceptable to the Managing Owner. The Managing
Owner shall be entitled to require additional supporting documentation to approve an exchange
request, such as trust instruments, death certificates, appointments as executor or administrator
or certificates of corporate authority.

          (d) The Managing Owner, in its sole discretion, may reject any Exchange Request for any of the
reasons for which it may reject a subscription (as specified in Section 3.04(e)(iii)). The
Managing Owner, in its sole and absolute discretion, may change any of the procedural and notice
requirements applicable to exchanges upon written notice to the Limited Owners.

     7.05. Special Redemption Date. If the Per Unit Net Asset Value of a Fund declines to
less than fifty percent (50%) of the Per Unit Net Asset Value of such Fund as of the immediately
preceding Valuation Point (a “Decline Date”), the Managing Owner shall send a notice of
such decline (a “Decline Notice”) by first class mail, postage prepaid, to each Limited
Owner who holds Units in such Fund within seven (7) Business Days following such Decline Date. In
the Decline Notice, the Managing Owner shall declare a “Special Redemption Period” during
which time Limited Owners may elect to redeem their Units in the applicable Fund, upon proper
written notice to the Managing Owner as described in the Decline Notice. Such Special Redemption
Period shall be within 30 Business Days following the Decline Date. No Redemption Fees shall be
assessed during any Special Redemption Period.

ARTICLE VIII

LIMITED OWNERS

     8.01. No Management or Control; Limited Liability. Limited Owners shall not be
entitled to participate in the management or control of the Trust’s or any Fund’s business nor
shall they transact any business for the Trust or any Fund or have the power to sign for or bind
the Trust or any Fund, said power being vested solely and exclusively in the Managing Owner. Except
as provided in Section 8.03, no Limited Owner shall be bound by, or be personally liable
for, the expenses, liabilities or obligations of the Trust or any Fund in excess of his Capital
Contributions plus his share of the Trust Estate of any Fund in which such Limited Owners owns
Units and profits remaining in such Fund(s), if any; provided, however, that each
Limited Owner shall be responsible for payment of the fees and expenses applicable to Limited
Owners that are set forth in the Registration Statement and as are expressly set forth in this
Agreement. Except as expressly provided herein, all Limited Units, once issued, shall be fully
paid and no assessment of any kind shall be made against any Limited Owner. No salary shall be
paid to any Limited Owner in his capacity as a Limited Owner, nor shall any Limited Owner have a
drawing account or earn interest on his contribution.

     8.02. Rights and Duties. The Limited Owners shall have the following rights, powers,
privileges, duties and liabilities:

          (a) Each Limited Owner shall have the right to obtain information reasonably relating to the
Trust or any Fund in which such Limited Owner holds a Unit for any purpose reasonably related to
the Limited Owner’s interest as a beneficial owner of the Trust and the applicable Fund, including
matters relating to a Limited Owner’s voting rights hereunder or the

53

 

exercise of a Limited Owner’s rights under federal proxy law, including such reports as are
set forth in Article IX and such information as is set forth in Section 4.03(k).
In the event that the Managing Owner neglects or refuses to produce or mail to a Limited Owner a
copy of the information set forth in the preceding sentence or in Section 4.03(k), the
Managing Owner shall be liable to such Limited Owner for the costs, including reasonable attorney’s
fees, incurred by such Limited Owner to compel the production of such information, and for any
actual damages suffered by such Limited Owner as a result of such refusal or neglect;
provided, however, it shall be a defense of the Managing Owner that the actual
purpose of the Limited Owner’s request for such information was not reasonably related to the
Limited Owner’s interest as a beneficial owner of the Trust and the applicable Fund (e.g.,
to secure such information in order to sell it, or to use the same for a commercial purpose
unrelated to the participation of such Limited Owner in the Trust and/or the applicable Fund). The
foregoing rights are in addition to, and do not limit, other remedies available to Limited Owners
under Federal or state Law.

          (b) Each Limited Owner shall have the right to receive from the assets of the Fund in which it
holds Units the share of the distributions provided for in this Agreement in the manner and at the
times provided for in this Agreement.

          (c) Except for a Limited Owner’s redemption and exchange rights set forth in Article
VII or upon a mandatory redemption effected by the Managing Owner pursuant to Section
7.03, no Limited Owner shall have the right to demand and receive the return of its capital
account other than upon the dissolution and winding up of the Fund in which it holds Units and only
to the extent of funds available therefor. In no event shall a Limited Owner be entitled to demand
or receive property other than cash. In accordance with Section 3.10, except with respect
to Fund, Class or Sub-Class differences, no Limited Owner shall have priority over any other
Limited Owner either as to the return of capital or as to profits, losses or distributions. No
Limited Owner shall have the right to bring an action for partition against the Trust or any Fund,
Class or Sub-Class.

          (d) Voting Rights.

          (i) Limited Owners holding Units representing a majority in Net Asset Value of each
affected Fund as of the Valuation Point on the date on which the vote is held (not including
Units held by the Managing Owner and its Affiliates), with each Fund voting separately as a
class, may approve amendments to this Agreement as set forth in Section 11.01.

          (ii) Limited Owners holding Units representing a majority in Net Asset Value of each
affected Fund (not including Units held by the Managing Owner and its Affiliates), with each
Fund voting separately as a class, may vote to continue the Trust and/or such Fund as
provided in Section 13.01(b) and/or terminate such Fund as provided in Section
13.01(e).

          (iii) Limited Owners holding Units representing a majority in Net Asset Value of each
affected Fund (not including Units held by the Managing Owner and its Affiliates), with each
Fund voting separately as a class, may vote to (A) elect a successor Managing Owner as
provided in Section 4.12, (B) approve a material change in a Fund’s

54

 

basic investment policies or structure, (C) approve the termination of any Contract
entered into between the Trust and/or such Fund and the Managing Owner or any Affiliate
thereof for any reason, without penalty, upon sixty (60) days’ prior written notice to the
Managing Owner or its Affiliate, (D) remove the Managing Owner of such Fund as provided in
Section 4.12(b), upon sixty (60) days’ prior written notice to the Managing Owner,
and/or (E) elect one or more additional Managing Owners.

          (e) Except as set forth above or elsewhere in this Agreement, Limited Owners shall have no
voting or other rights with respect to the Trust and/or any Fund. Prior to the exercise by the
Limited Owners of the rights set forth in Section 8.02(d), the Trust and/or the applicable
Fund will, if practicable and deemed reasonably prudent by the Managing Owner, provide the Limited
Owners with an opinion of independent legal counsel in each state where the Trust and/or such Fund
may be deemed to be conducting its business with respect to whether or not such exercise would
constitute such participation in the control of Trust or Fund business such as would adversely
affect the Limited Owners’ limited liability under the laws of such state.

     8.03. Limitation on Liability.

          (a) Except as provided in Sections 4.06(g), 5.03(f) and 6.06, and as
otherwise provided under Delaware Law, Limited Owners shall be entitled to the same limitation of
personal liability as is from time to time extended to stockholders of private corporations for
profit organized under the general corporation law of Delaware and no Limited Owner shall be liable
for claims against, or debts of the Trust or any Fund in excess of his Capital Contribution to a
Fund and his share of the Trust Estate and undistributed profits, except in the event that the
liability is founded upon (i) misstatements or omissions contained in such Limited Owner’s
Subscription Agreement delivered in connection with his purchase of Units or (ii) the fees and
expenses payable by Limited Owners, as set forth in the Registration Statement and as are expressly
set forth in this Agreement. In addition, subject to the exceptions set forth in the immediately
preceding sentence, neither the Trust nor any applicable Fund nor the Managing Owner shall make a
claim against a Limited Owner with respect to amounts distributed to such Limited Owner or amounts
received by such Limited Owner upon redemption unless, under Delaware Law, such Limited Owner is
liable to repay such amount.

          (b) The applicable Fund shall indemnify (as an Extraordinary Fee and Expense in accordance
with Section 4.07), to the maximum extent permitted by Law and this Agreement, and to the
extent of the Trust Estate attributable to that Fund, each Limited Owner (excluding the Managing
Owner to the extent of its ownership of any Limited Units) against any claims of liability asserted
against such Limited Owner solely because he is a beneficial owner of Units of such Fund (other
than for taxes for which such Limited Owner is liable under Section 6.06 or for the other
fees and expenses for which Limited Owners are expressly responsible or liable under this
Agreement).

          (c) Each written Contract, instrument, certificate or undertaking made or issued by the
Managing Owner with respect to the Trust and/or the applicable Fund shall give notice to the effect
that (i) the same was executed or made by or on behalf of the Trust and/or the applicable Fund,
(ii) the obligations and liabilities arising under such Contract, instrument, certificate or
undertaking are not enforceable against Limited Owners or their assets individually

55

 

but are enforceable only against the assets and property of the Trust and/or the applicable
Fund and (iii) no resort shall be had to Limited Owners or their assets for satisfaction of any
obligation or claim thereunder. Appropriate references in each written Contract, instrument,
certificate or undertaking may be made to this Agreement and may contain such additional protective
provisions as the Managing Owner deems appropriate, but the omission thereof shall not operate to
make such written Contract, instrument, certificate or undertaking enforceable against the Limited
Owners or their assets individually or otherwise invalidate such Contract, instrument, certificate
or undertaking. Nothing contained in this Section 8.03 shall diminish the limitation on
the liability of each Fund set forth in Sections 3.06 and 3.07.

ARTICLE IX

BOOKS OF ACCOUNT AND REPORTS

     9.01. Books of Account. Proper books of account for the Trust and each Fund shall be
kept and shall be audited annually by an independent certified public accounting firm selected by
the Managing Owner in its sole discretion, and there shall be entered therein all transactions,
matters and things relating to the Trust’s and/or each Fund’s business as are required by the CE
Act and the regulations promulgated thereunder, and all other applicable rules and regulations, and
as are usually entered into books of account kept by Persons engaged in a business of like
character. The books of account shall be kept at the principal office of the Trust and each
Limited Owner (or any duly constituted designee of a Limited Owner) shall have, at all times during
normal business hours, free access to and the right to inspect and copy the same for any purpose
reasonably related to the Limited Owner’s interest as a beneficial owner of any Fund, including
such access as is required under CFTC rules and regulations. Such books of account shall be kept,
and the Trust and each Fund shall report its Profits and Losses on, the accrual method of
accounting for financial accounting purposes on a Fiscal Year basis as described in Article
X.

     9.02. Annual Reports and Quarterly Statements. Each Limited Owner shall be furnished
as of the end of each calendar quarter and as of the end of each Fiscal Year with any reports or
information which the Managing Owner, in its sole discretion, determines to be necessary or
appropriate and/or required under applicable Law, including the CE Act and the regulations
promulgated thereunder, and within the time period and in the manner required under applicable Law,
including the CE Act and the regulations promulgated thereunder. Notwithstanding the foregoing,
the Managing Owner intends to seek relief from the CFTC from the requirement that certified audited
financial statements for the Fiscal Year 2007 be prepared and delivered by the Trust and the Funds.

     9.03. Tax Information. Appropriate tax information of a Fund (adequate to enable each
Limited Owner to complete and file his Federal tax return) shall be delivered to each Limited Owner
with respect to such Fund as soon as practicable following the end of each Fiscal Year but
generally no later than March 15.

     9.04. Calculation of Net Asset Value and National Net Asset Value of a Fund.
The Managing Owner will calculate the Net Asset Value and Notional Net Asset Value of each
Fund each Business Day. The Managing Owner will make available to a Limited Owner the Net Asset
Value and Notional Net Asset Value and the Per Unit Net Asset Value for each Fund upon

56

 

request and
as and in the manner required under applicable Law, including the CE Act and the regulations
promulgated thereunder.

     9.05. Other Reports. The Managing Owner shall send such other reports and
information, if any, to the Limited Owners as it may deem necessary or appropriate in its sole
discretion or as may be required under applicable Law, including the CE Act and the regulations
promulgated thereunder. The Managing Owner shall notify each Limited Owner of (a) any change of
Trustee or the Managing Owner, and (b) any other material change affecting the fees, compensation
or type of expense reimbursements to the Trustee, the Managing Owner or any other Person.
Notification for occurrences described in clause (b) shall be sent to Limited Owners within seven
(7) Business Days of such occurrence. Included in such notification shall be a description of (i)
any material effect such changes may have on Limited Owners’ Units, and (ii) Limited Owners’ voting
rights set forth in Section 8.02(d) and redemption rights set forth in Section
7.01. The Managing Owner shall submit to federal and state authorities all reports and
information required to be filed with them, including, as applicable, the monthly, annual and other
reports and information described in Section 9.02 and this Section 9.05.

     9.06. Maintenance of Records. The Managing Owner shall maintain (a) for a period of
at least eight (8) Fiscal Years or such longer period as may be required by applicable Law,
including the CE Act and the regulations issued thereunder, (i) all books of account required by
Section 9.01; (ii) a list of the names and last known address of, and number of Units owned
by, all Owners; (iii) a copy of the Certificate of Trust and all certificates of amendment thereto,
together with executed copies of any powers of attorney pursuant to which any certificate has been
executed; (iv) copies of each Fund’s Federal, state and local income tax returns and reports, if
any; and (v) a record of the information obtained to indicate that an investment in Units is
suitable and appropriate for each Subscriber, as set forth in the Registration Statement, and (b)
for a period of at least six (6) Fiscal Years or such longer period as may be required by
applicable Law, including the CE Act and the regulations issued thereunder, copies of any written
trust agreements, Subscription Agreements and financial statements of the Trust and each Fund.

     9.07. Certificate of Trust. Except as otherwise provided in the Trust Act or this
Agreement, the Managing Owner shall not be required to mail a copy of any Certificate of Trust
filed with the Secretary of State to each Limited Owner; provided, that the Managing Owner
shall maintain such Certificates at the principal office of the Trust and that such Certificates
shall be available for inspection and copying by the Limited Owners in accordance with this
Agreement. The Certificate of Trust shall not be amended in any respect if the effect of such
amendment is to diminish the limitation on inter-series liability under Section 3804 of the Trust
Act.

ARTICLE X

FISCAL YEAR

     10.01. Fiscal Year. The fiscal year of the Trust and each Fund (“Fiscal
Year”) shall begin on January 1st of each year and end on the 31st day of December
of each year. The first Fiscal Year commenced on August 17, 2006, and ended on the 31st day of
December, 2006.

57

 

ARTICLE XI

AMENDMENT OF TRUST AGREEMENT; MEETINGS

     11.01. Amendments to this Agreement.

          (a) Amendments to this Agreement may be proposed by the Managing Owner or by Limited Owners
holding Units equal to at least 10% of the Net Asset Value of each Fund (excluding Units held by
the Managing Owner and its Affiliates), unless the proposed amendment affects only a certain Fund,
in which case such amendment may be proposed by the Managing Owner or Limited Owners holding Units
equal to at least 10% of the Net Asset Value of such Fund (excluding Units held by the Managing
Owner and its Affiliates). The Managing Owner shall promptly seek an opinion of independent legal
counsel as to whether the amendment would (i) be legal, valid and binding and (ii) as set forth in
Section 8.02(e), adversely affect the limitation on liability of Limited Owners set forth
in Section 8.03 or elsewhere in this Agreement. Within 15 days following such proposal (or
in the case of an amendment proposed by Limited Owners, receipt thereof by the Managing Owner), the
Managing Owner shall submit to the Limited Owners of each affected Fund (i) a copy of any proposed
amendment, (ii) a statement as to the legality of such amendment, the effect of such amendment on
the limitation on liability of Limited Owners and any other relevant information with respect to
such proposed amendment that the Managing Owner may deem necessary and/or appropriate in its sole
discretion, (iii) the Managing Owner’s recommendation(s) as to the proposed amendment and (iv) if
obtainable within such period, a summary of the opinion of counsel described in the preceding
sentence. The amendment shall become effective only upon (i) the written approval or affirmative
vote of Limited Owners holding Units representing at least a majority of the Net Asset Value of
each Fund (excluding Units held by the Managing Owner and its Affiliates) or, if the proposed
amendment affects only a certain Fund, of Limited Owners holding Units representing at least a
majority of the Net Asset Value of such Fund (excluding Units held by the Managing Owner and its
Affiliates); provided, that if this Agreement or applicable Law requires a higher
percentage of Limited Owners to approve or authorize an action, then such action shall be approved
or authorized only if the minimum number of Limited Owners required under this Agreement or
applicable Law is obtained and (ii) receipt by the Trust or the applicable Fund, as the case may
be, of an opinion of independent legal counsel to the effect that the amendment is legal, valid and
binding and, as set forth in Section 8.02(e), will not adversely affect the limitations on
liability of the Limited Owners described in Section 8.03. Notwithstanding anything to the
contrary in this Agreement, except as otherwise provided below, reduction of the capital account of
any Limited Owner or modification of the percentage of Profits, Losses or distributions to which a
Limited Owner is entitled hereunder (except in each case in respect of fees
and expenses for which the Trust, the applicable Fund or such Limited Owner is responsible)
shall not be affected by amendment to this Agreement without such assignee’s approval.

          (b) Notwithstanding anything to the contrary in Section 11.01(a), the Managing Owner
may, without the approval of any or all Limited Owners, make such amendments to this Agreement as
(i) are necessary to add to the representations, duties or obligations of the Managing Owner or
surrender any right or power granted to the Managing Owner herein for the benefit of the Limited
Owners, (ii) are necessary to cure any ambiguity, to correct or supplement any provision herein
which may be inconsistent with any other provision herein or in the Registration Statement, or to
make any other provision with respect to matters or

58

 

questions arising under this Agreement or the
Registration Statement which will not be inconsistent with the provisions of the Agreement or the
Registration Statement, or (iii) the Managing Owner deems necessary or advisable in its sole
discretion; provided, however, that no amendment shall be adopted pursuant to this
clause (iii) unless the adoption thereof (A) is not adverse to the interests of the Limited Owners;
(B) is consistent with Section 4.01; (C) except as otherwise provided in Section
11.01(c), does not affect the allocation of Profits and Losses among the Limited Owners or
between the Limited Owners and the Managing Owner; (D) does not adversely affect the limitation on
liability of the Limited Owners described in Article VIII and elsewhere in this Agreement;
or (D) does not adversely affect the status of each Fund as a partnership for Federal income tax
purposes.

          (c) Notwithstanding anything to the contrary in Sections 11.01(a) and (b), the
Managing Owner may, without the approval of any or all Limited Owners, amend the provisions of
Article VI relating to the allocations of Profits, Losses, Disposition Gain, Disposition
Loss and distributions among the Owners if the Trust is advised at any time by the Trust’s
accountants or legal counsel that the allocations provided in Article VI are unlikely to be
respected for Federal income tax purposes, either because of the promulgation of new or revised
Treasury Regulations under Section 704 of the Code, other developments in the Law, or for any other
reason. The Managing Owner is empowered to amend such provisions to the minimum extent necessary
in accordance with the advice of the accountants and counsel to effect the allocations and
distributions provided in this Agreement. New allocations made by the Managing Owner in reliance
upon the advice of the accountants or counsel described above shall be deemed to be made pursuant
to the obligation of the Managing Owner to the Trust or a Fund and the Limited Owners, and no such
new allocation shall give rise to any claim or cause of action by any Limited Owner.

          (d) Upon amendment of this Agreement, the Certificate of Trust shall also be amended, if
required by the Trust Act, to reflect such change.

          (e) No amendment shall be made to this Agreement without the consent of the Trustee if such
amendment would adversely affect any of the rights, duties or liabilities of the Trustee;
provided, however, that the Trustee may not withhold its consent for any action
which the Limited Owners are permitted to take under Section 8.02(d). The Trustee shall
execute and file any amendment to the Certificate of Trust if so directed by the Managing Owner or
if such amendment is required in the opinion of the Trustee. A copy of any amendment made to this
Agreement shall be promptly provided to the Trustee by the Managing Owner.

          (f) No provision of this Agreement may be amended, waived or otherwise modified orally; all
amendments, waivers and modifications shall be effective only if made by a written instrument
adopted in accordance with Section 8.02(d) and this Section 11.01.

          (g) Notwithstanding anything contained in this Agreement to the contrary, no amendment or
change may be made to this Agreement, any material contract relating to the Funds or any matter
relating to the management or administration of the Funds which, in the opinion of the counsel to
the Funds, may jeopardize or adversely affect in any manner whatsoever, the limited liability of
the Limited Owners of the Funds and no Limited Owner of the Funds shall be permitted to effect,
consent to or approve, in any manner whatsoever, such

59

 

amendment or change, whether or not such
amendment or change is required by law or the policies of applicable securities regulatory
authorities in effect from time to time.

     11.02. Meetings of the Trust and Funds. Meetings of the Owners of the Trust or any
Fund thereof may be called by the Managing Owner and will be called by the Managing Owner, for any
matters for which the Limited Owners may vote as set forth in this Agreement, upon the written
request of Limited Owners holding Units not less than 10% of the Net Asset Value of the Trust or
the applicable Fund (excluding Units held by the Managing Owner and its Affiliates). Such call for
a meeting shall be deemed to have been made upon the receipt by the Managing Owner of a written
request from the requisite percentage of Limited Owners. The Managing Owner shall deposit in the
United States mail, within fifteen (15) days of its determination to hold a meeting of the Owners
of the Trust or a Fund or after receipt of said request, as applicable, written notice to all
Owners of the Trust or the applicable Fund of the meeting and the purpose of the meeting, which
shall be held on a date, not less than 30 nor more than 60 days after the date of mailing of said
notice, at a reasonable time and place. Any notice of meeting shall be accompanied by a
description of action(s) proposed to be taken at the meeting and an opinion of independent legal
counsel as to the effect of such proposed action on the limitations on liability of the Limited
Owners as described in Section 8.03. Owners may vote in person or by proxy at any such
meeting.

     11.03. Action Without a Meeting. Any action required or permitted to be taken by
Owners with respect to the Trust or a Fund by vote may be taken without a meeting by written
consent setting forth the actions so taken if such consents are executed by the minimum number of
Owners necessary to approve such action under this Agreement or under applicable Law. Such written
consents shall be treated for all purposes as votes at a meeting.

     11.04. Solicitation of Votes or Consents. If the vote or consent of any Owner to any
action of the Trust or any Fund is solicited by the Managing Owner, the solicitation shall be
effected by notice to each Owner given in the manner provided in Section 15.04. The vote
or consent of each Owner so solicited shall be deemed conclusively to have been cast or granted as
requested in the notice of solicitation, whether or not the notice of solicitation is actually
received by that Owner, unless the Owner expresses written objection to the vote or consent by
notice given in the manner provided in
Section 15.04 and actually received by the Trust within 20 days after the notice of
solicitation is effected.

     11.05. Reliance on Votes or Consents. The Managing Owner and all Persons dealing with
the Trust and each Fund shall be entitled to act in reliance on any vote or consent which is deemed
cast or granted pursuant to this Article XI and shall be fully indemnified by the Trust
and/or the applicable Fund in so doing (with such indemnification treated as Extraordinary Fees and
Expenses for purposes of Section 4.07). Any action taken or omitted in reliance on any such
deemed vote or consent of one or more Owners shall not be void or voidable by reason of timely
communication made by or on behalf of all or any of such Owners in any manner other than as
expressly provided in Section 15.04.

60

 

ARTICLE XII

TERM

     12.01. Term. The term for which the Trust and each Fund is to exist shall commence on
the date of the filing of the Certificate of Trust, and shall expire on August 1, 2050, unless
sooner terminated pursuant to the provisions of Article XIII or as otherwise provided by
law.

ARTICLE XIII

TERMINATION

     13.01. Events Requiring Dissolution of the Trust. The Trust shall dissolve at any
time upon the happening of any of the following events:

          (a) The expiration of the Trust term as provided in Article XII;

          (b) The (x) filing of a certificate of dissolution or revocation of the Managing Owner’s
charter (and the expiration of ninety (90) days after the date of notice to the Managing Owner of
revocation without a reinstatement of its charter) or withdrawal, removal, adjudication or
admission of bankruptcy or insolvency of the Managing Owner (each of the foregoing events an
“Event of Withdrawal”) unless (i) at the time there is at least one remaining Managing
Owner and that remaining Managing Owner agrees to carry on the business of the Trust and the Funds
or (ii) within ninety (90) days of such Event of Withdrawal all the remaining Owners agree in
writing to continue the business of the Trust and to select, effective as of the date of such
event, one or more successor Managing Owners. If the Trust is terminated as the result of an Event
of Withdrawal and a failure of all remaining Owners to continue the business of the Trust and to
appoint a successor Managing Owner as provided in clause (b)(ii) above, within 120 days of such
Event of Withdrawal, Limited Owners holding Units representing at least a majority of the Net Asset
Value of each Fund (not including Units held by the Managing Owner and its Affiliates) may elect to
continue the business of the Trust and each Fund by forming a new statutory trust (the
“Reconstituted Trust”) on the same terms and provisions as set forth in this Agreement
(whereupon the parties hereto shall execute and deliver any documents or instruments
as may be necessary to reform the Trust and each Fund). Any such election must also provide
for the election of a Managing Owner to the Reconstituted Trust. If such an election is made, all
Limited Owners of the Trust shall be bound thereby and continue as Limited Owners of the
Reconstituted Trust;

          (c) The occurrence of any event which would make unlawful the continued existence of the
Trust;

          (d) The failure to sell the Subscription Minimums for all Funds during the Initial Offering
Period;

          (e) The suspension, revocation or termination of the Managing Owner’s registration as a
commodity pool operator under the CE Act, as amended, or its membership as a commodity pool
operator with the NFA, unless at the time there is at least one remaining Managing Owner whose
registration or membership as a commodity pool operator has not been suspended, revoked or
terminated;

61

 

          (f) The Trust becomes insolvent or bankrupt;

          (g) Limited Owners of each Fund holding Units representing at least a majority of the Net
Asset Value of each Fund (excluding Units held by the Managing Owner or any Affiliate thereof) vote
to dissolve the Trust, notice of which is sent to the Managing Owner not less than ninety (90) days
prior to the effective date of such termination; or

          (h) Determination by the Managing Owner that the Funds’ aggregate net assets in relation to
the operating expenses of the Funds make it unreasonable or imprudent to continue the business of
the Trust.

     13.02. Events Requiring Dissolution of a Fund. A Fund shall dissolve at any time upon
the happening of any of the following events:

          (a) The Trust shall have been dissolved pursuant to Section 13.01;

          (b) The occurrence of any event which would make unlawful the continued existence of such
Fund;

          (c) The failure to sell the Subscription Minimum for such Fund during the Initial Offering
Period;

          (d) Such Fund becomes insolvent or bankrupt;

          (e) Limited Owners holding Units representing at least a majority of the Net Asset Value of
such Fund (excluding Units held by the Managing Owner or any Affiliate thereof) vote to dissolve
such Fund, notice of which is sent to the Managing Owner not less than ninety (90) days prior to
the effective date of such Fund’s termination; or

          (f) Determination by the Managing Owner that such Fund’s aggregate net assets in relation to
the operating expenses of such Fund makes it unreasonable or imprudent to continue the business of
such Fund.

     13.03. No Termination Upon Events Related to Limited Owner. The death, legal
disability, bankruptcy, insolvency, dissolution, or withdrawal of any Limited Owner (as long as
such Limited Owner is not the sole Limited Owner of the Trust or a Fund) shall not result in the
termination of the Trust or a Fund, and such Limited Owner, his estate, custodian or personal
representative shall have no right to withdraw or value such Limited Owner’s Units except as
provided in Article VII. Each Limited Owner (and any assignee thereof) expressly agrees
that in the event of his death, he waives on behalf of himself and his estate, and he hereby
directs the legal representative of his estate and any person interested therein to waive, the
furnishing of any inventory, accounting or appraisal of the assets of the Fund in which they own
Units and any right to an audit or examination of the books of the Fund in which they own Units,
except for such rights as are set forth in Article IX relating to the books of account and
reports of the applicable Fund.

62

 

     13.04. Distributions on Dissolution.

          (a) Upon the dissolution of the Trust or any Fund, the Managing Owner (or in the event there
is no Managing Owner, such Person as the Limited Owners holding Units equal to at least 10% of the
Net Asset Value of the Trust or the affected Fund, as the case may be, may approve (the
“Liquidating Trustee”) shall take full charge of the Trust’s or the applicable Fund’s
assets and liabilities. The Liquidating Trustee shall promptly notify the Trustee of its
appointment. Any Liquidating Trustee so appointed shall have and may exercise, without further
authorization or approval of any of the parties hereto, all of the powers conferred upon the
Managing Owner under the terms of this Agreement with respect to the Trust or the affected Fund, as
the case may be, subject to all of the applicable limitations, contractual and otherwise, upon the
exercise of such powers; provided, that the Liquidating Trustee shall not have general liability
for the acts, omissions, obligations and expenses of the Trust or any Fund.

          (b) Thereafter, the business and affairs of the Trust or the any dissolved Fund, as the case
may be, shall be wound up and all of its assets shall be liquidated as promptly as is consistent
with obtaining fair value therefor, and the proceeds therefrom shall be applied and distributed in
the following order of priority: (a) to the expenses of liquidation and termination and to
creditors, including Owners who are creditors, to the extent otherwise permitted by law, in
satisfaction of liabilities of the Fund (whether by payment or the making of reasonable provision
for payment thereof) other than liabilities for distributions to Owners, and (b) to the Managing
Owner and each Limited Owner pro rata in accordance with his positive book capital account balance,
less any amount owing by such Owner to the Fund, after giving effect to all adjustments made
pursuant to Article VI and all distributions theretofore made to the Owners pursuant to
Article VI. After the distribution of all remaining assets of the Fund, the Managing Owner
will contribute to the Fund an amount equal to the lesser of (i) the deficit balance, if any, in
its book capital account, and (ii) the excess of 1.01% of the total Capital Contributions of the
Limited Owners over the capital previously contributed by the Managing Owner. Any Capital
Contributions made by the Managing Owner pursuant to this Section shall be applied first to
satisfy any amounts then owed by the Fund to its creditors, and the balance, if any, shall be
distributed to those Owners in the Fund whose book capital account balances (immediately following
the distribution of any liquidation proceeds) were positive, in proportion to their respective
positive book capital account balances.

          (c) Dissolution of the Trust shall be treated as the separate dissolution of each of the Funds
then existing according to the procedure set forth in Section 13.04(b).

     13.05. Termination; Certificate of Cancellation. Following dissolution and
distribution of the assets of all Funds, the Trust shall terminate and Managing Owner or
Liquidating Trustee, as the case may be, shall execute and cause such certificate of cancellation
of the Certificate of Trust to be filed in accordance with the Trust Act. Evidence of such filing
shall promptly be provided to the Trustee by the Managing Owner or Liquidating Trustee, as the case
may be. Notwithstanding anything to the contrary in this Agreement, the existence of the Trust as
a separate legal entity shall continue until the filing of such certificate of cancellation.

63

 

ARTICLE XIV

POWER OF ATTORNEY

     14.01. Power of Attorney. Each Limited Owner shall execute and deliver to the Managing
Owner a Power of Attorney as part of the Subscription Agreement, or in such other form as may be
prescribed by the Managing Owner. Each Limited Owner, by its deemed execution and delivery hereof
(pursuant to such Power of Attorney), irrevocably constitutes and appoints the Managing Owner and
its officers and directors, with full power of substitution, as the true and lawful
attorney-in-fact and agent for such Limited Owner file, prosecute, defend, settle or compromise
litigation, claims or arbitrations on behalf of the Trust and each Fund in the execution,
acknowledgment, filing and publishing of Trust and Fund documents, including the following:

          (a) Any certificates and other instruments, including applications for authority to do
business and amendments thereto, which the Managing Owner deems appropriate or necessary in its
sole discretion to qualify or continue the Trust as a statutory trust in the jurisdictions in which
the Trust or a Fund may conduct business, so long as such qualifications and continuations are in
accordance with the terms of this Agreement or any amendment hereto, or which may be required to be
filed by the Trust, a Fund or the Owners under the Laws of any jurisdiction;

          (b) Any instrument which may be required to be filed by the Trust or a Fund under the Laws of
any state or by any governmental agency, or which the Managing Owner deems advisable or necessary
in its sole discretion to file; and

          (c) This Agreement and any documents which may be required or appropriate to effect an
amendment to this Agreement approved under the terms of the Agreement or a continuation of the
Trust, the admission of the signer of the Power of Attorney as a Limited Owner or of others as
additional or Substituted Limited Owners, or the termination of the Trust,
provided in each case such continuation, admission or termination is in accordance with the
terms of this Agreement.

     14.02. Effect of Power of Attorney. The Power of Attorney granted by each Limited
Owner to the Managing Owner as part of the Subscription Agreement or in such other form as may be
prescribed by the Managing Owner:

          (a) Is a special, irrevocable Power of Attorney coupled with an interest, and shall survive
and not be affected by the death, disability, dissolution, liquidation, termination or incapacity
of the Limited Owner;

          (b) May be exercised by the Managing Owner for each Limited Owner by a facsimile signature of
one of its officers or by a single signature of one of its officers acting as attorney-in-fact for
all of them; and

          (c) Shall survive the delivery of an assignment by a Limited Owner of the whole or any portion
of his Limited Units; except that where the assignee thereof has been become a Substituted Limited
Owner in accordance with Section 5.03, the Power of Attorney of the assignor shall survive
the delivery of such assignment for the sole purpose of enabling the

64

 

Managing Owner to execute,
acknowledge and file any instrument necessary to effect such Transfer. Each Limited Owner agrees
to be bound by any representations made by the Managing Owner and by any successor thereto,
determined to be acting in good faith pursuant to such Power of Attorney and not constituting
negligence or misconduct.

     14.03. Limitation on Power of Attorney. The Power of Attorney granted by each Limited
Owner to the Managing Owner shall not authorize the Managing Owner to act on behalf of Limited
Owners in any situation in which this Agreement requires the approval of Limited Owners unless such
approval has been obtained as required by this Agreement. In the event of any conflict between
this Agreement and any instruments filed by the Managing Owner or any new Managing Owner pursuant
to this Power of Attorney, this Agreement shall control.

ARTICLE XV

MISCELLANEOUS

     15.01. Governing Law. This Agreement and the validity and construction of this
Agreement and all amendments hereto shall be governed by the laws of the State of Delaware, and the
rights of all parties hereto and the effect of every provision hereof shall be subject to and
construed according to the laws of the State of Delaware without regard to the conflict of laws
provisions thereof; provided, however, that the parties hereto intend that the
provisions of this Agreement shall control over any contrary or limiting statutory or common Law of
the State of Delaware (other than the Trust Act) and that, to the maximum extent permitted by
applicable Law, there shall not be applicable to the Trust, the Trustee, the Managing Owner, the
Owners or this Agreement any provision of
the Laws (statutory or common) of the State of Delaware (other than the Trust Act) pertaining
to trusts which relate to or regulate in a manner inconsistent with the terms hereof, including:
(a) the filing with any court or governmental body or agency of trustee accounts or schedules of
trustee fees and charges, (b) affirmative requirements to post bonds for trustees, officers,
agents, or employees of a trust, (c) the necessity for obtaining court or other governmental
approval concerning the acquisition, holding or disposition of real or personal property, (d) fees
or other sums payable to trustees, officers, agents or employees of a trust, (e) the allocation of
receipts and expenditures to income or principal, (f) restrictions or limitations on the
permissible nature, amount or concentration of trust investments or requirements relating to the
titling, storage or other manner of holding of trust assets, or (g) the establishment of fiduciary
or other standards or responsibilities or limitations on the acts or powers of trustees or managers
that are inconsistent with the limitations on liability or authorities and powers of the Trustee or
the Managing Owner set forth or referenced in this Agreement. Section 3540 of Title 12 of the
Delaware Code shall not apply to the Trust. The Trust shall be of the type commonly called a
“statutory trust,” and without limiting the provisions hereof, the Trust may exercise all powers
that are ordinarily exercised by such a trust under Delaware law. The Trust specifically reserves
the right to exercise any of the powers or privileges afforded to statutory trusts and the absence
of a specific reference herein to any such power, privilege or action shall not imply that the
Trust may not exercise such power or privilege or take such actions.

65

 

     15.02. Provisions In Conflict With Law or Regulations.

          (a) The provisions of this Agreement are severable, and if the Managing Owner shall determine,
with the advice of counsel, that any one or more of such provisions (the “Conflicting
Provisions”) are in conflict with the Code, the Trust Act or other applicable Federal or state
laws, the Conflicting Provisions shall be deemed never to have constituted a part of this
Agreement, even without any amendment to this Agreement; provided, however, that
such determination by the Managing Owner shall not affect or impair any of the remaining provisions
of this Agreement or render invalid or improper any action taken or omitted prior to such
determination. No Managing Owner or Trustee shall be liable for making or failing to make such a
determination.

          (b) If any provision of this Agreement shall be held invalid or unenforceable in any
jurisdiction, such holding shall not in any manner affect or render invalid or unenforceable such
provision in any other jurisdiction or any other provision of this Agreement in any jurisdiction.

     15.03. Construction. In this Agreement, unless the context otherwise requires, words
used in the singular or in the plural include both the plural and singular and words denoting any
gender include all genders. The title and headings of different parts are inserted for convenience
and shall not affect the meaning, construction or effect of this Agreement.

     15.04. Notices.
All notices or communications under this Agreement (other than requests for redemption of
Units, notices of assignment, transfer, pledge or encumbrance of Units, and reports and notices by
the Managing Owner to the Limited Owners) shall be in writing and shall be effective upon personal
delivery, or if sent by mail, postage prepaid, or if sent electronically, by facsimile or by
overnight courier; and addressed, in each such case, to the address set forth in the books and
records of the Trust or such other address as may be specified in writing, of the party to whom
such notice is to be given, upon the deposit of such notice in the United States mail, upon
transmission and electronic confirmation thereof or upon deposit with a representative of an
overnight courier, as the case may be. Requests for redemption, notices of assignment, transfer,
pledge or encumbrance of Units shall be effective upon timely receipt by the Managing Owner or the
Administrator (as specified in the Registration Statement) in writing and at the time specified
under this Agreement.

     15.05. Counterparts. This Agreement may be executed in several counterparts, and all
so executed shall constitute one agreement, binding on all of the parties hereto, notwithstanding
that all the parties are not signatory to the original or the same counterpart.

     15.06. Binding Nature of Agreement. The terms and provisions of this Agreement shall
be binding upon and inure to the benefit of the heirs, custodians, executors, estates,
administrators, personal representatives, successors and permitted assigns of each Owner. For
purposes of determining the rights of any Owner or assignee hereunder, each Fund, the Trust and the
Managing Owner may rely upon the Fund/Trust records as to who are Owners and Permitted Assignees,
and all Owners and Permitted Assignees agree that each Fund, the Trust and the Managing Owner, in
determining such rights, shall rely on such records and that Limited Owners and assignees shall be
bound by such determination.

66

 

     15.07. No Legal Title to Trust Estate. No Owner shall have legal title to any part of
the Trust Estate.

     15.08. Creditors. No creditor of any Owner shall have any right to obtain possession
of, or otherwise exercise legal or equitable remedies with respect to the Trust Estate.

     15.09. Integration. This Agreement constitutes the entire agreement among the parties
hereto pertaining to the subject matter hereof and supersedes all prior agreements and
understandings pertaining thereto.

67

 

     IN WITNESS WHEREOF, the undersigned have duly executed this Declaration of Trust and Agreement
as of the day and year first above written.

CSC TRUST COMPANY OF DELAWARE,

as Trustee

	 	 	 	 	 
	By:
	 	 	 	 
	 

	 	 

Name: Shawn P. Wilson
	 	 
	 

	 	Title: Vice President	 	 

BROOKSHIRE RAW MATERIALS

MANAGEMENT, LLC,

As Managing Owner

	 	 	 	 	 
	By:
	 	 	 	 
	 

	 	 

Name: John Marshall
	 	 
	 

	 	Title:	 	 

 

 

EXHIBIT A-1

CERTIFICATE OF TRUST

BROOKSHIRE RAW MATERIALS (U.S.) TRUST

This Certificate of Trust is filed in accordance with the provisions of the Trust Act (12 Del. C.
Section 3801 et seq.) and sets forth the following:

     FIRST: The name of the trust is “BROOKSHIRE RAW MATERIALS (U.S.) TRUST” (the “Trust”).

     SECOND: The name and the business address of the Delaware trustee is CSC TRUST COMPANY OF
DELAWARE, 2711 Centerville Road, Suite 210, Wilmington, Delaware, 19808.

     THIRD: Pursuant to Section 3806(b)(2) of the Trust Act, the Trust shall issue one or more
series of beneficial interests having the rights, powers and duties as set forth in the Declaration
of Trust and Agreement of the Trust dated August 17, 2006, as amended and restated on July ___,
2007, as the same may be amended from time to time (each a “Fund”).

     FOURTH: Notice of Limitation of Liability of each Fund: Pursuant to Section 3804 of the Trust
Act, there shall be a limitation on liability of each particular Fund such that the debts,
liabilities, claims, obligations and expenses incurred, contracted for or otherwise existing with
respect to, in connection with or arising under a particular Fund shall be enforceable against the
assets of that Fund only, and not against the assets of the Trust generally or the assets of any
other Fund.

CSC TRUST COMPANY OF DELAWARE,

as Trustee

	 	 	 	 	 
	By:

	 	/s/	 	 
	 

	 	 

	 	 
	Name:

	 	Shawn P. Wilson	 	 
	Title:

	 	Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]